



(11) **EP 1 137 792 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Description Paragraph(s) 51, 71, 77, 91-93, 131, 136, 151
- (48) Corrigendum issued on:
12.12.2007 Bulletin 2007/50
- (45) Date of publication and mention of the grant of the patent:
09.05.2007 Bulletin 2007/19
- (21) Application number: **99958951.8**
- (22) Date of filing: **12.11.1999**
- (51) Int Cl.:
C12N 15/86 ^(2006.01) **C12N 5/10** ^(2006.01)
C07K 14/705 ^(2006.01) **A61K 39/00** ^(2006.01)
A61K 35/76 ^(2006.01) **C12Q 1/00** ^(2006.01)
- (86) International application number:
PCT/US1999/026866
- (87) International publication number:
WO 2000/034494 (15.06.2000 Gazette 2000/24)

(54) **A RECOMBINANT VECTOR EXPRESSING MULTIPLE COSTIMULATORY MOLECULES AND USES THEREOF**

RECOMBINANTER VECTOR, WELCHER MEHRERE KOSTIMULATORISCHE MOLEKÜLE EXPRIMIERT UND DESSEN VERWENDEN

VECTEUR RECOMBINE EXPRIMANT DES MOLECULES COSTIMULANTES MULTIPLES ET LEURS UTILISATIONS

- | | |
|---|--|
| <p>(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE</p> <p>(30) Priority: 09.12.1998 US 111582 P</p> <p>(43) Date of publication of application:
04.10.2001 Bulletin 2001/40</p> <p>(60) Divisional application:
07107699.6 / 1 865 065</p> <p>(73) Proprietors:
• THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Rockville, MD 20852 (US)
• THERION BIOLOGICS CORPORATION
Cambridge, MA 02142 (US)</p> | <p>(72) Inventors:
• SCHLOM, Jeffrey
Potomac, MD 20854 (US)
• HODGE, James
Gaithersburg, MD 20879 (US)
• PANICALI, Dennis
Acton, MA 01720 (US)</p> <p>(74) Representative: Gervasi, Gemma
Notarbartolo & Gervasi S.p.A.
Corso di Porta Vittoria, 9
20122 Milano (IT)</p> <p>(56) References cited:
WO-A-96/10419 WO-A-98/04727
US-A- 5 738 852</p> <p>• HODGE, J.W. ET AL.: "A triad of costimulatory molecules synergize to amplify T-cell activation" CANCER RES, vol. 59, 15 November 1999 (1999-11-15), pages 5800-5807, XP000882899</p> |
|---|--|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**Field of the Invention**

[0001] The present invention relates to a recombinant vector comprising foreign genes encoding three costimulatory molecules and optionally a foreign gene encoding a target antigen. The invention further relates to a recombinant virus comprising foreign genes encoding at least three costimulatory molecules and optionally a foreign gene encoding at least one target antigen or immunological epitope thereof. More specifically, the present invention relates to a recombinant poxvirus comprising foreign genes encoding at least the costimulatory molecules: one molecule from the B7 family, LFA-3 and ICAM-1 and optionally a foreign gene encoding at least one target antigen or immunological epitope thereof and uses thereof as immunogens and vaccines. The invention further relates to antigen presenting cells transfected, infected or transduced by a recombinant vector comprising foreign genes encoding three costimulatory molecules and optionally a foreign gene encoding at least one target antigen or immunological epitope thereof.

Background of the Invention

[0002] The extent of the primary response of T cells, which involves their activation, expansion, and differentiation, is paramount to a successful immune response to an antigen. The initiation of an immune response requires at least two signals for the activation of naive T cells by antigen presenting cells (APC) (1-5). The first signal is antigen specific, delivered through the T-cell receptor via the peptide/major histocompatibility complex, and causes the T cell to enter the cell cycle. The second, or "costimulatory," signal is required for cytokine production and proliferation. At least three distinct molecules normally found on the surface of professional APC have been proposed as capable of providing the second signal critical for T-cell activation: B7.1 (CD80), Intercellular adhesion molecule-1 (ICAM-1; CD54), and Leukocyte function-associated antigen-3 (LFA-3; human CD58; murine CD48) (2, 6, 7). The T-cell ligands for these costimulatory molecules are distinct. B7-1 interacts with the CD28 and CTLA-4 molecules, ICAM-1 interacts with the CD11a/CD18 (LFA-1/ α 2 integrin) complex, and LFA-3 interacts with the CD2 (LFA-2) molecules. It is not known whether these costimulatory molecules perform equivalent functions or carry out specialized functions at specific stages of an induced immune response (2). These molecules have been individually shown to costimulate T-cell proliferation in vitro (6). However, because they may be expressed simultaneously on APC, it has been difficult to examine relative potencies of individual costimulatory molecules during the induction of T-cell proliferation (2).

[0003] As it has been proposed that both antigen and costimulatory molecules must be expressed in proximity to each other to properly co-engage the T cell and costimulatory receptors (8, 9), the admixture of several recombinant viruses could be utilized to explore the potential cooperation of costimulatory molecules. The disadvantage of this approach, however, is that the admixture of three or more viruses has a statistically diminished probability of co-infecting the same cell, thereby making a multi-gene construct much more desirable for use with three costimulatory molecule genes.

[0004] WO 91/02805, published March 7, 1991, discloses a recombinant retrovirus vector construct which directs the expression of a target antigen, an MHC protein and other proteins involved in immune interactions which are missing or under-represented in a target cell.

[0005] Akagi, et al. 1997, J. Immunotherapy Vol. 20 (1):38-47 disclose an admixture of a recombinant vaccinia virus containing a modified MUC1 gene (rV-MUC1), and a recombinant vaccinia virus containing the gene for the murine costimulatory molecule B7 (rV-B7).

[0006] Cavallo, P. et al. 1995, Eur. J. Immunol., 25:1154-1162 disclose that transfection of B7-1 cDNA into three ICAM-1⁺ tumor cell lines is sufficient to induce rejection in syngeneic mice.

[0007] Chen, L. et al. 1994, J. Exp. Med., 179:523-532 disclose a recombinant retrovirus vector containing cDNA for murine B7 and the use of the vector in transducing various tumors.

[0008] Damle, N.K. et al 1992, J. Immunol Vol 148 (No. 7): 1985-1992 disclose the use of an antigen presenting cell (APC)-independent in vitro culture system consisting of immobilized combinations of monoclonal antibodies directed at the TCR/CD3 complex and soluble Ig chimeras (RG) of four distinct APC - associated costimulatory molecules to compare the abilities of these molecules to costimulate T cell proliferation.

[0009] Dubey, C. et al 1995, J Immunol 155: 45-57 disclose a study of the relative contribution of ICAM-1: LFA-1 and B7: CD28/CTLA-4 costimulatory pathways in naïve T cell activation, using either anti-CD28 antibody or fibroblast cell lines transfected with I-E^k, which express either no costimulatory molecules, ICAM-1 alone, B7-1 alone, or ICAM-1 and B7-1 together.

[0010] Fenton, R.G. et al, 1998 Vol. 21, No. 2, pp 95-108, disclose transfection of the costimulatory molecule B7-1 gene into three HLA-A2-expressing human melanoma cell lines, and their capacity to stimulate primary human T cells. The three melanoma lines also expressed detectable levels of the costimulatory molecules ICAM-1 (CD54) and LFA-3 (CD58).

[0011] Gjorloff Wingren, A. et al 1995, Critical Reviews in Immunol 15 (3 & 4): 235-253 disclose that with co-transfection

of HLA-DR, B7 and LFA-3 into CHO cells, these molecules cooperate in activation of both naïve and memory T cells and allow responses at picomolar concentrations of the antigen, staphylococcal enterotoxin B (SEB).

[0012] Goldbach-Mansky, R. et al 1992, International Immunol. 4(No. 12): 1351-1360 disclose that CD4⁺ T cells respond to staphylococcal enterotoxin B (SEB) in the presence of the LFA-3, ICAM-1 and B7 positive erythroleukemic cell line K562, murine L cells, and human B7 transfected L cells.

[0013] Hodge, J.W. et al 1994, Cancer Research 54:5552-5555 disclose the construction and characterization of recombinant vaccinia viruses containing the murine B7.1 and B7.2 genes.

[0014] Hodge, J.W. et al 1995, Cancer Research 55: 3598-3603 Cancer Research 55:3598-3603 disclose an admixture of recombinant vaccinia murine B7.1 (rV-B7) plus recombinant vaccinia expressing the human carcinoembryonic antigen gene (rV-CEA) and the use of this admixture for anti-tumor activity.

[0015] Parra, et al 1993, Scand J. Immunol 38: 508-514, Parra, E. et al 1994, J. Immunol 153: 2479-2487, and Parra, et al. 1997, J. Immunol., 458:637-642 disclose CHO cells transfected with the human HLA-DR4 molecule (CHO-DR4); HLA-DR4 and B7 (CHO-DR4/B7), HLA-DR4 and LFA-3 (CHO-DR4/LFA3); HLA-DR4 and ICAM-1 (CHO-DR4/ICAM-I); or DR4, B7 and LFA-3 (CHO-DR4B7/LFA-3) genes.

[0016] Thomas, R. et al. 1993 J. Immunol. 151:6840-6852 disclose that freshly obtained dendritic cells (DC) express similar densities of HLA-DR and the accessory molecules LFA-3, ICAM-1 and B7 as monocytes.

[0017] Uzendoski, K et al. May 1997, Human Gene Therapy 8:851-860 disclose the construction, characterization and immunological consequences of a recombinant vaccinia virus expressing the murine costimulatory molecule, ICAM-1.

[0018] WO 96/10419, published April 11, 1996, of PCT/US95/12624 discloses subject matter relating to a single recombinant viral vector which has incorporated one or more genes or portion thereof encoding an immunostimulatory molecule and one or more genes or portion thereof encoding an antigen of a disease state.

[0019] Robinson et al U.S. Patent No. 5,738,852 discloses a retroviral vector containing a polynucleotide sequence encoding a target antigen of an infectious agent and a polynucleotide sequence encoding a B7 costimulatory molecule.

[0020] The present invention is a vector containing foreign DNA encoding at least three costimulatory molecules, alone or in combination with foreign DNA encoding at least one target antigen or immunological epitope thereof which allows functional expression of each foreign DNA in an infected host cell.

Summary of the Invention

[0021] The present invention provides a recombinant vector comprising foreign or exogenous genes or portions thereof encoding three costimulatory molecules. Genes or functional portions thereof encoding costimulatory molecules having utility in the present invention include but are not limited to a B7 family member, and ICAM-1, LFA-3, 4-1BBL, CD59, CD40, CD70, VCAM-1, OX-40L molecules, functional portions and human homologs thereof. The vector of the invention may further provide a foreign gene encoding at least one target antigen or immunological epitope thereof in combination with the foreign genes encoding three costimulatory molecules. The foreign gene encoding at least one target antigen or immunological epitope thereof may be derived from cells, tissues or organisms such as viruses, bacteria, protozoans, parasites, yeast, tumor cells, preneoplastic cells, hyperplastic cells, tissue specific cells, or synthetic antigens. The vector may further provide a foreign gene encoding at least one or a combination of cytokines, chemokines and flt-3L.

[0022] The recombinant vector for use in the present invention group consists of bacterial vectors, virus vectors, nucleic acid based vectors and the like. The recombinant virus vectors include but are not limited to poxvirus, adenovirus, herpes virus, alphavirus, retrovirus, picornavirus, iridovirus and the like. The poxvirus include but are not limited to the orthopox, avipox, suipox and capripox.

[0023] The present invention provides a recombinant virus comprising foreign genes or portions thereof encoding three costimulatory molecules for providing an enhanced immune response to a target cell, target antigen or immunological epitope thereof which is greater than a response provided by a recombinant virus comprising a foreign gene or genes encoding single or double costimulatory molecules. The recombinant virus of the invention may further provide a foreign gene encoding at least one target antigen or immunological epitope thereof in combination with the foreign genes encoding three costimulatory molecules. The recombinant virus may further provide a foreign gene encoding other classes of immunostimulatory molecules such as cytokines including but not limited to IL-2, IL-12, GM-CSF and the like, chemokines such as MIP1, MIP2, RANTES and the like, and Flt-3L which stimulates DC proliferation.

[0024] The present invention further provides a recombinant poxvirus comprising foreign genes or portions thereof encoding three costimulatory molecules for providing an enhanced immune response to a target cell, target antigen or immunological epitope thereof which is greater than a response provided by a recombinant poxvirus comprising a foreign gene or genes encoding single or double costimulatory molecules. The recombinant poxvirus of the invention may further provide a foreign gene encoding at least one target antigen or immunological epitope thereof in combination with the foreign genes encoding three costimulatory molecules.

[0025] The present invention also provides a recombinant poxvirus comprising a nucleic acid sequence encoding and

expressing three costimulatory molecules, said nucleic acid sequence comprising a nucleic acid sequence encoding at least one molecule from the B7 family of costimulatory molecules, a nucleic acid sequence encoding an ICAM-1 costimulatory molecule, and a nucleic acid sequence encoding an LFA-3 costimulatory molecule. The recombinant virus further provides a multiplicity of poxvirus promoters which regulate expression of each foreign gene.

[0026] The present invention provides a recombinant virus produced by allowing a plasmid vector comprising foreign DNA encoding the costimulatory molecules to undergo recombination with a parental virus genome to produce a recombinant virus having inserted into its genome the foreign DNA. The recombinant virus produced by recombination may further contain a foreign gene encoding at least one target antigen or immunological epitope thereof provided by the plasmid vector.

[0027] The present invention also provides a recombinant poxvirus produced by allowing a plasmid vector comprising foreign DNA encoding the costimulatory molecule, LFA-3, ICAM-1 and at least one molecule from the B7 family to undergo recombination with a parental poxvirus genome to produce a recombinant poxvirus having inserted into its genome the foreign DNA and a multiplicity of poxvirus promoters capable of controlling the expression of the foreign DNA. The recombinant poxvirus produced by recombination may further contain a foreign gene encoding at least one target antigen or immunological epitope thereof provided by the plasmid vector.

[0028] An object of the invention is to provide an immunogen for enhancement of immune responses against target cells, target antigens or immunological epitopes thereof comprising a recombinant vector having foreign nucleic acid sequences encoding three costimulatory molecules. The vector may further comprise a foreign nucleic acid sequence encoding at least one target antigen or immunological epitope thereof.

[0029] Another object of the invention is to provide an immunogen for enhancement of immune responses against target cells, target antigens or immunological epitopes thereof comprising a recombinant virus vector having foreign nucleic acid sequences encoding three costimulatory molecules. The recombinant virus vector may further comprise a foreign nucleic acid sequence encoding at least one or more target antigens or immunological epitopes thereof.

[0030] Yet another object of the invention is to provide an immunogen for enhancement of immune responses against target cells, target antigens or immunological epitopes thereof comprising a recombinant poxvirus vector comprising a foreign nucleic acid sequence encoding the costimulatory molecules LFA-3, ICAM-1 and one molecule from the B7 family and a foreign nucleic acid sequence encoding at least one target antigen or immunological epitope thereof.

[0031] The vector of the present invention provides a vaccine for eliciting and enhancing immune responses against target cells, target antigens or epitopes thereof for protection and/or treatment of disease states. The vector vaccine comprises foreign nucleic acid sequences encoding three costimulatory molecules. The vector vaccine may also comprise foreign nucleic acid sequences encoding one or more target antigens or immunological epitopes thereof for producing a monovalent or polyvalent vaccine against a disease.

[0032] The present invention provides pharmaceutical compositions comprising a vector having foreign nucleic acid sequences encoding three costimulatory molecules and a pharmaceutically acceptable carrier. The vector may further comprise a foreign nucleic acid sequence encoding at least one target antigen or immunological epitope thereof. The vector may additionally comprise a nucleic sequence encoding a cytokine, chemokine, flt-3L, or combination thereof.

[0033] The present invention provides a pharmaceutical composition comprising a recombinant virus vector which comprises foreign or exogenous genes or functional portions thereof encoding three costimulatory molecules, a foreign gene encoding at least one target antigen or immunological epitope thereof, and a pharmaceutically acceptable carrier.

[0034] The present invention also provides pharmaceutical compositions comprising a recombinant poxvirus comprising foreign genes or portions thereof encoding three costimulatory molecules and a pharmaceutically acceptable carrier. The recombinant poxvirus may further comprise a foreign nucleic acid sequence encoding at least one target antigen or immunological epitope thereof.

[0035] Another aspect of the invention is a pharmaceutical composition comprising a recombinant poxvirus comprising foreign genes or portions thereof encoding three costimulatory molecules, and may further comprise a foreign gene or portion thereof encoding at least one target antigen or immunological epitope thereof, and a pharmaceutically acceptable carrier or immunological epitope thereof.

[0036] The present invention also provides a pharmaceutical composition comprising a first vector comprising foreign genes or functional portions thereof encoding the costimulatory molecules and a second vector comprising foreign genes encoding at least one target antigen or immunological epitope thereof and a pharmaceutically acceptable carrier.

[0037] The present invention provides host cells infected, transfected or transduced with a first vector comprising foreign genes encoding three costimulatory molecules causing expression of the three costimulatory molecules in the host cells. The first vector or a second vector may further provide a foreign gene encoding at least one target antigen or immunological epitope thereof to the host cell.

[0038] The present invention provides antigen-presenting cells (APCs) or tumor cells infected, transfected or transduced with a first vector comprising foreign or exogenously provided genes encoding three costimulatory molecules causing expression or overexpression of the three costimulatory molecules. The first vector or a second vector may further provide a foreign gene encoding at least one target antigen or immunological epitope thereof to the host cell.

[0039] The present invention further provides host cells infected with a recombinant poxvirus causing expression of the three costimulatory molecules, and optionally causing expression of a target antigen or immunological epitope thereof.

[0040] Another aspect of the invention is a dendritic cell (DC) and precursor thereof infected, transfected or genetically engineered to overexpress genes encoding three exogenous costimulatory molecules. The DCs and precursors thereof

[0041] Yet another aspect of the invention is a DC and precursors thereof genetically engineered to overexpress genes encoding three exogenous costimulatory molecules. The DCs and precursor thereof may further be engineered to express foreign genes encoding at least one target antigen or immunological epitope thereof.

[0042] The present invention further provides a DC and precursors thereof genetically engineered to overexpress genes encoding a B7 molecule, ICAM-1 and LFA-3. The DCs and precursor thereof may further be engineered to express foreign genes encoding at least one target antigen or immunological epitope thereof.

[0043] The present invention provides methods and a plasmid vector for recombination with a parental virus designed to produce a recombinant virus capable of expressing foreign nucleic acid sequences encoding three costimulatory molecules comprising (a) a multiplicity of viral promoters, (b) the foreign nucleic acid sequences encoding the three costimulatory molecules, (c) DNA sequences flanking the constructs of elements (a) and (b), the flanking sequences at both the 5' and 3' ends being homologous to a region of a parental virus genome where elements (a) and (b) are to be inserted. The plasmid vector may further provide a foreign nucleic acid sequence encoding at least one target antigen or immunological epitope thereof. The plasmid vector may also provide a gene encoding a selectable marker.

[0044] The present invention also provides methods and a plasmid vector for recombination with a parental poxvirus designed to produce a recombinant poxvirus capable of expressing foreign nucleic acid sequences encoding the costimulatory molecules LFA-3, ICAM-1 and a B7 molecule which comprises (a) a multiplicity of poxviral promoters, (b) the foreign nucleic acid sequences encoding the LFA-3, ICAM-1 and a B7 molecule, (c) DNA sequences flanking the construct of elements (a) and (b), the flanking sequences at both 5' and 3' ends being homologous to a region of a parental poxvirus genome where elements (a) and (b) are to be inserted. The plasmid vector may further provide a foreign nucleic acid sequence encoding at least one target antigen or immunological epitope thereof. The plasmid vector may also provide a gene encoding a selectable marker.

[0045] One aspect of the invention is a method of enhancing immunological responses in a mammal to at least one target cell, target antigen or immunological epitope thereof comprising administration of a first vector comprising foreign nucleic acid sequences encoding three costimulatory molecules, each costimulatory molecule expressed in a cell in the mammal in an amount effective to enhance at least one immunological response in the mammal. Genes or functional portions thereof encoding costimulatory molecules having utility in the present invention include but are not limited to a B7 family member, ICAM-1, LFA-3, 4-1BBL, CD59, CD40, CD70, VCAM-1, OX-40L and homologs and portions thereof. A foreign nucleic acid sequence encoding at least one target antigen or immunological epitope thereof may further be provided in the method by the first vector or by a second vector.

[0046] In addition to genes or portion thereof encoding three costimulatory molecules, a foreign or exogenous nucleic acid sequence or functional portions thereof encoding at least one or a combination of other classes of immunostimulatory molecules may also be provided by the first vector, by the second vector, or by a third vector. Other classes of immunostimulatory molecules includes cytokines such as IL-2, IL-12, GM-CSF and the like, chemokines such as MIP1, MIP2, RANTES and the like and Flt-3L.

[0047] An aspect of the invention is a method of enhancing an antigen-specific T cell immune response in a mammal to a target cell, target antigen or immunological epitope thereof comprising administration of a foreign recombinant poxvirus comprising nucleic acid sequences encoding three costimulatory molecules LFA-3, ICAM-1 and B7 molecule, each costimulatory molecule expressed in a cell in the mammal in an amount effective to enhance at least one T-cell immune response in which the enhancement is greater than the additive sum of enhancement provided by administration of single or double costimulatory molecules.

[0048] In another method of enhancing immunological responses, APCs or tumor cells expressing foreign or exogenously provided genes encoding three costimulatory molecules are provided to a mammal in an effective amount to enhance immunological responses. The APC or tumor cell may further express foreign genes encoding at least one target antigen or immunological epitope thereof for enhancement of immune responses. A target antigen or immunological epitope thereof may be administered to the mammal prior to, concurrently with or subsequent to the administration of the APC or tumor cell. In addition, or alternatively, APCs or tumor cells are pulsed with at least one target antigen or immunological epitope thereof prior to administration to the mammal.

[0049] The present invention provides methods of enhancing humoral responses in a mammal to a target cell, target antigen or immunological epitope thereof comprising administration of a recombinant vector comprising foreign nucleic acid sequences encoding three costimulatory molecules to a mammal in an amount effective to enhance an humoral response. The vector may further comprise nucleic acid sequences encoding at least one target antigen or immunological epitope thereof. The invention further provides an isolated antibody or functional portion thereof against a target cell, target antigen or immunological epitope thereof produced by the method.

[0050] The present invention also provides antibody specific for a target antigen or immunological epitope thereof produced in response to administration of a recombinant poxvirus comprising foreign genes encoding B7, ICAM-1 and LFA-3 and genes encoding one or more target antigens or epitopes thereof.

Brief Description of the Drawings

[0051] These and other objects, features and many of the attendant advantages of the invention will be better understood upon a reading of the detailed description of the invention.

Figure 1. Genomic structure of plasmid pT5032 comprising nucleic acid sequences encoding murine LFA-3, ICAM-1 and B7.1, flanked by portions of the Hind III M region of the vaccinia genome.

Figure 2. Genomic structure of plasmid pT5047 comprising nucleic acid sequences encoding murine LFA-3, ICAM-1, B7.1, and the *lacZ* gene, flanked by portions of the Hind III J region of the vaccinia genome.

Figure 3. Genomic structure of plasmid pT5031 comprising nucleic acid sequences encoding murine LFA-3, ICAM-1 and B7.1 and a nucleic acid sequence encoding CEA, flanked by portions of the Hind III M region of the vaccinia genome.

Figures 4A through 4C. Genomic structure of recombinant vaccinia viruses expressing three murine costimulatory molecules with (Figure 4C) or without (Figures 4A and B) a tumor-associated antigen. Figure 4A shows the genomic structure of recombinant vaccinia, vT171. Figure 4B shows the genomic structure of recombinant vaccinia vT199. Figure 4C shows the genomic structure of recombinant vaccinia vT172. Hind III M and Hind III J are the sites of insertion in the poxvirus genomes of the foreign genes. Promoters 30K, 13; sE/L, 7.5K, 40K and C1 are poxviral promoters. Bam HI and Hind III restriction sites in the inserted sequences are shown, with the distance of each site (in kilobase pairs) from the 5' end of the insertion (0) listed above each site in parentheses (not drawn to scale).

Figure 5. Genomic structure of plasmid pT8001 comprising nucleic acid sequences encoding murine B7.1, LFA-3, ICAM-1 and the *lacZ* gene, flanked by portions of the BamHI J region of the fowlpox genome.

Figure 6. Genomic structure of plasmid pT5049 comprising a nucleic acid sequence encoding the tumor associated antigen, CEA, and murine B7.1, LFA-3, and ICAM-1, in combination with the *lacZ* gene, flanked by portions of the BamHI J region of the fowlpox genome.

Figures 7A through 7D. Genomic structure of recombinant fowlpox viruses expressing three murine costimulatory molecules with (Fig. 7B, 7C and 7D) or without (Fig. 7A) a tumor-associated antigen (TAA). Figure 7A shows the genomic structure of recombinant fowlpox vT222. Figure 7B shows the genomic structure of recombinant fowlpox vT194. Figure 7C shows the genomic structure of recombinant fowlpox expressing MUC-1, B7.1, ICAM-1 and LFA-3. Figure 7D shows the genomic structure of recombinant fowlpox expressing a tumor-associated antigen, B7.1, ICAM-1 and LFA-3. BamHI J is the site of insertion in the fowlpox virus genome of the foreign genes. sE/L, 13, 7.5K, C1, 40K and 30 K are poxviral promoters. P1-P5 denote five different poxvirus promoters. BamHI and HindIII restriction sites in the inserted sequences are shown, with the distance of each site (in kilobase pairs) from the 5' end of the insertion (0) listed above each site in parentheses (not drawn to scale).

Figure 8. Genomic structure of plasmid pT5064 comprising nucleic acid sequences encoding human LFA-3, human ICAM-1, human B7.1 and the *lacZ* gene, flanked by portions of the HindIII J region of the vaccinia genome.

Figures 9A through 9C Genomic structure of recombinant poxvirus expressing three human costimulatory molecules LFA-3, ICAM-1 and B7.1 along with the *lacZ* gene with (Figure 9B, C) or without (Figure 9A) a tumor associated antigen, HindIII J is the site of insertion in the vaccinia virus genome of the foreign genes. BamHI J is the site of insertion in the fowlpox virus genome. 30K, 13, sE/L, 40K and C1 are poxviral promoters. BglII and HindIII restriction sites in the inserted sequences are shown, with the distance of each site (in kilobase pairs) from the 5' end of the insertion (0) listed above each site in parentheses (not drawn to scale).

Figure 10. Genomic structure of plasmid pT8016 comprising nucleic acid sequences encoding CEA (6D) and human LFA-3, ICAM-1, B7.1, and the *E. coli lacZ* gene, flanked by portions of the HindIII J region of the vaccinia genome.

Figure 11. Genomic structure of recombinant vaccinia virus vT238 expressing CEA (6D) and three human costimulatory molecules. HindIII J is the site of insertion in the poxvirus genome of the foreign genes. 40K, 30K, 13, sE/L, and C1 are poxviral promoters.

Figure 12. Genomic structure of plasmid pT8019 comprising nucleic acid sequences encoding murine LFA-3, ICAM-1, B7.1, and the *E. coli lacZ* gene, flanked by portions of the BamHI J region of the fowlpox genome.

Figure 13A and 13B. Genomic structure of recombinant fowlpox viruses expressing murine or human costimulatory molecules. Figure 13A shows the genomic structure of recombinant fowlpox vT251. Figure 13B shows the genomic structure of recombinant fowlpox vT232. BamHI J is the site of insertion in the poxvirus genome of the foreign genes. 30K, 13, sE/L and C 1 are poxviral promoters.

Figure 14. Genomic structure of plasmid pT5072 comprising nucleic acid sequences encoding human LFA-3, ICAM-1, B7.1, and the *E. coli lacZ* gene, flanked by portions of the BamHI J region of the fowlpox genome.

Figure 15. Genomic structure of plasmid pT8020 comprising nucleic acid sequences encoding MUC-1, murine LFA-3, ICAM-1, B7.1, and the *E. coli lacZ* gene, flanked by portions of the BamHI J region of the fowlpox genome.

Figure 16A through 16D. Genomic structure of recombinant fowlpox viruses expressing murine or human costimulatory molecules with at least one tumor-associated antigen. Figure 16A shows the genomic structure of recombinant fowlpox vT250. Figure 16B shows the genomic structure of recombinant fowlpox vT242. Figure 16C shows the genomic structure of recombinant fowlpox vT236. Figure 16D shows the genomic structure of recombinant fowlpox vT257. BamHI J is the site of insertion in the poxvirus genome of the foreign genes. 40K, 7.5K, 30K, 13, sE/L, and C1 are poxviral promoters.

Figure 17. Genomic structure of plasmid pT2186 comprising nucleic acid sequences encoding MUC-1, human LFA-3, ICAM-1, B7.1, and the *E. coli lacZ* gene, flanked by portions of the BamHI J region of the fowlpox genome.

Figure 18. Genomic structure of plasmid pT2187 comprising nucleic acid sequences encoding CEA (6D), human LFA-3, ICAM-1, B7.1, and the *E. coli lacZ* gene, flanked by portions of the BamHI J region of the fowlpox genome.

Figure 19. Genomic structure of plasmid pT5080 comprising nucleic acid sequences encoding PSA, PSMA, human LFA-3, ICAM-1, B7.1, and the *E. coli lacZ* gene, flanked by portions of the BamHI J region of the fowlpox genome.

Figure 20. Genomic structure of plasmid pT5085 comprising nucleic acid sequences encoding murine LFA-3, ICAM-1, B7.1, and the *E. coli lacZ* gene, flanked by portions of the deletion III region of the MVA genome.

Figures 21A and 21B. Genomic structure of recombinant MVA viruses expressing murine or human costimulatory molecules with or without tumor-associated antigens. Figure 21 A shows the genomic structure of recombinant MVA vT264. Figure 21 B shows the genomic structure of recombinant MVA vT260. Deletion III is the site of insertion in the poxvirus genome of the foreign genes. 40K, 7.5K, 30K, I3, sE/L, and C1 are poxviral promoters.

Figure 22. Genomic structure of plasmid pT5084 comprising nucleic acid sequences encoding PSA, PSMA, human LFA-3, ICAM-1, B7.1, and the *E. coli lacZ* gene, flanked by portions of the deletion III region of the MVA genome.

Figure 23. Costimulatory molecule surface expression following infection with recombinant viruses. MC38 tumor cells were infected for 5 hours at 5 MOI (multiplicity of infection; pfu/cell) with the indicated virus. After infection, cells were immunostained with FITC-labeled monoclonal antibodies (MAb) specific for the costimulatory molecule. Shaded areas are fluorescence intensity of the specific MAb while unshaded areas are the fluorescence intensity of the appropriate isotype control antibody (see Materials and Methods).

Figures 24A and 24B. Effect of multiple costimulatory molecules on T-cell proliferation. Naive murine T cells, in the presence of varying concentrations of Con A to provide the first signal, were co-cultured with MC38 stimulator cells infected with either recombinant vaccinia (Figure 24A) or recombinant fowlpox (Figure 24B) vectors. Recombinant vectors were wild-type (i.e., V-Wyeth or WT-FP [open squares]), rV-LFA-3 (closed triangle), rV-ICAM-1 or rF-ICAM-1 (closed circles), rV-B7-1 or rF-B7-1 (closed diamonds), and rV-B7-1/ICAM-1/LFA-3 or rF-CEA/B7-1/ICAM-1/LFA-3 (closed squares). Uninfected MC38 cells are open circles. Proliferation assay is as described in Materials and Methods.

Figures 25A through 25D. Specificity of costimulation delivered via recombinant vaccinia viruses. T cells, in the presence of Con A, were co-cultured with MC38 stimulator cells infected with V-Wyeth (Figure 25A), rV-B7-1 (Figure 25B), rV-ICAM-1 (Figure 25C), and rV-LFA-3 (Figure 25D), as denoted by open circles. Infected stimulator cells in the presence of costimulatory molecule-specific MAb are denoted by closed circles, and isotype control antibody is denoted by closed triangles.

Figure 26. Relative capacity of B7-1, ICAM-1, LFA-3 and the coexpression of all three costimulatory molecules to deliver the second signal for T-cell proliferation. In the presence of Con A (2.5 μ g/ml), 100,000 T cells were co-cultured with 10,000 MC38 cells. The stimulator MC38 cells expressing one or all of the costimulatory molecules were added to the wells in various ratios in combination with V-Wyeth-infected stimulator cells to a total of 10^4 MC38 cells/well. MC38 cells were infected with V-Wyeth (open square), rV-LFA-3 (closed triangles), rV-ICAM-1 (closed circles), rV-B7-1 (closed diamonds), or rV-B7-1-ICAM-1-LFA-3 (closed squares). Cells were co-cultured for 48 hours. During the final 18 hours, 3 H-Thymidine was added to measure T-cell proliferation. Inset panel depicts proliferation values obtained from a culture in which 3% of the MC38 stimulator cells were infected with the vectors shown. Thus, in this experiment, the final ratio of stimulator cells to T cells was 0.003. Note the relatively poor effect of rVB7.1/ICAM under these conditions as compared to rV-B7/ICAM/LFA-3.

Figures 27A through 27D. Effect of costimulation on specific T-cell populations. Murine CD4⁺ (Figure 27A) or CD8⁺ T cells (Figure 27B) were co-cultured with uninfected MC38 cells (open circle), or cells infected with V-Wyeth (open squares), rV-LFA-3 (closed triangles), rV-ICAM-1 (closed circles), rV-B7-1 (closed diamonds) or rV-B7-1/ICAM-1/LFA-3 (closed squares) at a 10:1 ratio for 48 hours in the presence of various concentrations of Con. A. During the final 18 hours, 3 H-Thymidine was added to measure T-cell proliferation. Figures 27C and 27D show the proliferative responses of purified CD4⁺ and CD8⁺ cells, respectively, when co-cultured in the presence of vector-infected MC38 stimulator cells at a low Con A concentration (0.625 μ g/ml).

Figures 28A through 28D. Effect of costimulation on cytokine production. Murine CD4⁺ (Figures 28A and 28C) or CD8⁺ (Figures 28B and 28D) T cells were purified as described in Materials and Methods and co-cultured with

the indicated MC38 vector-infected stimulator cells for 24 hours in the presence of 2.5 $\mu\text{g/ml}$ Con A. Supernatant fluids were analyzed for production of IL-2 (Figures 28A and 28B) and IFN- γ (Figures 28C and 28D) by capture ELISA. Figures 29A through 29C. Effect of costimulation on cytokine RNA expression. Figure 29A: murine CD4⁺ or CD8⁺ T cells were co-cultured with MC38 stimulator cells infected with V-Wyeth (lane A), rV-B7-1 (lane B), rV-ICAM-1 (lane C), rV-LFA-3 (lane D) or rV-B7-1/ICAM-1/LFA-3 (lane E) at a T- cell to stimulator cell ratio of 10:1 for 24 hours in the presence of 2.5 $\mu\text{g/ml}$ Con A. Following culture, T-cell RNA was analyzed by multiprobe RNase protection assay. The quantitative representation of results from the autoradiograph is normalized for expression of the house-keeping gene L32 in Figure 29B (CD4⁺ cells) and Figure 29C (CD8⁺ cells). Order of histogram bars (from left to right) is MC38/V-Wyeth, MC38/B7-1, MC38/ICAM-1, MC38/LFA-3, and MC38B7-1/ICAM-1/LFA-3.

Figure 30. C57BL/6 mice (5/group) were administered HBSS (closed squares) or vaccinated with 10⁷ pfu rV-CEA (closed triangles) or rV-CEA/TRICOM (closed circle). One hundred days later, mice were inoculated with 1 x 10⁶ MC38 carcinoma cells expressing CEA and survival was monitored. All mice other than the rV-CEA/TRICOM group developed tumors and were sacrificed when tumors exceeded 20 mm in length or width, or when the mice were moribund. Figure 30: In a second experiment, C57BL/6 mice (5/group) were vaccinated with 10⁷ pfu rV-CEA, rV-CEAB7.1, rV-CEA/TRICOM or HBSS buffer. Lymphoproliferative responses from pooled splenic T cells were analyzed 22 days following vaccination. Values represent the stimulation index of the mean cpm of triplicate samples vs. media. Standard deviation never exceeded 10%. Antigens used were Con A (5 $\mu\text{g/ml}$), CEA (100 $\mu\text{g/ml}$) and ovalbumin (100 $\mu\text{g/ml}$)

Figure 31 shows a schematic of an *in vitro* costimulation assay of dendritic cells.

Figures 32A and 32B show the proliferative response of naive CD4⁺ (Figure 32A) or naive CD8⁺ (Figure 32B) T cells stimulated with progenitor DCs infected with rV-B7/ICAM-1/LFA-3 or DCs (noninfected, ie, CD 34⁺ cells treated with GM-CSF + IL-4 for 6 days) in the presence of Con A.

Figures 33A and 33B show the proliferative response of naive CD4⁺ (Figure 33A) or naive CD8⁺ (Figure 33B) T cells stimulated with progenitor DCs infected with rV-B7/ICAM-1/LFA-3 or DCs infected with rV-B7/ICAM-1/LFA-3 or V-Wyeth (control).

Figure 34 shows the mixed lymphocyte reaction (MLR) of Balb/C splenocytes vs. irradiated C57bl/6 dendritic cells infected with 25 MOI of V-Wyeth or rV-TRICOM. ³H-thymidine pulsed on day 3, harvest on day 4, □ DC (uninfected), ■ DC (V-Wyeth infected), □ DC (rV-TRICOM infected).

Figure 35 shows the proliferative response of responder T cells (CAP-M8 T-cell line specific for CEA peptide 8) at various APC ratios harvested on day 5 after stimulation with peptide-pulsed DCs infected with rV-TRICOM and rested 2 days with 10 u/ml IL2 (no APC or peptide). Peptide 8 - (EAQNTTYL) in assay at 1 $\mu\text{g/ml}$ final concentration. ³H-thymidine added on day 2, T cells harvested on day 3. 0=DC(V-Wyeth) - pep and Δ = DC (rV-TRICOM) - pep results are at baseline.

Figures 36A and 36B. Efficiency of poxviral infection of murine dendritic cells (DC). DC were infected with 25 MOI rV-TRICOM or 50 MOI rF CEA/TRICOM for 5h. DC infected with TRICOM vectors exhibit enhanced capacity to stimulate naive T-cells. All DC populations were co-cultured for 48h with T-cells at a ratio of 10:1 in the presence of different concentrations of Con A to provide signal-1. ³H-thymidine was added during the final 18h. Figure 36A: Uninfected DC (closed squares), mock-infected DC (closed diamonds), or DC infected with V-WT (closed inverse triangles), rV-B7.1 (open triangles) or rV-TRICOM (open circles). Figure 36B: DC (closed squares), mock-infected DC (closed diamonds), or DC infected with WT-FP (closed inverse triangles), rF-B7.1 (open triangles) or rF-TRICOM (open circles).

Figures 37A through 37F. Enhanced allostimulatory activity by DC infected with vaccinia (Figures 37 A, C, E) or fowlpox (Figures 37 B, D, F) vectors. Uninfected DC (closed squares); mock-infected DC (closed diamonds); or DC infected with wild-type poxviral vectors (V-WT or F-WT, closed inverse triangles), rV-B7.2 or rF-B7.1 (open triangles), or rV-TRICOM or rF-TRICOM (open circles) were co-cultured with allogeneic (Figures 37A-D) or syngeneic T cells (Figures 37E-F) for 5 days. ³H-thymidine was added during the final 18h.

Figures 38A through 38F. Effect of vaccinia infection of DC on peptide-specific T-cell proliferation. Uninfected DC (closed squares), or DC infected with V-WT (closed inverse triangles), rV-B7.1 (open triangles) or rV-TRICOM (open circles) were co-cultured with OVA peptide-specific T cells (Figures 38A, C, E) or CAP-M8 peptide-specific T cells (Figures 38 B, D, F). Experimental conditions included a fixed effector:stimulator cell ration of 10:1 in the presence of various concentrations of the appropriate peptides (Figure 38A-D), negative control peptides (open squares, either VSVN (Figure 38A), or FLU-NP (Figure 38B), or a fixed peptide concentration of 1 μM in the presence of various effector:stimulator cell ratios (Figures 38E and F).

Figures 39A and 39B. Effect of rV-TRICOM infection with DC matured with TNF- α or CD40. DC (closed squares), or DC cultured with either 100 ng/ml TNF- α (open triangles), or 5 $\mu\text{g/ml}$ CD40 mAb (open circles) for the final 24h of culture were used to stimulate CAP-M8-specific effector T cells (Figure 39A). The proliferation of CAP-M8 T cells in response to these DC populations after infection with 25 MOI rV-TRICOM (Figure 39B). For all panels, the T-cell: DC ratio was 10:1, while the CAP-M8 peptide concentration was 1 $\mu\text{g/ml}$. Closed circles denote proliferation of CAP-

M8 T cells stimulated with all DC populations in the presence of 1 μ g/ml VSVN peptide.

Figures 40A through 40H: Effect of vaccinia infection of DC on induction of CTL activity. DC (Figure 40B), or DC infected with V-WT (Figure 40C), or rV-TRICOM (Figure 40D) were pulsed with 10 μ M OVA peptide for 2h. DC populations were administered intravenously to mice (1 x 10⁵ cells/mouse). Control mice were immunized subcutaneously with 100 μ g OVA peptide in Ribi/Detox adjuvant (Figure 40A). Fourteen days later spleens were harvested, restimulated for 6 days with the corresponding peptide, and assessed for lytic ability against EL-4 cells pulsed with either OVA (closed squares) or VSVN peptides (open squares). Inset numbers depict CTL activity as expressed in lytic units. Also shown is the effect of vaccinia infection of DC on induction of CTL activity. DC (Figure 40F), or DC infected with V-WT (Figure 40G), or rV-TRICOM (Figure 40H) were pulsed with 10 μ M CAP-M8 peptide for 2h. DC populations were administered intravenously to mice (1 x 10⁵ cells/mouse). Control mice were immunized subcutaneously with 100 μ g CAP-M8 peptide in Ribi/Detox adjuvant (Figure 40E). Fourteen days later spleens were harvested, restimulated for 6 days with the corresponding peptide, and assessed for lytic ability against EL-4 cells pulsed with either CAP-M8 (closed squares) or FLU-NP peptides (open squares). Inset numbers depict CTL activity as expressed in lytic units.

Figures 41A through 41C: Effect of multiple immunizations with vaccinia-infected DC on induction of CTL activity. DC (closed squares), or DC infected with V-WT (closed inverse triangles) or rV-TRICOM (open circles) were pulsed with 10 μ M CAP-M8 peptide for 2h. DC populations were administered intravenously to mice (1 x 10⁵ cells/mouse) 1, 2 or 3 times at 7 day intervals. Control mice were immunized subcutaneously with 100 μ g CAP-M8 peptide in Ribi/Detox adjuvant (crosses). Fourteen days after the final immunization, spleens were harvested, restimulated for 6 days with CAP-M8, and assessed for lytic ability against EL-4 cells pulsed with CAP-M8 or control peptide VSVN (not shown).

Figures 42A and 42B. Effect of vaccinia and fowlpox TRICOM-infected splenocytes on T cell proliferation. Naïve murine T cells were co-cultured with autologous splenocytes infected with either recombinant vaccinia or fowlpox vectors. Co-culture was performed in varying concentrations of Con-A as Signal-1. Recombinant vectors were wild type (i.e. V-WT, FP-WT, open diamond), rV-B7-1 or rF-B7-1, (open circles) or rV-TRICOM or rF-TRICOM (closed squares). Uninfected splenocytes are shown as open triangles.

Figures 43A through 43D. Effect of TRICOM vector infected splenocytes on allogeneic T cells. Naïve Balb/C T cells were co-cultured with C57B 1/6 splenocytes infected with recombinant vaccinia (Figure 43A and C) or fowlpox (Figures 43B and D) vectors for either 2 days (Figures 43A and B) or 5 days (Figure 43C and 43D). Recombinant vectors were V-WT or FP-WT, open-diamonds, rV-B7-1 or rF-B7-1 (open circles), or rV-TRICOM or rF-TRICOM (closed squares). Uninfected splenocytes are indicated as open triangles. Proliferation induced by DC is indicated as closed squares.

Figures 44A through 44F. Effect of rV-TRICOM-infected splenocytes on specific T cell populations. Naïve murine T cells were fractionated with CD3⁺, CD4⁺, and CD8⁺ subpopulations. T cells were co-cultured with either uninfected autologous BMDC or splenocytes infected with recombinant vaccinia vectors. Varying Con-A concentrations (Figures 44A-C) or varying number of stimulator cells (Figure 44D-F) provided the first signal. T cell proliferation in response to mature BMDC is indicated by open squares, and to uninfected splenocytes by open triangles. Recombinant vectors were wild-type (V-WT, open diamonds) or rV-TRICOM (closed squares).

Figures 45A through 45F. Effect of rV-TRICOM-infected bone marrow cells on specific T cell populations. Naïve murine T cells were fractionated into CD3⁺, CD4⁺, and CD8⁺ subpopulations. T cells were co-cultured with either uninfected autologous BMDC or splenocytes infected with recombinant vaccinia vectors. Varying Con-A concentrations (Figure 45A-C) or varying number of stimulator cells (Figure 45D-F) provided the first signal. T cell proliferation in response to mature BMDC is indicated by open squares, and to uninfected splenocytes by open triangles. Recombinant vectors were wild-type (V-WT, open diamonds) or rV-TRICOM (closed squares).

Figures 46A through 46D. Effect of rV-TRICOM-infected splenocytes or bone marrow (BM) cells on peptide-specific memory CD8⁺ T cells. CAP-M8-specific T cells were co-cultured with autologous splenocytes (Figures 46A and B) or bone marrow cells (Figures 46C and D) infected with recombinant vaccinia vectors. The analysis was carried out using two sets of conditions: a) a 10:1 fixed ratio of responder: stimulator cells that were cultured in the presence of several concentrations of CAP-M8 peptide (Figures 46A and 46C), or b) a fixed concentration of peptide (1 μ M) at various responder:stimulator ratios (Figures 46B and 46D). Recombinant vectors were wild type (open diamonds), and rV-TRICOM (closed squares). Uninfected splenocytes are shown as open triangles. BM are shown as open squares.

Figure 47. Shows production of IFN- γ by human T cells isolated from peripheral blood mononuclear cells (PBMC) using rF-TRICOM-infected human dendritic cells pulsed with CEA peptides, CAP-1 or CAP1, 6D.

Figure 48. Shows production of IFN- γ by human T cells using rF-TRICOM-infected human dendritic cells pulsed with PSA peptide, PSA-3.

Figure 49. Shows production of IFN- γ by human T cells isolated from PBMC using rF-TRICOM-infected human dendritic cells pulsed with Flu peptide 58-66.

Figure 50. Shows production of IFN- γ by human T cells isolated from PBMC using rF-TRICOM-or rF-B7.1-infected human dendritic cells pulsed with Flu peptide 58-66 at various effector:APC ratios.

Figure 51. Shows production of IFN- γ by human T cells from donor 868 using rF-TRICOM-infected human dendritic cells pulsed with HPV peptide (11-20) after one or two *in vitro* stimulation (IVS).

Figure 52. Shows production of IFN- γ by human T cell line using rF-TRICOM-or rF-B7.1-infected human dendritic cells pulsed with HPV peptide (11-20).

Figure 53. Shows production of IFN- γ by a human T cell line using rF-TRICOM-or rF-B7.1-infected human dendritic cells pulsed with various concentrations of HPV peptide (11-20).

Figure 54. Shows production of IFN- γ by human T cells using rF-TRICOM or rF-B7.1-infected human dendritic cells pulsed with HPV E7 peptide 11-20 at various effector:APC ratios.

Detailed Description of the Invention

[0052] The present invention is a recombinant vector comprising foreign genes encoding three costimulatory molecules, in combination, or the functionally active portions of each costimulatory molecule.

[0053] As used herein a functionally active portion is that portion of the molecule responsible for binding to its respective ligand, triggering an appropriate costimulatory signal for immune-cell activation. One method of determining functional activity is to assess the induction of naive T-cell proliferation by delivering the costimulatory molecule to a target cell *in vitro* as described herein. A functional portion of a costimulatory molecule stimulates at least 20% increase in T cell proliferation.

[0054] The term foreign gene or foreign nucleic acid sequence or functional portion thereof as used herein is a gene, nucleic acid sequence or functional portion thereof that is exogenously provided by a recombinant vector to a host cell or organism. The exogenous gene or portion thereof which is provided to the host cell or host organism may be one which is not endogenously present in the host cell or organism or may be endogenously present and functional or non-functional. In the case in which a functional endogenous gene is present in the host cell or organism, the foreign or exogenously provided gene or functional portion thereof results in overexpression of the gene product.

[0055] The recombinant vectors of the present invention have utility in providing enhanced immunological response to cells of the immune system including but not limited to T lymphocytes, B lymphocytes, NK cells, antigen-presenting cells (APCs) and the like. The enhancement of the immunological response using the recombinant vectors expressing three costimulatory molecules is synergistic as compared to the use of a single costimulatory molecule or the use of two costimulatory molecules in enhancing immunological responses. The immunological response may be a cellular and/or humoral immune response and may be directed to a specific target antigen or epitope thereof or may be a generalized immune enhancing or upregulating effect as demonstrated by increased cytokine release, increase proliferation by immune cells, increased mitogen responsiveness and the like. The enhancement in an immune response preferably includes hyperstimulation or high intensity T cell stimulation (HITS) as a result of stimulation using the recombinant vectors of the present invention or cells transfected, transduced or induced by the recombinant vector of the present invention.

[0056] The foreign genes encoding the costimulatory molecules may be obtained from a variety of sources. The selection of the source of foreign genes encoding the costimulatory molecules may depend on the species to be immunized or treated using the recombinant vector.

[0057] The foreign genes encoding the costimulatory molecules may be murine-derived, human-derived, simian-derived, and may be chemically synthesized based on mammalian genes. The foreign genes encoding the costimulatory molecules may also be avian-derived or chemically synthesized based on avian costimulatory molecule genes. The recombinant vectors of the present invention are useful as immunogens and as vaccines in stimulating an enhancement of immunological responses to target cells, target antigens and immunological epitopes thereof. Such level of enhancement of a immune response using the present recombinant vectors comprising genes encoding three costimulatory molecules has not been obtainable using a single or double costimulatory molecule.

[0058] Genes or functional portions thereof encoding costimulatory molecules having utility in the present invention include but are not limited to B7.1, B7.2, ICAM-1, LFA-3, 4-1BBL, CD59, CD40, CD70, VCAM-1, OX-40L, mammalian homologs and the like. The recombinant vector of the present invention comprises genes encoding three costimulatory molecules for synergistic enhancement of immune responses which is not obtainable by the use of a single or a double costimulatory molecule. Genes encoding various combinations of costimulatory molecules are an ambit of the invention for use in the recombinant vector and may include such combinations as B7.1, or B7.2, ICAM-1, LFA-3; B7.1, or B7.2, ICAM-1, LFA-3; B7.1, or B7.2, ICAM-1, 4-1BBL; B7.1, or B7.2, ICAM-1, LFA-3, 4-1BBL; CD59, VCAM-1; and B7.1, or B7.2; CD59, CD40, 4-1BBL, CD70 and VCAM-1, B7.1, or B7.2; OX-40L, 4-1BBL; and the like depending on the desired immune response and the disease or condition to be treated. Based on the dramatic synergistic immune responses achieved using a recombinant vector encoding three costimulatory molecules as compared to the use of a recombinant vector encoding one or two costimulatory molecules, a recombinant vector encoding four, five or more costimulatory

molecules will result in a synergistic immune response or immune response equal to/or greater than that using a recombinant vector encoding three costimulatory molecules.

[0059] B7 represents a family of costimulatory molecules which are members of the Ig gene superfamily. The members include murine B7.1 (CD80) and B7.2 (CD86). B7.1 and B7.2 are the natural ligands of CD28/CTLA-4 (CD152). The gene sequence of murine B7.1 is disclosed in Freeman et al (J. Immunol. 143:2714-2722, 1989) and in GENBANK under Accession No. X60958. The gene sequence of murine B7.2 is disclosed in Azuma et al (Nature 366:76-79, 1993) and in GENBANK under Accession No. L25606 and MUSB72X.

[0060] The human homologs of the murine B7 costimulatory molecules and functional portions thereof are an ambit of the present invention and have particular utility in recombinant vectors for human clinical use. The human homolog of the murine B7 costimulatory molecules include CD80, the homolog of murine B7.1, and CD86, the homolog of B7.2. The gene sequence of human B7.1 (CD80) is disclosed in GENBANK under Accession No. M27533, and the gene sequence of human B7.2 (CD86) is disclosed under Accession No. U04343 and AF099105. A license may be required to practice this invention.

[0061] For use in the present invention, a recombinant vector may contain a foreign nucleic acid sequence encoding molecule from the B7 costimulatory molecule family, or a combination of B7 costimulatory molecules or functional portions thereof in addition to other costimulatory molecules. The combination of B7 costimulatory molecules includes but is not limited to two or more B7.1 molecules, two or more B7.2 molecules, B7.1 and B7.2 and the like. In one embodiment the recombinant vector contains a foreign nucleic acid sequence encoding the B7.1 molecule in combination with foreign nucleic acid sequences encoding LFA-3 and ICAM-1.

[0062] Intercellular adhesion molecule-1 (murine ICAM-1, CD54) and the human homolog, CD54, also acts as a costimulatory molecule. Its ligand is leukocyte function-associated antigen-1 (LFA-1, CD11a/CD18) which is expressed on the surface of lymphocytes and granulocytes. The gene for murine ICAM-1 is disclosed in GenBank under Accession No. X52264 and the gene for the human ICAM-1 homolog, (CD54), is disclosed in Accession No. J03132. In one embodiment, the recombinant vector of the present invention contains a foreign nucleic acid sequence encoding at least one murine ICAM-1 molecule, human homolog, other mammalian homolog or functional portion thereof in addition to foreign nucleic acid sequences encoding two or more additional costimulatory molecules.

[0063] The costimulatory molecule leukocyte function antigen 3, murine LFA-3 and its human homolog LFA-3 (CD58), a glycosyl-phosphatidylinositol-linked glycoprotein, is a member of the CD2 family within the immunoglobulin gene superfamily. The natural ligand of LFA-3 is CD2 (LFA-2) which is expressed on thymocytes, T cells, B cells and NK cells. The gene for murine LFA-3 is disclosed in GenBank under Accession No. X53526 and the gene for the human homolog is disclosed in Accession No. Y00636.

[0064] The T cell antigen 4-1BBL is a costimulatory molecule that relays costimulatory signals in antigen-stimulated primary T cell cultures and in lectin-driven activation of thymocytes (Hurtado, J.C. et al J. Immunol. 158(6):2600-2609, 1997). 4-1BBL belongs to the tumor necrosis factor receptor superfamily, a group of cysteine-rich cell surface molecules (Vinay, D.S. et al, Seminars in Immunology, 1998, Vol. 10, pp. 481-489). The gene for the murine 4-1BBL is disclosed in GenBank under Accession No. U02567. The gene for the human homolog, hu4-1BBL is disclosed in GenBank under Accession No. U03397.

[0065] OX-40L is a type II membrane protein with limited homology to TNF and is stimulatory to OX-40⁺ T cells *in vitro*. The murine and human OX-40L cDNAs have 68% homology at the nucleotide level and 46% at the amino acid level. Human OX-40L stimulates human T cells exclusively, while murine OX-40L stimulates both human and mouse T cells. APC express OX-40L and can transmit the OX-40L: OX40R signal during presentation of antigen to CD4⁺ T cells. OX-40L signaling is important for differentiation of human dendritic cells and leads to increased production of IL-12, TNF- α , IL-1B, and IL-6. (Weinberg, A.D. et al 1998 Seminars in Immunology, Vol. 10:471-480). OX-40L is a potent costimulatory molecule for sustaining primary CD4⁺ T cell responses, used in combination with B7-1 (Gramaglia, I. et al 1998 J. Immunology, Vol. 161:6510-7).

[0066] Vectors having utility in the present invention are capable of causing expression of at least three or more foreign genes, preferably five or more foreign genes. Vectors having utility in the present invention include any vector capable of causing functional expression of three foreign costimulatory molecules gene products in a host cell. In addition to the genes encoding three costimulatory molecules, the vector is also capable of causing the expression of at least one foreign gene encoding at least one target antigen or immunological epitope thereof as well as a selectable marker.

[0067] Vectors of the present invention include but are not limited to bacterial vectors such as Salmonella, viral vectors, nucleic acid based vectors and the like. Viral vectors include but are not limited to poxvirus, Herpes virus, adenovirus, alphavirus, retrovirus, picornavirus, iridovirus, and the like. Poxviruses having utility in the present invention include replicating and non-replicating vectors. Such poxviruses include but are not limited to orthopox such as vaccinia, raccoon pox, rabbit pox and the like, avipox, suipox, capripox and the like. Poxviruses may be selected from the group consisting of vaccinia-Copenhagen, vaccinia-Wyeth strain, vaccinia-MVA strain, NYVAC, fowlpox, TROVAC, canarypox, ALVAC, swinepox, and the like. In one embodiment, the recombinant vector is a vaccinia virus. In another embodiment, the recombinant vector is fowlpox.

[0068] A preferred vector of the present invention is a recombinant virus, preferably a poxvirus. The recombinant poxviruses having utility in the present invention have a number of attributes, including (i) efficient delivery of genes to three cell types, including APC and tumor cells; (ii) high levels of protein expression; (iii) optimal presentation of antigens to the immune system; (iv) the ability to elicit cell-mediated immune responses as well as antibody responses; (v) transient, rather than permanent, genetic modification of cells, and (vi) the ability to use combinations of poxviruses from different genera, as they are not immunologically cross-reactive. Parental poxviruses useful in constructing the recombinant poxvirus of the present invention include but are not limited to orthopox virus such as replicating vaccinia virus (Perkus et al Science 229:981-984, 1985; Kaufman et al Int. J. Cancer 48:900-907, 1991, Moss Science 252:1662, 1991), highly attenuated vaccinia viruses such as MVA, modified vaccinia Ankara (Sutter and Moss, Proc. Nat'l Acad. Sci. U.S.A. 89:10847-10851; Sutter et al Virology 1994), vaccinia-Copenhagen and NYVAC: avipoxviruses (15) such as fowlpox virus (15), canary poxviruses, such as ALVAC and the like (Baxby and Paoletti, Vaccine 10:8-9, 1992; Rinns, M.M. et al (Eds) Recombinant Poxviruses CRC Press, Inc, Boca Raton 1992; Paoletti, E. Proc. Nat'l Acad. Sci. USA 93:11349-11353, 1996), and suipoxvirus, capripoxvirus and the like.

[0069] In one embodiment, the parental poxvirus is a vaccinia virus. In a particular embodiment, the vaccinia virus is a Wyeth strain or derivative thereof. A derivative of the Wyeth strain includes but is not limited to vTBC33 which lacks a functional K1L gene and the like. In yet another embodiment, the virus is Dry-Vax available as a smallpox vaccine from the Centers for Disease Control, Atlanta, GA. In another embodiment, the parental poxvirus is a strain of fowlpox, for example POXVAC-TC (Schering-Plough Corporation), and the like.

[0070] The recombinant vector of the present invention is able to infect, transfect or transduce host cells in a host. The host includes but is not limited to mammals, birds, fish and the like. The host cells are any cell amenable to infection, transfection or transduction by the recombinant vector and capable of expressing the foreign genes from the recombinant vector at functional levels. The host cells include but are not limited to professional APC and antigen presenting precursor cells such as monocytes, macrophages, DC, Langerhans cells and the like. The recombinant vector of the present invention may also infect tumor cells or other cell types such as fibroblasts or muscle cells. Infection of the host cells allows expression of each foreign, exogenous costimulatory molecule and expression of the foreign nucleic acid sequence encoding target antigen(s) if present in the recombinant vector. The host cells express, or are engineered to express, the appropriate MHC (HLA) Class I or II molecules for appropriate antigenic presentation to CD4⁺ and/or CD8⁺ T cells. As such virtually any mammalian cell may be engineered to become an appropriate antigen presenting cell expressing three costimulatory molecules.

[0071] The recombinant vector of the present invention comprises at least one expression control element operably linked to the nucleic acid sequence. The expression control elements are inserted in the vector to control and regulate the expression of the nucleic acid sequence (Ausubel et al, 1987, in "Current Protocols in Molecular Biology, John Wiley and Sons, New York, New York). Expression control elements are known in the art and include promoters. Promoters useful in the present invention are poxviral promoters as are known in the art which include but are not limited to 30K, I3, sE/L, 7.5K, 40K, C1 and the like. The nucleic acid sequence of the 30K promoter is disclosed in GenBank Accession No. M35027 at base numbers 28,012 through 28,423 (antisense). The nucleic acid sequence of I3 is disclosed in GenBank Accession No. J03399 at base numbers 1100 through 1301 (antisense). The nucleic acid sequence of the 7.5K promoter is disclosed in GenBank Accession No. M35027 at base numbers 186550 through 186680. The nucleic acid sequence of the 40K promoter is disclosed in Genbank Accession No. M13209 at base numbers 9700 through 9858 (antisense). The nucleic acid sequence of the C1 promoter is disclosed in Genbank Accession No. M59027 at base numbers 1 through 242 and in U.S. Patent No. 5,093,258. The sequence of the sE/L promoter is disclosed in Reference 16. Other poxvirus promoters may be used, such as, those described by Davison and Moss (J. Mol. Biol. 210:749-769, (1989). Any of these promoters can be synthesized by using standard methods in the art. The selection of an appropriate promoter is based on its timing and level of expression. Early or early/late promoters are preferred. In a preferred embodiment, the promoter or combination of promoters utilized allow for optimal expression of each costimulatory molecule in an infected host to provide a synergistic immune response. In a preferred embodiment, each foreign gene encoding a costimulatory molecule is controlled by a separate and distinct promoter.

[0072] In the case of nucleic acid-based vectors, the constructs may be either nucleic acid (DNA or RNA) or associated with/or encapsulated in a lipid carrier. Optionally, the lipid carrier molecule and/or construct may provide targeting and/or expression in a particular target cell type or types. Naked DNA vectors may be prepared by methods described in U.S. Patent No. 5,827,703. For the transcriptional initiation region, or promoter element, any region may be used with the proviso that it provides the desired level of transcription of the DNA sequence of interest. The transcriptional initiation region may be native to or homologous to the host cell and/or to the DNA to be transcribed, or foreign or heterologous to the host cell and/or the DNA sequence to be transcribed. Efficient promoter elements for transcription initiation of naked DNA include but are not limited to the SV40 (simian virus 40) early promoter, the RSV (Rous sarcoma virus) promoter, the adenovirus major late promoter, the human CMV (cytomegalovirus) immediate early I promoter, and the like. Nucleic acid-based vectors may be delivered to a host using a syringe, a catheter, or a needle-free injection device such as a gene gun.

[0073] In an embodiment of the invention, a recombinant vector is provided comprising a foreign nucleic acid sequence encoding a first costimulatory molecule or functional portion thereof under control of a first promoter, a foreign nucleic acid sequence encoding a second costimulatory molecule or functional portion thereof under control of a second promoter, and a foreign nucleic acid sequence encoding a third costimulatory molecule or functional portion thereof under control of a third promoter. The recombinant vector may further provide a foreign nucleic acid sequence encoding a target antigen or immunological portion thereof under control of a fourth promoter.

[0074] In one embodiment of the present invention, a recombinant poxvirus is provided comprising a nucleic acid sequence encoding LFA-3 or functional portion thereof under control of a 30K poxviral promoter, a nucleic acid sequence encoding ICAM-1 or portion thereof under control of an I3 poxviral promoter, and a nucleic acid sequence encoding B7.1 or portion thereof under control of an sE/L poxviral promoter. One example of such a recombinant poxvirus construct is vaccinia vT171 as depicted in Figure 11A. The recombinant poxvirus may further provide a nucleic acid sequence encoding a tumor associated antigen or immunological portion thereof. One embodiment of the invention is recombinant vaccinia vT172 as depicted in Figure 4C.

[0075] In another embodiment of the present invention, a recombinant poxvirus is provided comprising a nucleic acid sequence encoding B7.1 under control of a sE/L poxviral promoter, a nucleic acid sequence encoding LFA-3 or portion thereof under control of the I3 poxviral promoter, and a nucleic acid sequence encoding ICAM-1 or portion thereof under control of the 7.5K poxvirus promoter. Optionally the construct further comprises a nucleic acid sequence encoding at least one target antigen or immunological epitope thereof and/or a nucleic acid sequence encoding a selectable marker. One embodiment of such a recombinant poxvirus construct is vaccinia vT199 as depicted in Figure 4B containing a *lacZ* gene as the selectable marker.

[0076] In an embodiment of the invention a recombinant fowlpox virus comprises a nucleic acid sequence encoding B7.1 or portion thereof under control of the sE/L poxviral promoter, a nucleic acid sequence encoding LFA-3 or portion thereof under control of the 13 poxviral promoter, and a nucleic acid sequence encoding ICAM-1 or portion thereof under control of the 7.5K poxviral promoter. An example of this embodiment is fowlpox vT222 as depicted in Figure 4A. A recombinant fowlpox virus may further comprise a nucleic acid sequence encoding a target antigen, CEA, under control of the 40K poxviral promoter and a nucleic acid sequence encoding the selectable marker, *lacZ* under control of the C1 poxviral promoter. An example of this embodiment is fowlpox vT194 as depicted in Figure 4B.

[0077] In another embodiment, a recombinant fowlpox virus comprises a nucleic acid sequence encoding the tumor-associated antigen MUC-1 or portion thereof under the control of the 40K promoter, a nucleic acid sequence encoding LFA-3 or portion thereof under the control of the 30K promoter, a nucleic acid sequence encoding ICAM-1 or portion thereof under the control of the 13 promoter, and a nucleic acid sequence encoding B7.1 or portion thereof under the control of the sE/L promoter, as depicted in Figure 14C. The recombinant fowlpox virus may comprise a nucleic acid sequence encoding any tumor-associated antigen or portion thereof and nucleic acid sequences encoding LFA-3, ICAM-1 and B7.1, under the control of a multiplicity of promoters, as depicted in Figure 4D.

[0078] Another embodiment of the present invention is a recombinant vector comprising nucleic acid sequences encoding the human homologs of the costimulatory molecules LFA-3, B7 and ICAM-1. The recombinant vector may further provide the appropriate promoters to allow expression of each sequence in an infected host cell. One embodiment of the recombinant vector is vT224 depicted in Figure 9.

[0079] The present invention provides plasmid vectors comprising a foreign nucleic acid sequence encoding three costimulatory molecules. In one embodiment, foreign nucleic acid sequences are selected that encode three costimulatory molecules selected from the group consisting of B7, ICAM-1, LFA-3, 4-1BBL, CD59, CD40, CD70, VCAM-1, OX-40L and the like. In one embodiment of the present invention, plasmid vectors comprising a foreign nucleic acid sequence encoding B7 costimulatory molecule, a foreign nucleic acid sequence encoding an ICAM-1 costimulatory molecule and a foreign nucleic acid sequence encoding a LFA-3 costimulatory molecule are provided. The plasmid vectors of the present invention further provide at least one promoter sequence for controlling the expression of the costimulatory molecules. In a preferred embodiment each nucleic acid sequence encoding a costimulatory molecule is controlled by a separate discrete promoter sequence. For use in making a recombinant poxvirus, the plasmid vectors of the present invention further provide flanking viral nucleic acid sequences from a non-essential region of a poxvirus genome. The flanking viral nucleic acid sequences direct insertion of the foreign sequences into a parental poxviral genome via homologous recombination. The plasmid vectors of the present invention may further comprise one or more selectable markers for selection and identification of recombinant progeny containing the inserted foreign DNA as are known in the art including but not limited to the vaccinia K1L host range gene, the *E. coli lacZ* gene, antibiotic resistance genes, the gene encoding β -glucuronidase and the like.

[0080] In an embodiment, a plasmid vector of the present invention comprises a nucleic acid sequence encoding LFA-3 under control of the 30K promoter, a nucleic acid sequence encoding ICAM-1 under control of the 13 promoter and a nucleic acid sequence encoding B7 under control of the sE/L promoter, flanked by portions of the Hind III M region of the vaccinia genome. In one embodiment, the plasmid vector is as depicted in Figure 1 as pT5032.

[0081] Another embodiment of the plasmid vector of the present invention comprises a nucleic acid sequence encoding

B7 under control of the sE/L promoter, a nucleic acid sequence encoding LFA-3 under control of the 13 promoter and a nucleic acid sequence encoding ICAM-1 under control of the 7.5K promoter. The plasmid vector may further comprise a *lacZ* gene or portion thereof driven by a distinct promoter sequence. These sequences are flanked by portions of the Hind III J region of the vaccinia genome. A particular embodiment of the plasmid vector is depicted as pT5047 in Figure 2.

[0082] In another embodiment of the plasmid vector comprises in combination with the nucleic acid sequences encoding B7, ICAM-1, and LFA-3, a nucleic acid sequence encoding at least one target antigen or immunological epitope thereof. A promoter is provided for controlling the expression of the target antigen. A particular embodiment of the plasmid vector is depicted as pT5031 in Figure 3 and comprises a nucleic acid sequence encoding the target antigen, CEA.

[0083] In another particular embodiment the plasmid vector comprises a nucleic acid sequence encoding the tumor associated antigen, CEA, under control of the 40K promoter, a nucleic acid sequence encoding B7 under control of the sE/L promoter, a nucleic acid sequence encoding LFA-3 under control of a 13 promoter and a nucleic acid sequence encoding ICAM-1. The plasmid vector may further comprise a *lacZ* gene under control of a C1 promoter as depicted in Figure 6 as pT5049. Plasmid pT5049, was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110 on November 13, 1998 as ATCC Accession No. 203481 under the terms of the Budapest Treaty.

[0084] In yet another embodiment of the plasmid vector, the vector comprises a nucleic acid sequence encoding huLFA-3 under control the 30K promoter, a nucleic acid sequence encoding huICAM-1 under control of an 13 promoter and huB7.1 under control of the sE/L promoter. A particular embodiment of the plasmid vector is depicted as pT5064 in Figure 8, which was deposited with the ATCC on November 13, 1998 as ATCC Accession No. 203482 under the terms of the Budapest Treaty.

[0085] The plasmid vector of the present invention may be provided in kit form for use in methods of generating recombinant vectors. The kit may further provide a parental virus, and other reagents used in the recombination process.

[0086] The present invention further provides methods of generating recombinant poxviruses comprising nucleic acid sequences encoding three costimulatory molecules. One method of generation of recombinant poxviruses is accomplished via homologous recombination *in vivo* between parental poxvirus genomic DNA and a plasmid vector that carries the heterologous sequences to be inserted as disclosed in U.S. Patent No. 5,093,258. Plasmid vectors for the insertion of foreign sequences into poxviruses are constructed by standard methods of recombinant DNA technology (36). The plasmid vectors contain one or more chimeric foreign genes, each comprising a poxvirus promoter linked to a protein coding sequence, flanked by viral sequences from a non-essential region of the poxvirus genome. The plasmid is transfected into cells infected with the parental poxvirus using art accepted transfection methods, and recombination between poxvirus sequences on the plasmid and the corresponding DNA in the parental viral genome results in the insertion into the viral genome of the chimeric foreign genes from the plasmid. Recombinant viruses are selected and purified using any of a variety of selection or screening systems as are known in the art (14). Insertion of the foreign genes into the vaccinia genome is confirmed by polymerase chain reaction (PCR) analysis. Expression of the foreign genes is demonstrated by Western blot analysis. An alternative method of generation of recombinant poxviruses is accomplished by direct ligation (Pleiderer et al J. Gen. Virol. 76:2957-2962, 1995; Merchlinsky et al Virol. 238:444-451, 1997).

[0087] Use of the recombinant vector comprising nucleic acid sequences encoding three costimulatory molecules in combination with a nucleic acid sequence encoding at least one target antigen or epitope thereof is useful in enhancing an immune response against the target antigen or epitope thereof, and enhance the immune response against cells expressing the target antigen or epitope thereof. The magnitude of the immune response against the target antigen, epitope, or cells expressing target antigen obtained using the recombinant vector of the present invention is significantly greater than that achieved using systems employing a single or a double costimulatory molecule.

[0088] The recombinant vector encodes three costimulatory molecules in combination with a nucleic acid sequence encoding a target antigen or immunological epitope thereof for providing a synergistic immunological response to the target antigen or epitope thereof. In one embodiment, a recombinant poxvirus provides a nucleic acid sequence encoding B7, ICAM-1 and LFA-3, along with a nucleic acid sequence encoding at least one target antigen or immunological epitope thereof. In some instances it may be beneficial to provide more than one nucleic acid sequence to provide three target antigens or immunological epitopes thereof for the purpose of having a multivalent vaccine.

[0089] The target antigen, as used herein, is an antigen or immunological epitope on the antigen which is crucial in immune recognition and ultimate elimination or control of the disease-causing agent or disease state in a mammal. The immune recognition may be cellular and/or humoral. In the case of intracellular pathogens and cancer, immune recognition is preferably a T lymphocyte response.

[0090] The target antigen may be derived or isolated from a pathogenic microorganism such as viruses including HIV, (Korber et al, eds HIV Molecular Immunology Database, Los Alamos National Laboratory, Los Alamos, New Mexico 1977) influenza, Herpes simplex, human papilloma virus (U.S. Patent No. 5,719,054), Hepatitis B (U.S. Patent No. 5,780,036), Hepatitis C (U.S. Patent No. 5,709,995), EBV, Cytomegalovirus (CMV) and the like. Target antigen may be derived or isolated from pathogenic bacteria such as from Chlamydia (U.S. Patent No. 5,869,608), Mycobacteria, Le-

gionella, Meningioccus, Group A Streptococcus, Salmonella, Listeria, *Hemophilus influenzae* (U.S. Patent No. 5,955,596) and the like.

[0091] Target antigen may be derived or isolated from pathogenic yeast including *Aspergillus*, invasive *Candida* (U.S. Patent No. 5,645,992), *Nocardia*, Histoplasmosis, Cryptosporidia and the like.

[0092] Target antigen may be derived or isolated from a pathogenic protozoan and pathogenic parasites including but not limited to *Pneumocystis carinii*, *Trypanosoma*, *Leishmania* (U.S. Patent No. 5,965,242), *Plasmodium* (U.S. Patent No. 5,589,343) and *Toxoplasma gondii*.

[0093] Target antigen includes an antigen associated with a preneoplastic or hyperplastic state. Target antigen may also be associated with, or causative of cancer.

[0094] Such target antigen may be tumor specific antigen, tumor associated antigen (TAA) or tissue specific antigen, epitope thereof, and epitope agonist thereof. Such target antigens include but are not limited to carcinoembryonic antigen (CEA) and epitopes thereof such as CAP-1, CAP-1-6D (46) and the like (GenBank Accession No. M29540), MART-1 (Kawakami et al, J. Exp. Med. 180:347-352, 1994), MAGE-1 (U.S. Patent No. 5,750,395), MAGE-3, GAGE (U.S. Patent No. 5,648,226), GP-100 (Kawakami et al Proc. Nat'l Acad. Sci. USA 91:6458-6462, 1992), MLTC-1, MUC-2, point mutated ras oncogene, normal and point mutated p53 oncogenes (Hollstein et al Nucleic Acids Res. 22:3551-3555, 1994), PSMA (Israeli et al Cancer Res. 53:227-230, 1993), tyrosinase (Kwon et al PNAS 84:7473-7477, 1987, TRP-1 (gp75) (Cohen et al Nucleic Acid Res. 18:2807-2808, 1990; U.S. Patent No. 5,840,839), NY-ESO-1 (Chen et al PNAS 94: 1914-1918, 1997), TRP-2 (Jackson et al EMBOJ, 11:527-535, 1992), TAG72, KSA, CA-125, PSA, HER-2/neu/c-erbB2, (U.S. Patent No. 5,550,214), BRC-I, BRC-II, bcr-abl, pax3-fkhr, ews-fli-1, modifications of TAAs and tissue specific antigen, splice variants of TAAs, epitope agonists, and the like. Other TAAs may be identified, isolated and cloned by methods known in the art such as those disclosed in U.S. Patent No. 4,514,506. Target antigen may also include one or more growth factors and splice variants of each.

[0095] Possible human tumor antigens and tissue specific antigens as well as immunological epitopes thereof for targeting using the present invention include but are not limited to those exemplified in Table 1.

Table 1
Antigens and Epitopes Recognized by T Cells

Target antigens	Restriction element	Immunological Peptide epitope	SEQ. ID No.
Human target tumor antigens recognized by T cells			
gp 100	HLA-A2	KTWGQYWZY	
	HLA-A2	ITDQVPPSV	2
	HLA-A2	YLEPGPVTA	3
	HLA-A2	LLDGTATLRL	4
	HLA-A2	VLYRYGSFSV	5
MARTI-/Melan A	HLA-A2	AAGIGILTV	6
	HLA-A2	ILTVILGVL	7
	HLA-A31	MSLQRQFLR	8
Tyrosinase	HLA-A2	MLLAVLYCL	9
	HLA-A2	YMNGTMSQV	10
	HLA-B44	SEIWRDIDF	11
	HLA-A24	AFLPWHRLF	12
	HLA-DR4	QNILLSNAPLGPQFP	13
MAGE-1	HLA-DR4	SYLQDSDPDSFQD	14
	HLA-A1	EADPTGHSY	15
	HLA-Cw16	SAYGEPRKL	16
MAGE-3	HLA-A 1	EVDPIGHLY	17
	HLA-A2	FLWGPRALV	18
BAGE	HLA-Cw16	AARAVFLAL	19
GAGE-1,2	HLA-Cw6	YRPRPRRY	20
N-acetylglucos-aminyltransferase-V	HLA-A2	VLPDVFIRC	21
p15	HLA-A24	AYGLDFYIL	22
CEA		YLSGANLNL(CAPI)	23

(continued)

Antigens and Epitopes Recognized by T Cells

	Target antigens	Restriction element	Immunological Peptide epitope	SEQ. ID No.
5	Human target tumor antigens recognized by T cells			
			YLSGADLNL (CAP1-6D)	24
				37
10	β -catenin	HLA-A24	SYLDSGIHF	25
	MUM-1	HLA-B44	EEKLIVVLF	26
	CDK4	HLA-A2	ACDPHSGHFV	27
	HER-2/neu	HLA-A2	HSAVVGIL	28
15	(Breast and ovarian carcinoma)	HLA-A2	KIFGSLAFL	29
	Human papillomavirus-E6,E7	HLA-A2	YMLDLQPETT	30
	(cervical carcinoma)			
20	MUC-1	Non-MHC restricted	PDTRPAPGSTAPPAHGV TSA	31
		MHC restricted	(and portions thereof)	
	(Breast, ovarian and pancreatic carcinoma)			
25	PSA	A2, A3	FLTPKKLQCVDLHVISNDVCA-	32
			QVHPQKVTK	
			FLTPKKLQCV	33
			KLQCVDLHV	34
			VISNDVCAQV	35
30			QVHPQKVTK	36

[0096] For organisms which contain a DNA genome, a gene encoding a target antigen or immunological epitope thereof of interest is isolated from the genomic DNA. For organisms with RNA genomes, the desired gene may be isolated from cDNA copies of the genome. If restriction maps of the genome are available, the DNA fragment that contains the gene of interest is cleaved by restriction endonuclease digestion by methods routine in the art. In instances where the desired gene has been previously cloned, the genes may be readily obtained from the available clones. Alternatively, if the DNA sequence of the gene is known, the gene can be synthesized by any of the conventional techniques for synthesis of deoxyribonucleic acids.

[0097] Genes encoding an antigen of interest can be amplified by cloning the gene into a bacterial host. For this purpose, various prokaryotic cloning vectors can be used. Examples are plasmids pBR322, pUC and pEMBL.

[0098] The genes encoding at least one target antigen or immunological epitope thereof can be prepared for insertion into the plasmid vectors designed for recombination with a virus by standard techniques. In general, the cloned genes can be excised from the prokaryotic cloning vector by restriction enzyme digestion. In most cases, the excised fragment will contain the entire coding region of the gene. The DNA fragment carrying the cloned gene can be modified as needed, for example, to make the ends of the fragment compatible with the insertion sites of the DNA vectors used for recombination with a virus, then purified prior to insertion into the vectors at restriction endonuclease cleavage sites (cloning sites) as described herein.

[0099] Diseases may be treated or prevented by use of the present invention and include diseases caused by viruses, bacteria, yeast, parasites, protozoans, cancer cells and the like. The recombinant vector comprising three costimulatory molecules may be used as a generalized immune enhancer and as such has utility in treating diseases of no known etiological cause.

[0100] Preneoplastic or hyperplastic states which may be treated or prevented using a recombinant vector of the present invention include but are not limited to preneoplastic or hyperplastic states such as colon polyps, Crohn's disease, ulcerative colitis, breast lesions and the like.

[0101] Cancers which may be treated using the recombinant vector of the present invention include but are not limited to primary or metastatic melanoma, adenocarcinoma, squamous cell carcinoma, adenosquamous cell carcinoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkins lymphoma, Hodgkins lymphoma, leukemias, uterine cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, colon cancer, three myeloma, neuroblastoma,

NPC, bladder cancer, cervical cancer and the like.

[0102] The present invention provides a pharmaceutical composition comprising a recombinant vector comprising foreign genes encoding three costimulatory molecules in a pharmaceutically acceptable carrier. Three genes encoding a costimulatory molecule form part of the recombinant vector and may be selected from the group of genes encoding B7, ICAM-1, LFA-3, 4-1BBL, CD59, CD40, CD70, VCAM-1, OX-40L and the like. The recombinant vector may further comprise a nucleic acid sequence encoding at least one target antigen or immunological epitope thereof. In another embodiment, the pharmaceutical composition comprises a first recombinant vector comprising foreign genes encoding three costimulatory molecules, a second recombinant vector comprising nucleic acid sequences encoding at least one target antigen or immunological epitope thereof and a pharmaceutically acceptable carrier. Administration of the pharmaceutical composition provides host cells with the foreign genes encoding three costimulatory molecules.

[0103] In one embodiment, a pharmaceutical composition comprises a recombinant poxvirus containing foreign genes encoding three costimulatory molecules in a pharmaceutically acceptable carrier. The recombinant poxvirus may further comprise a nucleic acid sequence encoding at least one target antigen or immunological epitope thereof or alternatively, a second recombinant poxvirus may be provided encoding at least one target antigen or immunological epitope thereof.

[0104] The present invention provides a pharmaceutical composition comprising a recombinant poxvirus comprising a nucleic acid sequence encoding B7.1 to B7.2, a nucleic acid sequence encoding ICAM-1, and a nucleic acid sequence encoding LFA-3 and a pharmaceutically acceptable carrier. In addition to the B7, ICAM-1, LFA-3 construct, the recombinant poxvirus of the pharmaceutical composition may additionally comprise a nucleic acid sequence encoding at least one target antigen or immunological epitope thereof or the nucleic acid sequence encoding at least one target antigen or immunological epitope thereof may be provided in the composition by a second recombinant poxvirus.

[0105] The pharmaceutical composition may also comprise exogenously added immunostimulatory molecules as are known in the art including the costimulatory molecules B7, ICAM-1, LFA-3, 4-1BBL, CD59, CD40, CD70, VCAM-1, OX-40L and the like and/or cytokines and chemokines including but not limited to IL2, GM-CSF, TNF α , IFN γ , IL-12, RANTES, MIP-1 α , Flt-3L (U.S. Patent No. 5,554,512; 5,843,423) and the like for additional synergy or enhancement of an immune response. The cytokines and chemokines themselves may be provided in the composition or, alternatively, the cytokines and chemokines may be provided by a recombinant viral vector encoding the cytokine or chemokine.

[0106] The present invention also encompasses methods of treatment or prevention of a disease caused by pathogenic microorganisms or by cancer disclosed herein.

[0107] In the method of treatment, the administration of the recombinant vector of the invention may be for either "prophylactic" or "therapeutic" purpose. When provided prophylactically, the recombinant vector of the present invention is provided in advance of any symptom. The prophylactic administration of the recombinant vector serves to prevent or ameliorate any subsequent infection or disease. When provided therapeutically, the recombinant vector is provided at or after the onset of a symptom of infection or disease. Thus the present invention may be provided either prior to the anticipated exposure to a disease-causing agent or disease state or after the initiation of the infection or disease.

[0108] The term "unit dose" as it pertains to the inoculum refers to physically discrete units suitable as unitary dosages for mammals, each unit containing a predetermined quantity of recombinant vector calculated to produce the desired immunogenic effect in association with the required diluent. The specifications for the novel unit dose of an inoculum of this invention are dictated by and are dependent upon the unique characteristics of the recombinant virus and the particular immunologic effect to be achieved.

[0109] The inoculum is typically prepared as a solution in tolerable (acceptable) diluent such as saline, phosphate-buffered saline or other physiologically tolerable diluent and the like to form an aqueous pharmaceutical composition.

[0110] The route of inoculation may be scarification, intravenous (I.V.), intramuscular (I.M.), subcutaneous (S.C.), intradermal (I.D.), intraperitoneal (I.P.), intratumor and the like, which results in eliciting a protective response against the disease causing agent. The dose is administered at least once. Subsequent doses may be administered as indicated.

[0111] In one embodiment, heterologous prime-boost regimens are employed. In one example, the host is immunized at least once with a first vector such as a nucleic acid-based vector. Subsequent immunizations are performed with a poxvirus vector. In another example, the host is first immunized with a first poxvirus vector and then with a second poxvirus vector of a different genus.

[0112] In providing a mammal with the recombinant vector of the present invention, preferably a human, the dosage of administered recombinant vector will vary depending upon such factors as the mammal's age, weight, height, sex, general medical condition, previous medical history, disease progression, tumor burden and the like.

[0113] In general, it is desirable to provide the recipient with a dosage of recombinant virus in the range of about 10^5 to about 10^{10} plaque forming units, although a lower or higher dose may be administered.

[0114] The genetic definition of tumor-associated and tumor-specific antigens allows for the development of targeted antigen-specific vaccines for cancer therapy. Insertion of a tumor antigen gene in the genome of recombinant pox viruses in combination with genes encoding three costimulatory molecules is a powerful system to elicit a specific immune response in terms of prevention in individuals with an increased risk of cancer development (preventive immunization), to shrink tumors prior to surgery, to prevent disease recurrence after primary surgery (anti-metastatic vaccination), or

to expand the number of cytotoxic lymphocytes (CTL) *in vivo*, thus improving their effectiveness in eradication of diffuse tumors (treatment of established disease). Recombinant viruses of the present invention can elicit an immune response *ex vivo* in autologous lymphocytes (CD8⁺), either cytotoxic T lymphocytes and/or CD4⁺ helper T cells or NK cells prior to being transferred back to the tumor bearing patient (adoptive immunotherapy).

[0115] In cancer treatments, the recombinant vectors can be introduced into a mammal either prior to any evidence of cancers such as an adenocarcinoma or to mediate regression of the disease in a mammal afflicted with a cancer such as adenocarcinoma.

[0116] Depending on the disease or condition to be treated and the method of treatment, the recombinant vector may or may not comprise a nucleic acid sequence encoding a target antigen or immunological epitope thereof in addition to the genes encoding three costimulatory molecules. The target antigen or immunological epitope thereof may be provided endogenously by the host cell infected with the recombinant vector as, for instance, a tumor cell may endogenously express a tumor associated antigen or epitope thereof and may not require the addition of a foreign gene encoding an exogenous tumor associated antigen. In the case in which a tumor associated antigen is absent, not expressed or expressed at low levels in a host cell, a foreign gene encoding an exogenous tumor associated antigen may be provided. Further, genes encoding several different tumor associated antigens may be provided. The foreign gene encoding an exogenous tumor associated antigen may be provided by the same recombinant vector comprising genes encoding three costimulatory molecules or may be provided by a second recombinant vector in an admixture with the first recombinant vector.

[0117] Examples of methods for administering the recombinant vector into mammals include, but are not limited to, exposure of tumor cells to the recombinant virus *ex vivo*, or injection of the recombinant vector into the affected host by intravenous, S.C., I.D. or I.M. administration of the virus. Alternatively the recombinant vector or combination of recombinant vectors may be administered locally by direct injection into the cancerous lesion or tumor or topical application in a pharmaceutically acceptable carrier. The quantity of recombinant vector carrying the nucleic acid sequence of one or more tumor associated antigens (TAAs) in combination with nucleic acid sequences encoding three costimulatory molecules to be administered is based on the titer of virus particles. A preferred range of the immunogen to be administered is 10⁵ to 10¹⁰ virus particles per mammal, preferably a human. If the mammal to be immunized is already afflicted with cancer or metastatic cancer, the vaccine can be administered in conjunction with other therapeutic treatments.

[0118] In one method of treatment, autologous cytotoxic lymphocytes or tumor infiltrating lymphocytes may be obtained from blood, lymph nodes, tumor and the like from a patient with cancer. The lymphocytes are grown in culture and target antigen-specific lymphocytes are expanded by culturing in the presence of specific target antigen and either antigen presenting cells expressing three foreign costimulatory molecules or target antigen pulsed APCs of the present invention. The target antigen-specific lymphocytes are then reinfused back into the patient.

[0119] After immunization the efficacy of the vaccine can be assessed by production of antibodies or immune cells that recognize the antigen, as assessed by specific lytic activity or specific cytokine production or by tumor regression. One skilled in the art would know the conventional methods to assess the aforementioned parameters.

[0120] The present invention encompasses methods of enhancing antigen-specific T-cell responses by administration of an effective amount of a recombinant vector encoding three foreign costimulatory molecules and a target antigen into a mammal alone, or infecting a target cell with the vector, target antigen or immunological epitope thereof. In one embodiment of the method, a recombinant vector encoding molecule from the B7 family, ICAM-1 and LFA-3 is administered alone, or admixed with a target cell, target antigen or immunological epitope thereof. This immunization approach augments or enhances immune responses generated by the target antigen, providing a synergistic response compared to the use of single or double costimulatory molecules. The method of administering a recombinant vector containing genes encoding three costimulatory molecules results in increased target antigen-specific lymphoproliferation, enhanced cytolytic activity, enhanced cytokine secretion and longer lasting immunity to the target antigen as compared to the use of recombinant vector encoding a single or double costimulatory molecule. The recombinant vector may further comprise a nucleic acid sequence encoding at least one target antigen or immunological epitope thereof for synergistic enhancement of target-antigen-specific immune responses. Alternatively, the nucleic acid sequence encoding at least one target antigen or immunological epitope thereof is provided by a second recombinant vector, distinct from the vector encoding the three costimulatory molecules. In one embodiment of the method of enhancing antigen-specific T-cell responses, mammals, preferably humans, are immunized with an rV-HIV-1 epitope/B7-1/ICAM-1/LFA-3 construct. The efficacy of the treatment may be monitored *in vitro* and/or *in vivo* by determining target antigen-specific lymphoproliferation, target antigen-specific cytolytic response, clinical responses and the like.

[0121] The method of enhancing antigen-specific T-cell responses may be used for any target antigen or immunological epitope thereof. Of particular interest are tumor associated antigens, tissue specific antigens and antigens of infectious agents.

[0122] In addition to administration of the recombinant vector to the patient, other exogenous immunomodulators or immunostimulatory molecules, chemotherapeutic drugs, antibiotics, antifungal drugs, antiviral drugs and the like alone or in combination thereof may be administered depending on the condition to be treated. Examples of other exogenously

added agents include exogenous IL-2, IL-6, alpha-, beta- or gamma-interferon, GM-CSF, tumor necrosis factor, Flt-3L, cyclophosphamide, cisplatin, gancyclovir, amphotericin B, 5 fluorouracil and the like.

[0123] The present invention provides for host cells expressing three, exogenous foreign costimulatory molecules in which the molecules are provided by a recombinant vector having foreign nucleic acid sequences encoding three costimulatory molecules. The host cells may also express one or more endogenous target antigens or immunological epitopes thereof or may be engineered to express one or more exogenous, foreign target antigens or immunological epitopes thereof which may also be provided by the recombinant vector encoding three costimulatory molecules or by a second recombinant vector.

[0124] The host cells of the present invention, with utility in stimulating an antigen-specific immune response may be any cell capable of infection using the recombinant virus of the present invention and capable of expressing three, exogenous costimulatory molecules and may further be genetically engineered to express one or more exogenous target antigens or immunological epitopes thereof. Such host cells included but are not limited to tumor cells, antigen presenting cells, such as PBMC, dendritic cells, cells of the skin or muscle, and the like. Antigen presenting cells include, but are not limited to, monocytes, macrophages, dendritic cells, progenitor dendritic cells, Langerhans cells, splenocytes, B-cells, tumor cells, muscle cells, epithelial cells and the like.

[0125] In one embodiment, the host cells are tumor cells in which the tumor cells are exposed to the recombinant vector *in situ* or *in vitro* to cause expression of three foreign or exogenous costimulatory molecules on the tumor cells. The tumor cells may express an endogenous target antigen or the tumor cells may be further genetically engineered to express a target antigen such as TAA or immunological epitope thereof. Tumor cells expressing both the TAA along with three immunostimulatory molecules are administered to a mammal in an effective amount to result in tumor reduction or elimination in the mammal afflicted with a cancer.

[0126] The present invention also provides progenitor dendritic cells, dendritic cells (DC), DC subpopulations, and derivatives thereof overexpressing three costimulatory molecules in which three costimulatory molecules are exogenously provided by a recombinant vector having nucleic acid sequences encoding three costimulatory molecules. The progenitor DC and DC of the present invention express higher levels of costimulatory molecules, than levels endogenously expressed by a nontreated progenitor DC or DC. The APCs such as progenitor dendritic cells and dendritic cells may also express one or more endogenous target antigens or immunological epitopes thereof or exogenous target antigen may also be provided by the recombinant vector encoding three costimulatory molecules or by a second recombinant vector. The present invention further provides methods of using the three costimulatory molecule-overexpressing APCs, such as three costimulatory molecule-overexpressing progenitor dendritic cells and three costimulatory molecule-overexpressing dendritic cells in activating T cells *in vivo* or *in vitro* for vaccination and immunotherapeutic responses against one or more target cells, target antigens and immunological epitopes thereof.

[0127] The APCs such as progenitor dendritic cells, dendritic cells, DC subpopulations and derivatives thereof isolated from a source are infected, transfected or transduced with a recombinant vector comprising exogenous genes encoding three costimulatory molecules for a time period sufficient to allow functional overexpression of the three costimulatory molecules. Such multiple costimulatory molecule-overexpressing antigen presenting progenitor dendritic cells and dendritic cells may also be pulsed or incubated with at least one target cell, target cell lysate, target cell membrane, target antigen, or immunological epitope thereof, or with RNA or DNA of at least one target cell and administered to a species in an amount sufficient to activate the relevant T cell responses *in vivo*. In another embodiment, the antigen presenting progenitor dendritic cells and dendritic cells additionally express at least one foreign target antigen or immunological epitope thereof.

[0128] Host cells expressing three, exogenous costimulatory molecules may be provided in a dose of 10^3 to 10^9 cells. Routes of administration that may be used include intravenous, subcutaneous, intralymphatic, intratumoral, intradermal, intramuscular, intraperitoneal, intrarectal, intravaginal, intranasal, oral, via bladder instillation, via scarification, and the like.

[0129] In one embodiment, the three costimulatory molecule-overexpressing antigen presenting progenitor dendritic cells or dendritic cells are exposed to a target cell, target cell lysates, target cell membranes, target antigen or immunological epitope thereof or with DNA or RNA from at least one target cell *in vitro* and incubated with primed or unprimed T cells to activate the relevant T cell responses *in vitro*. The activated T cells alone or in combination with the progenitor DC or DC are then administered to a species such as a human for vaccination or immunotherapy against a target cell, target antigen or immunological epitope thereof. In one method of use, the progenitor dendritic cells or dendritic cells are advantageously used to elicit an immunotherapeutic growth inhibiting response against cancer cells.

[0130] In another embodiment, the three costimulatory molecule-overexpressing antigen-presenting cell, preferably a precursor DC or DC is fused with a target cell expressing a relevant target antigen or immunological epitope thereof to form a heterokaryon of APC and target cell by methods known in the art (Gong, J. et al Proc. Natl. Acad. Sci. USA 95:6279-6283, 1998). Such a fusion cell or chimeric APC/target antigen cell expresses both three costimulatory molecules and target antigen or immunological epitopes thereof. In a preferred embodiment the target cell is a hyperplastic cell, premalignant or malignant cell. The chimeric APC/target antigen cell may be used both *in vivo* and *in vitro* to enhance

immune responses of T and B lymphocytes.

[0131] Progenitor dendritic cells are obtained from bone marrow, peripheral blood and lymph nodes from a patient. The patient may have been previously vaccinated, or treated with a compound such as Flt-3L to enhance the number of antigen-presenting cells. Dendritic cells are obtained from any tissue such as the epidermis of the skin (Langerhans cells) and lymphoid tissues such as found in the spleen, bone marrow, lymph nodes, and thymus as well as the circulatory system including blood and lymph (veiled cells). Cord blood is another source of dendritic cells.

[0132] Dendritic cells may be enriched or isolated for use in the present invention using methods known in the art such as those described in U.S. Patent No. 5,788,963. Once the progenitor dendritic cells, dendritic cells and derivatives thereof are obtained, they are cultured under appropriate culture conditions to expand the cell population and/or maintain the cells in a state for optimal infection, transfection or transduction by a recombinant vector and for optimal target antigen uptake, processing and presentation. Particularly advantageous for maintenance of the proper state of maturity of dendritic cells in *in vitro* culture is the presence of both the granulocyte/macrophage colony stimulating factor (GM-CSF) and interleukin 4 (IL-4). Subpopulations of dendritic cells may be isolated based in adherence and/or degree of maturity based on cell surface markers. The phenotype of the progenitor DC, DC and subpopulations thereof are disclosed in Banchereau and Steinman Nature 392:245-252, 1998.

[0133] In one embodiment GM-CSF and IL-4 are each provided in a concentration of about 500 units/ml for a period of about 6 days (41,42). In another embodiment, TNF α and/or CD40 is used to cause precursor DC or DC to mature.

[0134] The progenitor dendritic cells or dendritic cells may be obtained from the individual to be treated and as such are autologous in terms of relevant HLA antigens or the cells may be obtained from an individual whose relevant HLA antigens (both class I and II, e.g. HLA-A, B, C and DR) match the individual that is to be treated. Alternatively, the progenitor dendritic cell is engineered to express the appropriate, relevant HLA antigens of the individual receiving treatment.

[0135] The progenitor dendritic cells and dendritic cells may be further genetically modified to extend their lifespan by such methods as EBV-transformation as disclosed in U.S. Patent No. 5,788,963.

[0136] The dendritic cells and precursors thereof may be provided in the form of a pharmaceutical composition in a physiologically acceptable medium. The composition may further comprise a target cell, target cell lysate, target cell membrane, target antigen or immunological epitope thereof. The composition may additionally comprise cytokines and/or chemokines such as IL-4 and GM-CSF for additional synergistic enhancement of an immune response.

[0137] In another embodiment, the APC of the present invention overexpressing three costimulatory molecules is useful in methods of evaluating efficacy of a vaccine by determination of antigen-specific lymphocyte proliferation and function. In such a method, lymphocytes are recovered from an individual who has been vaccinated with a target cell lysate, target cell membrane, target antigen or immunological epitope thereof. The lymphocytes are cultured *in vitro* with an APC of the present invention in the presence of the target cell, target cell lysate, target cell membrane, target antigen or immunological epitope thereof and an enhancement of antigen-specific lymphocyte numbers and functions determined by methods known in the art. An enhancement in numbers and/or functions is indicative of efficacy of the vaccine. The method is particularly useful in determining efficacy of peptide vaccines in stimulating an appropriate immune response.

[0138] In another embodiment, the APCs of the present invention expressing exogenous three costimulatory molecules are useful in a method of screening for novel immunogenic peptides from a multiplicity of peptides. In the method of screening, antigen presenting cells infected with a recombinant vector encoding three costimulatory molecules or functional portions thereof are pulsed with a multiplicity of peptides to form a peptide-pulsed antigen presenting cell. The peptide-pulsed antigen presenting cell is incubated with lymphoid cells and the immunoreactivity of the lymphoid cells measured. An enhancement of immunoreactivity of the lymphoid cells in the presence of the peptide-pulsed APC is indicative of an antigen specific response to the peptide. The peptide eliciting the enhanced response can be identified by eluting from tumor, by analysis of HLA binding, etc. The source of the multiplicity of peptides may be a combinatorial library which expresses a multiplicity of random peptides. The enhanced immunoreactivity may be a humoral or cell-mediated immune response and may be measured using standard techniques known in the art such as antigen-induced proliferation, cytotoxicity, antibody secretion, signal transduction, and the like. The novel peptides identified may be used as immunogens, vaccines or diagnostic agents. The proteins that contain the peptides may be identified by subtraction libraries and differential display gene technologies.

[0139] The recombinant vectors of the present invention as well as host cells infected, transfected or induced by the recombinant vector of the present invention are useful in methods of stimulating an enhanced humoral response both *in vivo* and *in vitro*. Such an enhanced humoral response may be monoclonal or polyclonal in nature. The enhancement of humoral responses using three costimulatory molecules is synergistic as compared to a humoral response using a single or double costimulatory molecule. The synergistic enhancement of a humoral response may be determined by increased proliferation and/or cytokine secretion by CD4⁺ T cells, increased proliferation or antibody production by B cells, increased antibody dependent cellular toxicity (ADCC), increased complement-mediated lysis, and the like. Antibody elicited using the recombinant vectors of the present invention or using host cells infected, transfected or induced by the recombinant vector of the present invention are expected to be higher affinity and/or avidity and higher titer than

antibody elicited by standard methods. The antibody elicited by methods using the recombinant vector may recognize immunodominant target epitopes or nondominant target epitopes.

[0140] This invention further comprises an antibody or antibodies elicited by immunization with the recombinant vector of the present invention. The antibody has specificity for and reacts or binds with the target antigen or immunological epitope thereof of interest. In this embodiment of the invention the antibodies are monoclonal or polyclonal in origin.

[0141] Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules or those portions of an immunoglobulin molecule that contain the antigen binding site, including those portions of immunoglobulin molecules known in the art as F(ab), F(ab'), F(ab')₂ and F(v). Polyclonal or monoclonal antibodies may be produced by methods known in the art. (Kohler and Milstein (1975) Nature 256, 495-497; Campbell "Monoclonal Antibody Technology, the Production and Characterization of Rodent and Human Hybridomas" in Burdon et al. (eds.) (1985) "Laboratory Techniques in Biochemistry and Molecular Biology," Volume 13, Elsevier Science Publishers, Amsterdam). The antibodies or antigen binding fragments may also be produced by genetic engineering. The technology for expression of both heavy and light chain genes in *E. coli* is the subject of the PCT patent applications: publication number WO 901443, WO 901443 and WO 9014424 and in Huse et al. (1989) Science 246:1275-1281.

[0142] In one embodiment the antibodies of this invention are used in immunoassays to detect the novel antigen of interest in biological samples.

[0143] In one embodiment, the antibodies of this invention generated by immunization with a recombinant vaccinia virus expressing a TAA and expressing B7-1, ICAM-1 and LFA-3 are used to assess the presence of the a TAA from a tissue biopsy of a mammal afflicted with a cancer expressing TAA using immunocytochemistry. Such assessment of the delineation of the a TAA antigen in diseased tissue can be used to prognose the progression of the disease in a mammal afflicted with the disease or the efficacy of immunotherapy. In this embodiment, examples of TAAs include but are not limited to CEA, PSA, and MUC-1. Conventional methods for immunohistochemistry are described in (Harlow and Lane (eds) (1988) In "Antibodies A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor, New York; Ausubel et al. (eds) (1987). In Current Protocols In Molecular Biology, John Wiley and Sons (New York, New York).

[0144] In another embodiment the antibodies of the present invention are used for immunotherapy. The antibodies of the present invention may be used in passive immunotherapy.

[0145] In providing a patient with the antibodies or antigen binding fragments to a recipient mammal, preferably a human, the dosage of administered antibodies or antigen binding fragments will vary depending upon such factors as the mammal's age, weight, height, sex, general medical condition, previous medical condition and the like.

[0146] The antibodies or antigen-binding fragments of the present invention are intended to be provided to the recipient subject in an amount sufficient to prevent, lessen or attenuate the severity, extent or duration of the disease or infection.

[0147] Anti-idiotypic antibodies arise normally during the course of immune responses, and a portion of the anti-idiotypic antibody resembles the epitope that induced the original immune response. In the present invention, the immunoglobulin gene or portion thereof of an antibody whose binding site reflects a target antigen of a disease state, is incorporated into the genome or portion thereof of a virus genome, alone or in combination with a gene or portion thereof of three immunostimulatory molecules, the resulting recombinant virus is able to elicit cellular and humoral immune response to the antigen.

[0148] The description of the specific embodiments will so fully reveal the general nature of the invention that others can readily modify and/or adopt for various purposes such specific embodiments without departing from the generic concept, and therefor such adaptations and modifications are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments.

[0149] All references and patents referred to are incorporated herein by reference.

Example 1

Generation of Recombinant Vaccinia, rV-TRICOM(mu1) No. vT171

[0150] The origin of vaccinia parental virus is the New York City Board of Health strain and was obtained by Wyeth from the New York City Board of Health and passaged in calves to create the Smallpox Vaccine Seed. Flow Laboratories received a lyophilized vial of the Smallpox Vaccine Seed, Lot 3197, Passage 28 from Drs. Chanock and Moss (National Institutes of Health). This seed virus was ether-treated and plaque-purified three times.

[0151] For the generation of rV-TRICOM(mu1), a plasmid vector, designated pT5032 was constructed to direct insertion of the foreign sequences into the M2L (30K) gene, which is located in the Hind III M region of the vaccinia genome. The murine LFA-3 gene is under the transcriptional control of the vaccinia 30K (M2L) promoter (34), the murine ICAM-1 gene is under the control of the vaccinia 13 promoter (18), and the murine B7.1 gene is under the control of the synthetic early/late (sE/L) promoter (32). These foreign sequences are flanked by DNA sequences from the Hind III M region of the vaccinia genome (see Figure 1). These flanking sequences include the vaccinia K1L host range gene (33). A derivative of the Wyeth strain of vaccinia was used as the parental virus in the construction of recombinant vaccinia virus. This

parental virus, designated vTBC33, lacks a functional K1L gene and thus cannot efficiently replicate on rabbit kidney RK₁₃ cells (38). The generation of recombinant vaccinia virus was accomplished via homologous recombination between vaccinia sequences in the vTBC33 vaccinia genome and the corresponding sequences in pT5032 in vaccinia-infected RK₁₃ cells transfected with pT5032. Recombinant virus, designated vT171, was selected by growth on RK₁₃ cells (ATCC, CCL 37). Plaques were picked from the cell monolayer and their progeny were further propagated. Two rounds of plaque isolation and replating on RK₁₃ cells resulted in the purification of the desired recombinant. The genomic structure of recombinant vT171 is depicted in Figure 4A.

Example 2

Generation of Recombinant Vaccinia, rV-TRICOM(mu2) No. vT199

[0152] For the generation of rV-TRICOM(mu2), a plasmid vector, designated pT5047, was constructed to direct insertion of the foreign sequences into the thymidine kinase (TK) gene, which is located in the Hind III J region of the vaccinia genome. The murine B7.1 gene is under the control of the sE/L promoter, the murine LFA-3 gene is under the transcriptional control of the 13 promoter, and the murine ICAM-1 gene is under the control of the vaccinia 7.5K promoter (39). In addition, the *E. coli lacZ* gene, under the control of the fowlpox virus C1 promoter (15) is included as a screen for recombinant progeny. These foreign sequences are flanked by DNA sequences from the Hind III J region of the vaccinia genome (see Figure 2). A plaque-purified isolate from the Wyeth (New York City Board of Health) strain of vaccinia was used as the parental virus for this recombinant vaccine. The generation of recombinant vaccinia virus was accomplished via homologous recombination between vaccinia sequences in the Wyeth vaccinia genome and the corresponding sequences in pT5047 in vaccinia-infected Hu143TK-cells (Bacchetti and Graham 1977) transfected with pT5047. Recombinant virus was identified using selection for TK virus in the presence of bromodeoxyuridine (BudR) in combination with a chromogenic assay, performed on viral plaques *in situ*, that detects expression of the *lacZ* gene product in the presence of halogenated indolyl-beta-D-galactoside (Bluo-gal), as described previously (31). Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT199, were picked from the cell monolayer and their progeny were replated under the selective conditions described above. In other recombinant viruses selected and purified in this manner, the only plaques that appeared under these selective conditions were blue, and these blue plaques were readily isolated and purified. However, in the case of vT199, only white plaques were observed at the second round of plaque-purification; no blue plaques were apparent. A new set of blue plaques were picked and replated; again, only white plaques were observed at the second round of plaque-purification. A final attempt, using yet another set of blue plaques, yielded both blue and white plaques after the second round of plaque-purification. Blue plaques were selected and replated. Two additional rounds of plaque-purification (a total of four rounds) yielded recombinant viruses that were 100% blue. The genomic structure of recombinant vT199 is depicted in Figure 4B.

Example 3

Generation of Recombinant Vaccinia rV-TAA/TRICOM(mu)

[0153] For the generation of rV-TAA/TRICOM(mu), a plasmid vector is constructed to direct insertion of the foreign sequences into the vaccinia genome. The TAA gene, the murine LFA-3 gene, the murine ICAM-1 gene, and the murine B7.1 gene are under the control of a multiplicity of promoters. These foreign sequences are flanked by DNA sequences from the vaccinia genome, into which the foreign sequences are to be inserted. The generation of recombinant vaccinia virus is accomplished via homologous recombination between vaccinia sequences in the vaccinia genome and the corresponding sequences in the plasmid vector in vaccinia-infected cells transfected with the plasmid vector. Recombinant plaques are picked from the cell monolayer under selective conditions and their progeny are further propagated. Additional rounds of plaque isolation and replating result in the purification of the desired recombinant virus.

Example 4

Generation of Recombinant Vaccinia rV-MUC-1/TRICOM(mu)

[0154] For the generation of rV-MUC-1/TRICOM(mu), a plasmid vector is constructed to direct insertion of the foreign sequences into the vaccinia genome. The MUC-1 gene, the murine LFA-3 gene, the murine ICAM-1 gene, and the murine B7.1 gene are under the control of a multiplicity of promoters. These foreign sequences are flanked by DNA sequences from the vaccinia genome into which the foreign sequences are to be inserted. The generation of recombinant vaccinia virus is accomplished via homologous recombination between vaccinia sequences in the vaccinia genome and the corresponding sequences in the plasmid vector in vaccinia-infected cells transfected with the plasmid vector. Re-

combinant plaques are picked from the cell monolayer under selective conditions and their progeny are further propagated. Additional rounds of plaque isolation and replating result in the purification of the desired recombinant virus.

Example 5

Generation of Recombinant Vaccinia rV-CEA/TRICOM(mu) No. vT172

[0155] For the generation of rV-CEA/TRICOM(mu), a plasmid vector, designated pT5031, was constructed to direct insertion of the foreign sequences into the M2L (30K) gene, which is located in the Hind III M region of the vaccinia genome (see Figure 3). The CEA gene is under the control of the 40K promoter (13), the murine LFA-3 gene is under the control of the 30K promoter, the murine ICAM-1 gene is under the control of the 13 promoter, and the murine B7.1 gene is under the control of the sE/L promoter. These foreign sequences are flanked by DNA sequences from the Hind III M region of the vaccinia genome, including the vaccinia K1L host range gene. vTBC33, described above, was used as the parental virus in the construction of the recombinant vaccinia virus. The generation of recombinant vaccinia virus was accomplished via homologous recombination between vaccinia sequences in the vTBC33 vaccinia genome and the corresponding sequences in pT5031 in vaccinia-infected RK₁₃ cells transfected with pT5031. Recombinant virus, designated vT172, was selected by growth on RK₁₃ cells as described above. Plaques were picked from the cell monolayer and their progeny were further propagated. Two rounds of plaque isolation and replating on RK13 cells resulted in the purification of the desired recombinant. The genomic structure of recombinant vT172 is depicted in Figure 4C.

Example 6

Generation of Recombinant Fowlpox, rF-TRICOM(mu) No. vT222

[0156] The origin of parental fowlpox virus used for the generation of recombinants was plaque-purified from a vial of a USDA-licensed poultry vaccine, POXVAC-TC, which is manufactured by Schering-Plough Corporation. The starting material for the production of POXVAC-TC was a vial of Vineland Laboratories' chicken embryo origin Fowlpox vaccine, obtained by Schering-Plough. The virus was passaged twice on the chorioallantoic membrane of chicken eggs to produce a master seed virus. The master seed virus was passaged 27 additional times in chicken embryo fibroblasts to prepare the POXVAC-TC master seed. To prepare virus stocks for the generation of POXVAC-TC product lots, the POXVAC-TC master seed was passaged twice on chicken embryo fibroblasts. One vial of POXVAC-TC, Serial # 96125, was plaque-purified three times on primary chick embryo dermal cells.

[0157] For the generation of rF-TRICOM(mu), a plasmid vector, designated pT8001, was constructed to direct insertion of the foreign sequences into the BamHI J region of the fowlpox genome. The murine B7.1 gene is under the control of the sE/L promoter, the murine LFA-3 gene is under the control of the 13 promoter, the murine ICAM-1 gene is under the control of the 7.5K promoter, and the *lacZ* gene is under the control of the C1 promoter. These foreign sequences are flanked by DNA sequences from the BamHI J region of the fowlpox genome (see Figure 5). A plaque-purified isolate from the POXVAC-TC (Schering-Plough Corporation) strain of fowlpox was used as the parental virus for this recombinant vaccine. The generation of recombinant fowlpox virus was accomplished via homologous recombination between fowlpox sequences in the fowlpox genome and the corresponding sequences in pT8001 in fowlpox-infected primary chick embryo dermal cells transfected with pT8001. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT222, were picked from the cell monolayer and their progeny were replated. Six rounds of plaque isolation and replating in the presence of Blue-Gal resulted in the purification of the desired recombinant. The genomic structure of recombinant vT222 is depicted in Figure 7A.

Example 7

Generation of Recombinant Fowlpox rF-TAA/TRICOM(mu)

[0158] For the generation of rF-TAA/TRICOM(mu), a plasmid vector is constructed to direct insertion of the foreign sequences into the BamHI J region of the fowlpox genome. The TAA gene, the murine LFA-3 gene, the murine ICAM-1 gene, and the murine B7.1 gene are under the control of a multiplicity of promoters. In addition, the *lacZ* gene is under the control of the C1 promoter. These foreign sequences are flanked by DNA sequences from the BamHI J region of the fowlpox genome. A plaque-purified isolate from the POXVAC-TC (Schering-Plough Corporation) strain of fowlpox is used as the parental virus for this recombinant vaccine. The generation of recombinant fowlpox virus is accomplished via homologous recombination between fowlpox sequences in the fowlpox genome and the corresponding sequences in the plasmid vector in fowlpox-infected primary chick embryo dermal cells transfected with the plasmid vector. Recom-

binant virus is identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appear blue against a clear background. Positive plaques are picked from the cell monolayer and their progeny are replated. Additional rounds of plaque isolation and replating in the presence of Blueo-Gal result in the purification of the desired virus.

Example 8

Generation of Recombinant Fowlpox rF-MUC-1/TRICOM(mu)

[0159] For the generation of rF-MUC-1/TRICOM(mu), a plasmid vector is constructed to direct insertion of the foreign sequences into the BamHI J region of the fowlpox genome. The MUC-1 gene, the murine LFA-3 gene, the murine ICAM-1 gene, and the murine B7.1 gene are under the control of a multiplicity of promoters. In addition, the *lacZ* gene is under the control of C1 promoter. These foreign sequences are flanked by DNA sequences from the BamHI J region of the fowlpox genome. A plaque-purified isolate from the POXVAC-TC (Schering-Plough Corporation) strain of fowlpox is used as the parental virus for this recombinant vaccine. The generation of recombinant fowlpox virus is accomplished via homologous recombination between fowlpox sequences in the fowlpox genome and the corresponding sequences in the plasmid vector in fowlpox-infected primary chick embryo dermal cells transfected with the plasmid vector. Recombinant virus is identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appear blue against a clear background. Positive plaques are picked from the cell monolayer and their progeny are replated. Additional rounds of plaque isolation and replating in the presence of Blueo-Gal result in the purification of the desired recombinant virus.

Example 9

Generation of Recombinant Fowlpox, rF-CEA/TRICOM(mu) No. vT194

[0160] For the generation of rF-CEA/TRICOM(mu), a plasmid vector, designated pT5049, was constructed to direct insertion of the foreign sequences into the BamHI J region of the fowlpox genome. The CEA gene is under the control of the vaccinia 40K promoter, the murine B7-1-gene is under the control of the sE/L promoter, the murine LFA-3 gene is under the transcriptional control of the I3 promoter, the murine ICAM-1 gene is under the transcriptional control of the vaccinia 7.5K promoter, and the *lacZ* gene is under the control of the C1 promoter. These foreign sequences are flanked by DNA sequences from the BamHI J region of the fowlpox genome (see Figure 6). A plaque-purified isolate from the POXVAC-TC (Schering Corporation) strain of fowlpox was used as the parental virus for this recombinant vaccine. The generation of recombinant fowlpox virus was accomplished via homologous recombination between fowlpox sequences in the fowlpox genome and the corresponding sequences in pT5049 in fowlpox-infected primary chick embryo dermal cells transfected with pT5049. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT194, were picked from the cell monolayer and their progeny were replated. Five rounds of plaque isolation and replating in the presence of Blueo-Gal resulted in the purification of the desired recombinant. The genomic structure of recombinant fowlpox vT194 is depicted in Figure 7B.

Example 10

Generation of Recombinant Vaccinia, rV-TRICOM (hu) No. vT224

[0161] For the generation of rV-TRICOM(hu), a plasmid vector, designated pT5064, was constructed to direct insertion of the foreign sequences into the thymidine kinase (TK) gene, which is located in the Hind III J region of the vaccinia genome. The human LFA-3 gene is under the control of the 30K promoter, the human ICAM-1 gene is under the control of the 13 promoter, and the human B7.1 gene is under the control of the sE/L promoter. In addition, the *E. coli lacZ* gene, under the control of the C1 promoter, is included as a screen for recombinant progeny. These foreign sequences are flanked by DNA sequences from the Hind III J region of the vaccinia genome (see Figure 8). A plaque-purified isolate from the Wyeth (New York City Board of Health) strain of vaccinia was used as the parental virus for this recombinant vaccine. The generation of recombinant vaccinia virus was accomplished via homologous recombination between vaccinia sequences in the Wyeth vaccinia genome and the corresponding sequences in pT5064 in vaccinia-infected CV-1 cells (ATTC, CCL 70) transfected with pT5064. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT224, were picked from the cell monolayer and their progeny were replated. Five rounds of plaque isolation and replating in the presence of Blueo-Gal resulted in the purification of the desired recombinant. The genomic

structure of recombinant vT224 is depicted in Figure 9A.

Example 11

Generation of Recombinant Vaccinia rV-TAA/TRICOM(hu)

[0162] For the generation of rV-TAA/TRICOM(hu), a plasmid vector is constructed to direct insertion of the foreign sequences into the thymidine kinase (TK) gene, which is located in the Hind III J region of the vaccinia genome. The TAA gene, the human LFA-3 gene, the human ICAM-1 gene, the human B7.1 gene, and the *E. coli lacZ* gene are under the control of a multiplicity of poxvirus promoters. These foreign sequences are flanked by DNA sequences from the Hind III J region of the vaccinia genome. A plaque-purified isolate from the Wyeth (New York City Board of Health) strain of vaccinia is used as the parental virus for this recombinant vaccine. The generation of recombinant vaccinia virus is accomplished via homologous recombination between vaccinia sequences in the Wyeth vaccinia genome and the corresponding sequences in the plasmid vector in vaccinia-infected CV-1 cells (ATTC, CCL 70) transfected with the plasmid. Recombinant virus is identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appear blue against a clear background. Positive plaques are picked from the cell monolayer and their progeny are replated. Additional rounds of plaque isolation and replating in the presence of Blueo-Gal result in the purification of the desired recombinant.

Example 12

Generation of Recombinant Fowlpox rF-TAA/TRICOM(hu)

[0163] For the generation of rF-TAA/TRICOM(hu), a plasmid vector is constructed to direct insertion of the foreign sequences into the BamHI J region of the fowlpox genome. The TAA gene, the human LFA-3 gene, the human ICAM-1 gene, the human B7.1 gene, and the *E. coli lacZ* gene are under the control of a multiplicity of poxvirus promoters. These foreign sequences are flanked by DNA sequences from the BamHI J region of the fowlpox genome. A plaque-purified isolate from the POXVAC-TC (Schering-Plough Corporation) strain of fowlpox is used as the parental virus for this recombinant vaccine. The generation of recombinant fowlpox virus is accomplished via homologous recombination between fowlpox sequences in the fowlpox genome and the corresponding sequences in the plasmid vector in fowlpox-infected primary chick embryo dermal cells transfected with the plasmid vector. Recombinant virus is identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appear blue against a clear background. Positive plaques are picked from the cell monolayer and their progeny are replated. Additional rounds of plaque isolation and replating in the presence of Blueo-Gal result in the purification of the desired recombinant virus.

Example 13

Generation of Recombinant Vaccinia Virus, rV-CEA (6D)/TRICOM(bu) No. vT238

[0164] For the generation of rV-CEA(6D)/TRICOM(hu), a plasmid vector, designated pT8016, was constructed to direct insertion of the foreign sequences into the thymidine kinase (TK) gene, which is located in the Hind III J region of the vaccinia genome. The CEA gene was altered by *in vitro* mutagenesis to express full-length protein containing one modified epitope. This mutation changed the encoded amino acid at position 576 from asparagine to aspartic acid. The modified gene, designated CEA(6D), was designed to enhance the immunogenicity of CEA (Zaremba et al, 1997, Cancer Res. 57:4570-4577). The CEA(6D) gene is under the control of the 40K promoter. The human LFA-3 gene is under the control of the 30K promoter, the human ICAM-1 gene is under the control of the I3 promoter, and the human B7.1 gene is under the control of the sE/L promoter. In addition, the *E. coli lacZ* gene, under the control of the C1 promoter, is included as a screen for recombinant progeny. These foreign sequences are flanked by DNA sequences from the Hind III J region of the vaccinia genome (see Figure 10). A plaque-purified isolate from the Wyeth (New York City Board of Health) strain of vaccinia was used as the parental virus for this recombinant vaccine. The generation of recombinant vaccinia virus was accomplished via homologous recombination between vaccinia sequences in the Wyeth vaccinia genome and the corresponding sequences in pT8016 in vaccinia-infected CV-1 cells (American Type Culture Collection (ATCC), Rockville, MD, CCL 70) transfected with pT8016. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT238, were picked from the cell monolayer and their progeny were replated. Six rounds of plaque isolation and replating in the presence of Blueo-Gal resulted in the purification of the desired recombinant. The genomic structure of recombinant vaccinia virus vT238 is shown in Figure 11.

Example 14**Generation of Recombinant Fowlpox Virus, rF-TRICOM(mu) No. vT251**

[0165] For the generation of rF-TRICOM(mu), a plasmid vector, designated pT8019, was constructed to direct insertion of the foreign sequences into the BamHI J region of the fowlpox genome. The murine LFA-3 gene is under the control of the 30K promoter, the murine ICAM-1 gene is under the control of the I3 promoter, the murine B7.1 gene is under the control of the sE/L promoter, and the *lacZ* gene is under the control of the C1 promoter. These foreign sequences are flanked by DNA sequences from the BamHI J region of the fowlpox genome (see Figure 12). A plaque-purified isolate from the POXVAC-TC (Schering-Plough Corporation) strain of fowlpox was used as the parental virus for this recombinant vaccine. The generation of recombinant fowlpox virus was accomplished via homologous recombination between fowlpox sequences in the fowlpox genome and the corresponding sequences in pT8019 in fowlpox-infected primary chick embryo dermal cells transfected with pT8019. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT251, were picked from the cell monolayer and their progeny were replated. Three rounds of plaque isolation and replating in the presence of Blue-Gal resulted in the purification of the desired recombinant. The genomic structure of recombinant vaccinia virus vT251 is shown in Figure 13A.

Example 15**Generation of Recombinant Fowlpox Virus, rF-TRICOM(hu) No. vT232**

[0166] For the generation of rF-TRICOM(hu), a plasmid vector, designated pT5072, was constructed to direct insertion of the foreign sequences into the BamHI J region of the fowlpox genome. The human LFA-3 gene is under the control of the 30K promoter, the human ICAM-1 gene is under the control of the 13 promoter, the human B7.1 gene is under the control of the sE/L promoter, and the *lacZ* gene is under the control of the C 1 promoter. These foreign sequences are flanked by DNA sequences from the BamHI J region of the fowlpox genome (see Figure 14). A plaque-purified isolate from the POXVAC-TC (Schering-Plough Corporation) strain of fowlpox was used as the parental virus for this recombinant vaccine. The generation of recombinant fowlpox virus was accomplished via homologous recombination between fowlpox sequences in the fowlpox genome and the corresponding sequences in pT5072 in fowlpox-infected primary chick embryo dermal cells transfected with pT5072. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT232 were picked from the cell monolayer and their progeny were replated. Four rounds of plaque isolation and replating in the presence of Blue-Gal resulted in the purification of the desired recombinant. The genomic structure of recombinant vaccinia virus vT232 is shown in Figure 13B.

Example 16**Generation of Recombinant Fowlpox Virus, rF-MUC-1/TRICOM(mu) No. vT250**

[0167] For the generation of rF-MUC-1/TRICOM(mu), a plasmid vector, designated pT8020, was constructed to direct insertion of the foreign sequences into the BamHI J region of the fowlpox genome. A truncated version of the MUC-1 gene was used, consisting of the signal sequence, ten copies of the tandem repeat sequence, and the 3' unique coding sequence. (SEQ ID NO:41). The nucleotide sequence of the tandem repeat region was altered to minimize homology between the repeats without changing the amino acid sequence. The gene was contained on an 1881 bp fragment which includes the truncated coding sequence, 6 nucleotides of the 5' untranslated region, and 186 nucleotides of the 3' untranslated region (Gendler et al, 1990, J. Biol. Chem. 265:15286-15293). The murine LFA-3 gene is under the control of the 30K promoter, the murine ICAM-1 gene is under the control of the 13 promoter, the murine B7.1 gene is under the control of the sE/L promoter, and the *lacZ* gene is under the control of the C 1 promoter. These foreign sequences are flanked by DNA sequences from the BamHI J region of the fowlpox genome (see Figure 15). A plaque-purified isolate from the POXVAC-TC (Schering-Plough Corporation) strain of fowlpox was used as the parental virus for this recombinant vaccine. The generation of recombinant fowlpox virus was accomplished via homologous recombination between fowlpox sequences in the fowlpox genome and the corresponding sequences in pT8020 in fowlpox-infected primary chick embryo dermal cells transfected with pT8020. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT250, were picked from the cell monolayer and their progeny were replated. Four rounds of plaque isolation and replating in the presence of Blue-Gal resulted in the purification of the desired recombinant. The genomic structure of recombinant vaccinia virus vT250 is shown in Figure 16A.

Example 17**Generation of Recombinant Fowlpox Virus, rF-MUC-1/TRICOM(hu) No. vT242**

[0168] For the generation of rF-MUC-1/TRICOM(hu), a plasmid vector, designated pT2186 was constructed to direct insertion of the foreign sequences into the BamHI J region of the fowlpox genome. A truncated version of the MUC-1 gene was used, as described in Example 16 above. The MUC-1 gene is under the control of the 40K promoter. The human LFA-3 gene is under the control of the 30K promoter, the human ICAM-1 gene is under the control of the I3 promoter, the human B7.1 gene is under the control of the sE/L promoter, and the *lacZ* gene is under the control of the C1 promoter. These foreign sequences are flanked by DNA sequences from the BamHI J region of the fowlpox genome (see Figure 17). A plaque-purified isolate from the POXVAC-TC (Schering-Plough Corporation) strain of fowlpox was used as the parental virus for this recombinant vaccine. The generation of recombinant fowlpox virus was accomplished via homologous recombination between fowlpox sequences in the fowlpox genome and the corresponding sequences in pT2186 in fowlpox-infected primary chick embryo dermal cells transfected with pT2186. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT242, were picked from the cell monolayer and their progeny were replated. Four rounds of plaque isolation and replating in the presence of Blueo-Gal resulted in the purification of the desired recombinant. The genomic structure of recombinant vaccinia virus vT242 is shown in Figure 16B.

Example 18**Generation of Recombinant Fowlpox Virus, rF-CEA(6D)/TRICOM(hu) No. vT236**

[0169] For the generation of rF-CEA(6D)/TRICOM(hu), a plasmid vector, designated pT2187, was constructed to direct insertion of the foreign sequences into the BamHI J region of the fowlpox genome. The CEA(6D) gene is under the control of the 40K promoter. The human LFA-3 gene is under the control of the 30K promoter, the human ICAM-1 gene is under the control of the 13 promoter, the human B7.1 gene is under the control of the sE/L promoter, and the *lacZ* gene is under the control of the C1 promote. These foreign sequences are flanked by DNA sequences from the BamHI J region of the fowlpox genome (see Figure 18). A plaque-purified isolate from the POXVAC-TC (Schering-Plough Corporation) strain of fowlpox was used as the parental virus for this recombinant vaccine. The generation of recombinant fowlpox virus was accomplished via homologous recombination between fowlpox sequences in the fowlpox genome and the corresponding sequences in pT2187 in fowlpox-infected primary chick embryo dermal cells transfected with pT2187. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT236, were picked from the cell monolayer and their progeny were replated. Eight rounds of plaque isolation and replating in the presence of Blueo-Gal resulted in the purification of the desired recombinant. The genomic structure of recombinant vaccinia virus vT236 is shown in Figure 16C.

Example 19**Generation of Recombinant Fowlpox Virus, rF-PSA/PSMA/TRICOM(hu) No. vT257**

[0170] For the generation of rF-PSA/PSMA/TRICOM(hu), a plasmid vector, designated pT5080, was constructed to direct insertion of the foreign sequences into the BamHI J region of the fowlpox genome. The gene encoding PSA was isolated by polymerase chain reaction amplification of cDNA derived from RNA from the human LNCaP cell line (CRL 1740, American Type Culture Collection (ATCC), Rockville, MD). The gene was contained on a 1346 bp fragment which includes the entire coding sequence for PSA, 41 nucleotides of the 5' untranslated region, and 552 nucleotides of the 3' untranslated region (Lundwall and Lilja, 1987, FEBS Lett. 214:317-322). The gene encoding PSMA was isolated by polymerase chain reaction amplification of cDNA derived from RNA from the human LNCaP cell line. The gene was contained on a 2298 bp fragment which includes the entire coding sequence for PSMA, 26 nucleotides of the 5' untranslated region, and 19 nucleotides of the 3' untranslated region (Israeli et al, 1993 Cancer Res. 53:227-230). The PSA gene is under the control of the 40K promoter and the PSMA gene is under the control of the 7.5K promoter. The human LFA-3 gene is under the control of the 30K promoter, the human ICAM-1 gene is under the control of the 13 promoter, the human B7.1 gene is under the control of the sE/L promoter, and the *lacZ* is under the control of the C1 promoter. These foreign sequences are flanked by DNA sequences from the BamHI J region of the fowlpox genome (see Figure 19). A plaque-purified isolate from the POXVAC-TC (Schering-Plough Corporation) strain of fowlpox was used as the parental virus for this recombinant vaccine. The generation of recombinant fowlpox virus was accomplished via homologous recombination between fowlpox sequences in the fowlpox genome and the corresponding sequences in pT5080

in fowlpox-infected primary chick embryo dermal cells transfected with pT5080. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT257, were picked from the cell monolayer and their progeny were replated. Five rounds of plaque isolation and replating in the presence of Blue-Gal resulted in the purification of the desired recombinant. The genomic structure of recombinant vaccinia virus vT257 is shown in Figure 16D.

Example 20

Generation of Recombinant MVA Virus, rMVA-TRICOM(mu) No. vT264

[0171] Modified Vaccinia Ankara (MVA) is an attenuated derivative of the Ankara strain of vaccinia virus (Meyer et al, 1991, J. Gen. Virol. 72:1031-10381. The seed stock from the MVA vaccine used as smallpox vaccine in humans was obtained from Dr. Anton Mayr (Institute for Medical Microbiology, Munich). The seed stock was plaque-purified two times on primary chick embryo dermal cells.

[0172] For the generation of rMVA-TRICOM(mu), a plasmid vector, designated pT5085, was constructed to direct insertion of the foreign sequences into the deletion III region of the MVA genome (Meyer et al, 1991, J. Gen. Virol. 72: 1031-1038). The murine LFA-3 gene is under the control of the 30K promoter, the murine ICAM-1 gene is under the control of the 13 promoter, the murine B7.1 gene is under the control of the sE/L promoter, and the *lacZ* gene is under the control of the C1 promoter. These foreign sequences are flanked by DNA sequences from the deletion III region of the MVA genome (see Figure 20). A plaque-purified isolate from the MVA vaccine seed stock was used as the parental virus for this recombinant vaccine. The generation of recombinant MVA was accomplished via homologous recombination between MVA sequences in the MVA genome and the corresponding sequences in pT5085 in MVA-infected primary chick embryo dermal cells transfected with pT5085. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT264 were picked from the cell monolayer and their progeny were replated. Four rounds of plaque isolation and replating in the presence of Blue-Gal resulted in the purification of the desired recombinant. The genomic structure of recombinant MVA vT264 is shown in Figure 21A.

Example 21

Generation of Recombinant MVA Virus, rMVA-PSA/PSMA/TRICOM(hu) No. vT260

[0173] For the generation of rMVA-PSA/PSMA/TRICOM(hu), a plasmid vector, designated pT5084, was constructed to direct insertion of the foreign sequences into the deletion III region of the MVA genome. The PSA gene is under the control of the 40K promoter and the PSMA gene is under the control of the 7.5K promoter. The human LFA-3 gene is under the control of the 30K promoter, the human ICAM-1 gene is under the control of the I3 promoter, the human B7.1 gene is under the control of the sE/L promoter, and the *lacZ* gene is under the control of the C1 promoter. These foreign sequences are flanked by DNA sequences from the deletion III region of the MVA genome (see Figure 22). A plaque-purified isolate from the MVA vaccine seed stock was used as the parental virus for this recombinant vaccine. The generation of recombinant MVA was accomplished via homologous recombination between MVA sequences in the MVA genome and the corresponding sequences in pT5084 in MVA-infected primary chick embryo dermal cells transfected with pT5084. Recombinant virus was identified using the chromogenic assay for the *lacZ* gene product described above. Viral plaques expressing *lacZ* appeared blue against a clear background. Positive plaques, designated vT260, were picked from the cell monolayer and their progeny were replated. Four rounds of plaque isolation and replating in the presence of Blue-Gal resulted in the purification of the desired recombinant. The genomic structure of recombinant MVA vT260 is shown in Figure 21B.

Example 22

Recombinant Poxviruses

[0174] The individual recombinant vaccinia viruses containing either the gene encoding murine costimulatory molecule B7-1 (designated rV-B7-1) or the gene encoding murine Intercellular adhesion molecule-1 (designated rV-ICAM-1) have been described (10, 11). The recombinant vaccinia virus containing the gene for murine CD48 [designated rV-LFA-3; murine CD48 is the homologue of human LFA-3 (CD58) (6)] was constructed in a similar fashion to rV-B7-1 and rV-ICAM-1, and has been described (12). In each of these single recombinant vaccinia viruses, the gene encoding the costimulatory molecule was put under the control of the vaccinia virus early/late 40K promoter (15), and the transgene was inserted into the *Hind III* M region of the genome of the Wyeth strain of vaccinia virus as described (13). Recombinant

fowlpox viruses were constructed by the insertion of foreign sequences into the *Bam*HI J region of the genome of the POXVAC-TC (Schering Corporation) strain of fowlpox virus as described (14). In recombinant viruses containing a single foreign gene, the gene is under control of the vaccinia 40K promoter. rV-B7-1/ICAM-1 is a recombinant vaccinia virus that contains the murine B7-1 gene under control of the synthetic early/late (sE/L) promoter (16) and the murine ICAM-1 gene under control of the 40K promoter. rV-B7-1/ICAM-1/LFA-3 is a recombinant vaccinia virus that contains the murine LFA-3 gene under control of the vaccinia 30K (M2L) promoter (17), the murine ICAM-1 gene under control of the vaccinia 13 promoter (18), and the murine B7-1 gene under control of the synthetic early/late (sE/L) promoter. rF-CEA/B7-1/ICAM-1/LFA-3 is a recombinant fowlpox virus that contains the human carcinoembryonic antigen (CEA) gene under control of the 40K promoter, the murine B7-1 gene under control of the sE/L promoter, the murine LFA-3 gene under control of the I3 promoter, and the murine ICAM-1 gene under control of the vaccinia 7.5K promoter (19). Non-recombinant vaccinia virus was designated V-Wyeth, while non-recombinant fowlpox virus was designated WT-FP.

Example 23

Expression of Recombinant Costimulatory Molecules

[0175] To confirm that each of the recombinant vectors could express the appropriate transgene(s), the murine adenocarcinoma cell line MC38 was infected with the various recombinant vaccinia or fowlpox constructs, and cell-surface expression of the transgene(s) was demonstrated by flow cytometry (Figure 23). Uninfected cells (data not shown) and cells infected with wild-type vaccinia failed to express any of the three costimulatory molecules. This observation was confirmed by PCR (data not shown). In contrast, cells infected with rV-B7-1 became strongly positive for B7-1 protein; cells infected with rV-ICAM-1 became positive for ICAM-1; and cells infected with rV-LFA-3 became positive for LFA-3 protein. Similar analysis of a construct containing two costimulatory molecules (rV-B7-1/ICAM-1) showed expression of B7-1 (78% positive with a mean fluorescent intensity (MFI) of 1012) and ICAM-1 (70% positive with a MFI of 690). Moreover, cells infected with the vaccinia multiple-gene construct rV-B7-1/ICAM-1/LFA-3 co-expressed all three costimulatory molecules. To determine if the recombinant fowlpox viruses expressed their recombinant proteins, MC38 cells were infected with the fowlpox constructs in a similar manner (Figure 23). Again, cells infected with wild-type fowlpox virus WT-FP failed to express any costimulatory molecule. Cells infected with rF-B7-1 became positive for B7-1 protein, and cells infected with rF-ICAM-1 became positive for ICAM-1 protein. A rF-LFA-3 vector was not constructed. However, cells infected with the fowlpox multiple-gene construct rF-CEA/B7-1/ICAM-1/LFA-3 co-expressed all three costimulatory molecules.

Characterization of Recombinant Viruses: Fluorescent Analysis of Protein Surface Expression

[0176] The MC38 murine colonic adenocarcinoma cell line has been described (20). Confluent MC38 cells were infected with vaccinia constructs (V-Wyeth, rV-B7-1, rV-ICAM-1, rV-LFA-3, rV-B7-1/ICAM-1/LFA-3) or fowlpox constructs (WT-FP, rF-B7-1, rF-ICAM-1, rF-CEA/B7-1/ICAM-1/LFA-3) at 5 MOI (multiplicity of infection; PFU/cell) for 5 hours. CEA was used in one rF construct as a marker gene only. After infection, cells were harvested and immunostained with FITC conjugated monoclonal antibodies (MAb) specific for murine CD80 (B7-1), CD54 (ICAM-1), or CD48 (LFA-3; PharMingen, San Diego, CA). Cell fluorescence was analyzed with a FACSCAN cytometer (Becton Dickinson, Mountain View, CA) with the Lysis II software.

In vitro Costimulation Analysis

[0177] Female C57BL/6 mice (6-8 weeks old) were obtained from Taconic Farms (Germantown, NY). Naive T cells were isolated from spleens mechanically dispersed through 70 m cell strainers (Falcon, Becton Dickinson, Franklin Lakes, NJ) to isolate single cell suspensions, and erythrocytes and dead cells were removed by centrifugation over Ficoll-Hypaque gradients (density=1.119 g/ml) (Sigma, St. Louis, MO). Populations consisting of approximately 95% T cells were obtained by passage of splenic mononuclear cells over two nylon wool columns sequentially (Robbins Scientific Corp., Sunnyvale, CA). For certain experiments, T cells were further fractionated into CD4⁺ and CD8⁺ populations by negative selection utilizing anti-CD4 or anti-CD8 paramagnetic beads (MiniMACS, Miltenyi Biotec, Auburn, CA). T cells were added at 10⁵/well in 96-well flat-bottomed plates (Costar, Cambridge, MA). Stimulator cells consisted of uninfected MC38 cells or cells infected for 5 hours with 5 MOI of vaccinia constructs (V-Wyeth, rV-B7-1, rV-ICAM-1, rV-LFA-3, rV-B7-1/ICAM-1/LFA-3) or fowlpox constructs (WT-FP, rF-B7-1, rF-ICAM-1, rF-CEA/B7-1/ICAM-1/LFA-3) fixed with 2% paraformaldehyde and added at 10⁴/well. Cells in all wells were cultured in a total volume of 200 μl of complete media (CM) [RPMI 1640 with fetal calf serum (10%), glutamine (2 mM), sodium pyruvate (1 mM), Hepes (7 mM), gentamicin (50 μg/ml), 2-mercaptoethanol (50 μM), and non-essential amino acids (0.1 mM), (Biofluids, Rockville, MD)] in the presence of several dilutions (5 to 0.625 μg/ml for 2 days) of Concanavalin-A (Con A, Sigma). Control wells received T

cells, stimulator cells and media only. For indicated experiments, plate-bound anti-CD3 (1.5 μ g/well-0.012 μ g/well) was substituted for Con A. Cells were labeled for the final 12-18 h of the incubation with 1 Ci/well 3 H-Thymidine (New England Nuclear, Wilmington, DE) and harvested with a Tomtec cell harvester (Wallac Incorporated, Gaithersburg, MD). The incorporated radioactivity was measured by liquid scintillation counting (Wallac 1205 Betaplate, Wallac, Inc.) The results from triplicate wells were averaged and are reported as mean CPM \pm SEM. For indicated experiments, the *in vitro* costimulation analysis was performed in the presence of either a MAb specific for the expressed costimulatory molecule or the matching isotype control antibody (Armenian hamster IgG, polyclonal). Antibodies used to block T-cell proliferation were Hamster anti-murine CD80 (B7-1; clone 16-10A1), Hamster anti-murine CD54 (ICAM-1; clone 3E2), or Hamster anti-murine CD48 (BCM-1; clone HM48-1), all from PharMingen. All antibodies were used at 25 μ g/ml final concentration.

Determination of Costimulatory Molecule Capacity

[0178] T cells and stimulator cells were prepared as described above. Fixed stimulator cells expressing one or more costimulatory molecules were added to wells in various ratios in combination with V-Wyeth-infected/fixed stimulator cells to a total of 10^4 /well. T cells (10^5 /well) were then added, and cells were cultured in a total volume of 200 μ l of CM in the presence of 2.5 μ g/ml Con A for 2 days and labeled for the final 12-18 h of the incubation with 1 μ Ci/well 3 H-Thymidine. The incorporated radioactivity was measured by liquid scintillation counting as before.

Cytokine Analysis

[0179] CD4⁺ and CD8⁺ T-cell populations were prepared as described above and added at 2.5×10^6 /well in a 6-well plate (Costar). Stimulator cell populations were prepared as above and added at 2.5×10^5 /well. Cells were cultured in a total volume of 5 ml of CM in the presence of 2.5 μ g/ml Con A for 24 hours. Supernatant fluids were collected and analyzed for murine IL-2, IFN γ , TNF- α , GM-CSF, and IL-4 by capture ELISA as described previously (21). Sensitivity of detection was 30, 100, 20, 20, and 20 pg/ml, respectively.

[0180] RNA populations from stimulated cells were also analyzed by multiprobe RNase protection assay (mpRPA). Defined riboprobes for murine cytokines were purchased from PharMingen. Assays were performed as described previously (22). Protected probe-tagged duplexes were separated by electrophoresis on 6% polyacrylamide gels. Dried gels were exposed to Biomax film (Kodak) at -70°C for 24-72 hours. Radioactivity contained in the bands was quantified using a Storm system phosphorimager (Molecular Dynamics, Sunnyvale, CA). The net CPM for a given band was calculated by the following formula [cpm of cytokine gene minus cpm of background] and was expressed as a percent of the housekeeping gene transcript L32.

Example 24

B7-1, ICAM-1, and LFA-3 Cooperate Synergistically to Enhance T-cell Proliferation

[0181] The B7-1, ICAM-1, and LFA-3 molecules have been shown individually to costimulate T-cell proliferation. However, because they may be expressed simultaneously on APC, it has been difficult to examine relative roles of individual costimulatory molecules during the induction of T-cell proliferation (2). To analyze the contribution of B7-1, ICAM-1 and/or LFA-3 molecules to the induction of naive T-cell proliferation, a modified *in vitro* model (23, 24) was employed where the first signal for T-cell activation was delivered via a pharmacological reagent (Con A). A panel of stimulator cells that differed only in costimulatory molecules was created using the MC38 cell line infected with various recombinant vaccinia (Figure 24A) or fowlpox (Figure 24B) viruses engineered to express costimulatory molecules. The second, or "costimulatory," signal was delivered to the T cell via one or more costimulatory molecules expressed on the surface of these "stimulator" MC38 cells. As shown in Figure 24A, both uninfected MC38 cells and MC38/V-Wyeth induced marginal proliferation of T cells at all levels of Con A examined. MC38/LFA-3 induced a small (2.1-fold) but significant ($P < 0.05$) increase in T-cell proliferation. Delivery of signal-2 via MC38/ICAM-1 induced a 3.5-fold increase in T-cell proliferation at 2.5 μ g/ml Con A. MC38/B7-1 induced a 7.8-fold and a 16-fold increase in proliferation at 2.5 and 1.25 μ g/ml Con A respectively. However, MC38B7-1/ICAM-1/LFA-3 (MC38 cells co-expressing all three costimulatory molecules) induced a 17.5-fold increase in T-cell proliferation at 2.5 μ g/ml Con A, and a 34-fold increase at 1.25 μ g/ml Con A. Moreover, at low Con A levels (0.625 μ g/ml), expression of ICAM-1 and LFA-3 did not induce T-cell proliferation. While B7-1 induced measurable proliferation (20,000 CPM) at 0.625 μ g/ml Con A, the coexpression of all three costimulatory molecules induced an even greater level of proliferation (100,000 CPM) (Figure 24A). These experiments were repeated four times with similar results.

[0182] MC38 stimulator cells were also prepared by infection with recombinant fowlpox vectors (Figure 24B). Again, uninfected MC38 or MC38/WT-FP induced marginal proliferation of T cells at all levels of Con A examined. MC38/rF-ICAM-1 supported a 2-fold increase, MC38/rF-B7-1 supported a 3.2-fold increase, and MC38/rF-B7-1/ICAM-1/LFA-3

supported a 6-fold increase in T-cell proliferation at 2.5 $\mu\text{g/ml}$ Con A. Similar results were obtained when this experiment was repeated two additional times. Similar results were also observed when the first signal was delivered via immobilized anti-CD3 (data not shown). The differences noted in proliferation supported by MC38/rV-B7-1/ICAM-1/LFA-3 and MC38/rF-CEA/B7-1/ICAM-1/LFA-3 (17.5-fold vs. 6-fold) are most likely due to the levels of expressed recombinant protein(s) following a 5-hour infection period (Figure 23). Specifically, approximately 70% of the cells infected with rV-B7-1/ICAM-1/LFA-3 express the costimulatory molecules, while approximately 40% of cells infected with rF-CEA/B7-1/ICAM-1/LFA-3 are positive. Those positive cells infected with the rF vectors express recombinant B7-1 and ICAM-1 at levels of 50% of those cells infected with rV-B7-1/ICAM-1/LFA-3 with the conditions used.

Example 25

Specificity of Costimulatory Molecule Contribution on T-cell Proliferation

[0183] To further confirm the specificity of the proliferative contribution of B7-1, ICAM-1, or LFA-3, MC38 stimulator cells were again prepared by infection with V-Wyeth, rV-B7-1, rV-ICAM-1, or rV-LFA-3 and co-cultured with naive murine T cells and Con A in the presence or absence of MAb specific for the given costimulatory molecule. As shown in Figure 3B, MC38B7-1 enhanced T-cell proliferation 4.5-fold more than that of MC38N-Wyeth (Figure 25A). This increased proliferation was inhibited 83% by the addition of a blocking MAb for murine B7-1. Similarly, MC38/ICAM-1 (Figure 25C) increased proliferation 2.25-fold, which was then reduced by 88% in the presence of anti-murine ICAM-1 MAb. Finally, MC38/LFA-3 (Figure 25D) increased proliferation 2.1-fold, which was then reduced by 98% in the presence of anti-murine CD48 MAb. For each group, incubation with the appropriate isotype control antibody (as specified in Materials and Methods) failed to block the noted proliferation. This experiment was repeated two additional times with similar results.

Example 26

Determination of Costimulatory Molecule Capacity

[0184] Modification of the *in vitro* costimulation assay allowed a quantitative estimation of the relative capacity of B7-1, ICAM-1, and/or LFA-3 to deliver the second signal for T-cell proliferation. To that end, stimulator cells (MC38 cells infected with the various recombinant vaccinia viruses) were titrated out by dilution with varying amounts of MC38 cells infected with V-Wyeth and co-cultured with a constant number of T cells in the presence of 2.5 $\mu\text{g/ml}$ Con A. The MC38 to T-cell ratio in these experiments remained constant at 1:10. As seen in Figure 4, MC38/LFA-3 (closed triangles) enhanced proliferation of T cells over that of MC38/V-Wyeth (open square) out to a concentration of 40% (i.e., of the stimulator cells in the well, 40% were infected with rV-LFA-3 and the remaining 60% were infected with V-Wyeth). MC38/ICAM-1 (closed circles) or MC38B7-1 (closed diamonds) supported increased proliferation out to a concentration of 13% and 6%, respectively. In contrast, MC38B7-1/ICAM-1/LFA-3 enhanced proliferation when less than 3% of stimulator cells contained the triad vector (extrapolated to less than 1% via linear least squares analysis). Given the titration curves of these individual costimulatory molecules, it appeared that the extent of T-cell proliferation mediated by ICAM-1 and B7-1 is 3-fold and 6-fold, respectively, more potent than that mediated by LFA-3 alone. Clearly the strongest proliferation, however, is mediated by B7-1/ICAM-1/LFA-3. It should be noted (Figure 26) that at relatively low stimulator cell concentrations (i.e., when 3%-6% of the MC38 cells are acting as stimulator cells), expression of LFA-3, ICAM-1, and even B7-1 alone does not enhance T-cell activation, while the three costimulatory molecules expressing stimulator cells substantially enhance T-cell activation. The data in Figure 26 (insert) shows proliferation results obtained when 3% of the MC38 stimulator cells were infected with the vectors denoted. Since each well contained 10^4 total MC38 cells and 10^5 naive T cells, the actual stimulator to T-cell ratio in these cultures was 0.003. Note that the MC38 cells infected with the two-gene construct (rV-B7-1/ICAM-1) induced little, if any, proliferation of T cells under these conditions, while MC38B7-1/ICAM-1/LFA-3 increased proliferation substantially ($p < 0.0001$).

Example 27

Costimulation of CD4⁺ and CD8⁺ T cells

[0185] To further characterize the T-cell response to costimulatory molecules expressed singly or in combination, the ability of B7-1, ICAM-1, and LFA-3 to costimulate purified CD4⁺ and CD8⁺ T cells was tested. Figure 5 shows the proliferation of purified CD4⁺ (Figure 27A) and CD8⁺ (Figure 27B) cells activated with suboptimal concentrations of Con A. The stratification of stimulator cell effects on proliferation was similar for both CD4⁺ and CD8⁺ cells: MC38/LFA-3 stimulated the weakest proliferation, followed by MC38/ICAM-1 and MC38/B7-1. MC38/B7-1/ICAM-1/LFA-3 were the most potent stimulator cells for CD4⁺ and CD8⁺ T cells. These experiments were repeated three additional times with

similar results. It should be noted that at very low concentrations of Con A (0.625 μ g/ml, Figure 5, panels C and D), there was no significant enhancement in activation of CD4⁺ or CD8⁺ T cells when either ICAM-1, LFA-3, B7-1, or the B7-1/ICAM-1 combination was used to provide the second signal. However, substantial activation of both T-cell subsets was observed when the vaccinia virus coexpressing the triad of costimulatory molecules was employed. Similar results

[0186] It has been reported that B7-1 costimulation prolongs IL-2 mRNA half life and upregulation of IL-2 transcription, resulting in production of considerable amounts of secreted IL-2 (4, 25). Additionally, T-cell costimulation with LFA-3 has been reported to have an effect on a variety of cytokines, notably IL-2 and IFN- γ (6). To determine qualitative and quantitative effects of costimulation by single or multiple costimulatory molecules on cytokine production, purified CD4⁺ and CD8⁺ T cells were again co-cultured with various stimulator cells expressing B7-1, ICAM-1, and LFA-3 alone or in combination in the presence of 2.5 μ g/ml Con A. Supernatant fluids were analyzed for IL-2, IFN- γ , TNF- α , GM-CSF, and IL-4 after 24 hours. Uninfected MC38 (data not shown) and MC38N-Wyeth induced a marginal quantity of IL-2 from CD4⁺ cells (Figure 28A), while MC38/B7-1 induced 3,979 pg/ml. However, T-cell stimulation with MC38B7-1/ICAM-1/LFA-3 induced a 10-fold greater amount of IL-2. Similarly, MC38B7-1 induced a marginal quantity of IL-2 from CD8⁺ cells (Figure 28B), while MC38B7-1/ICAM-1/LFA-3 induced a 20-fold greater amount (6,182 pg/ml). IFN- γ production by stimulated T cells was also examined. MC38B7-1 and MC38/LFA-3 induced only moderate amounts of IFN- γ from CD4⁺ cells (Figure 28C). In contrast, stimulation of CD4⁺ cells with MC38B7-1/ICAM-1/LFA-3 induced 4-fold more IFN- γ than stimulation with any other construct. Stimulation of CD8⁺ cells with MC38B7-1/ICAM-1/LFA-3 induced the greatest amount of IFN- γ greater than 6-fold more than CD8⁺ cells stimulated with any of the other constructs (Figure 28D). Stimulation of either cell type with any construct failed to mediate significant changes ($p > 0.05$) in the levels of secreted TNF- α , GM-CSF, or IL-4 (data not shown). It appears that the predominant culmination of stimulation via the triad construct (rV-B7-1/ICAM-1/LFA-3) was IL-2 secretion from CD4⁺ cells and IFN- γ secretion from CD8⁺ T cells. These experiments were repeated three additional times with similar results. Studies were also carried out comparing stimulator cells infected with the two-gene construct (rV-B7-1/ICAM-1) vs. the multi-gene construct (rV-B7-1/ICAM-1/LFA-3) for their ability to enhance cytokine production by T cells. Only small differences were observed between the two in IFN- γ production by either CD4⁺ or CD8⁺ cells, or in IL-2 production by CD8⁺ cells. But a substantial difference was seen in the stimulation of IL-2 production by CD4⁺ cells (5000 pg/ml employing MC38/B7-1/ICAM-1 vs. 39,600 pg/ml employing MC38/B7-1/ICAM-1/LFA-3).

[0187] Cytokine expression from CD4⁺ and CD8⁺ T cells stimulated with single or multiple costimulatory molecules was also analyzed at the RNA level utilizing the multiprobe RNase protection assay (mRPA). A representative radio-graphic profile and quantitative analysis from two independent experiments are depicted (Figure 29). Levels of IL-4, IL-5, IL-10, IL-15, and IL-6 were similar in CD4⁺ T cells stimulated with MC38/V-Wyeth, MC38/B7-1, MC38/ICAM-1, MC38/LFA-3, or MC38/B7-1/ICAM-1/LFA-3 (Figure 29, panel B histogram). IL-2 and IFN- γ expression levels were highest in CD4⁺ T cells stimulated with MC38B7-1/ICAM-1/LFA-3 when compared with CD4⁺ cells stimulated with MC38 cells expressing any single costimulatory molecule (Figure 29B). Slightly higher levels of IL-13, IL-9, and IL-6 were also noted in CD4⁺ cells stimulated with MC38B7-1/ICAM-1/LFA-3. Expression of cytokine genes was also analyzed in stimulated CD8⁺ T cells. Of the cytokine RNAs analyzed, IL-2 and particularly IFN- γ levels were significantly higher when these cells were stimulated with MC38B7-1/ICAM-1/LFA-3, compared to T cells stimulated with MC38 cells expressing any single costimulatory molecule. Thus, the predominant synergistic effect of the triad of costimulatory molecules in cytokine production was IL-2 in CD4⁺ cells and IFN- γ in CD8⁺ T cells.

Example 28

Effect of TRICOM costimulation on Apoptosis of Stimulated T cells

Apoptosis studies

[0188] To determine if stimulation of T cells with signal 1 and rV-TRICOM would lead to cell survival or programmed cell death (PCD), CD8⁺ T cells were activated with Con A for signal 1, cultured with either V-WT, rV-B7-1 or rV-TRICOM-infected MC38 cells for 48 hr, and replated for 24 hr in medium to measure apoptosis. Apoptosis was assessed using the TUNEL assay, as described by Gavrieli, Y et al. J. Cell Biol 119: 493-501, 1992. T cells activated by the combination of MC38 and Con A or MC38/V-WT and Con A in the absence of costimulatory signals exhibited high levels of spontaneous apoptosis (82.9 ± 1 , respectively). T cells activated by Con A and MC38/B7-1 or Con A and MC38/TRICOM exhibited substantially less spontaneous apoptosis (31.3 ± 3.8 and 30.7 ± 1 , respectively).

[0189] The results clearly demonstrate apoptosis in T cells stimulated with MC38 cells in the presence of Con A with or without V-WT infection (i.e., in the absence of signal 2). While Con A with MC38/TRICOM clearly stimulated CD8⁺ cells to far greater levels than Con A with MC38B7-1 and resulted in the production of higher levels of IFN- γ and IL-2, this did not result in any greater degree of apoptosis.

Example 29**Anti-tumor Effect of rV-CEA/TRICOM In vivo**

[0190] Studies were conducted to determine if an antigen-specific immune response could be enhanced using a TRICOM vector. A four-gene vaccinia recombinant was constructed that contained the human CEA gene and the B7-1, ICAM-1 and LFA-3 genes, designated rV-CEA/TRICOM, as disclosed herein. Six to eight-week-old female C57 BL/6 mice (Taconic Farms) or C57BL/6 mice transgenic for human CEA (Kass, E et al Cancer Res. 59: 676-683, 1999) were vaccinated by tail scarification with either Hank's Balanced Salt Solution (HBSS) or one time with 10^7 pfu rV-CEA, rV-CEA/B7-1 or rV-CEA/TRICOM, and spleens were harvested 22 days later. Lymphoproliferative activity of splenocytes was analyzed as described previously (5).

[0191] As seen in Figure 30 (insert), splenic T cells of mice vaccinated with rV-TRICOM showed higher levels of CEA-specific stimulation compared with T cells obtained from mice vaccinated with rV-CEA; Ovalbumin and Con A were used as controls. An experiment was then conducted to determine if rV-CEA/TRICOM could induce long-term immunity. Mice (5/group) were vaccinated one time with either V-WT, rV-CEA, or rV-CEA/TRICOM. One hundred days later, mice were challenged with a high dose (1×10^6) of MC38 colon carcinoma cells expressing CEA (5). All mice receiving V-WT and rV-CEA succumbed to tumors, while all mice vaccinated with rV-TRICOM were alive 50 days post-challenge (Fig. 30).

[0192] CEA-transgenic mice (Kass 1999, *ibid*; Thompson, J.A. et al. J. Clin. Lab. Anal. 5:344-366, 1999) in which the human CEA gene is expressed in normal adult gastrointestinal tissue, and whose serum is CEA-positive, were employed to determine if the rV-CEA/TRICOM vector could enhance T-cell responses to a self-antigen. CEA transgenic mice were separated into 5 mice/group. Two mice were vaccinated once with 10^7 pfu rV-CEA, rV-CEAB7-1, rV-CEA/TRICOM or buffer and were euthanized on day 30 to analyze CEA-specific T-cell responses. T-cell responses obtained after vaccination with rV-CEA/TRICOM were substantially greater than those obtained with rV-CEA (Table 2). Responses to ovalbumin and Con A were used as controls. The remaining 3 CEA-transgenic mice in each group were used to determine if anti-tumor responses to a CEA-expressing tumor could be enhanced employing a TRICOM vector. These mice were first inoculated s.c. with 4×10^5 MC38 carcinoma cells expressing the CEA gene (5). Four days later, mice were vaccinated one time at a distal site with 10^7 pfu viral recombinant or buffer. No tumors grew in mice vaccinated with rV-CEA/TRICOM, whereas tumors continued to grow in mice vaccinated with buffer, rV-CEA and rV-CEAB7-1 (Table 2). These results support the *in vivo* activity of TRICOM vectors.

Table 2. Enhanced Immune Response and Anti-Tumor Response of rV-CEA/TRICOM in CEA Transgenic Mice
Stimulation Index (SI)

	Con A	Oval	CEA	CEA	Tumor Value	
Immunogen	(5 μ g/ml)	(100 μ g/ml)	(100 μ g/ml)	(25 μ g/ml)	Day 14	Day 35
HBSS	109	1.0	1.3	2.0	698 \pm 928	3,674 \pm 3,107
rV-CEA	123	0.9	4.9	4.0	259 \pm 0	1,112 \pm 1,685
rV-CEA/B7- 1	93	1.3	7.1	4.3	150 \pm 236	2,696 \pm 1,936
rV-CEA/ TRICOM	111	1.1	19.2	15.9	0 \pm 0	\pm 0

C57BU6 CEA-transgenic mice (5 per group) were vaccinated via skin scarification with buffer or vaccinia recombinant (10^7 pfu) one time on Day 0. On Day 30, 2 mice were killed and splenic T cells were analyzed for T-cell proliferative responses. Each value represents the SI of the mean CPM of triplicate samples versus media. Standard deviation never exceeded 10%. On Day -4, 3 mice per group were given 4×10^5 MC38 colon carcinoma cells expressing CEA. Tumor volume is given at Days 14 and 35 post-vaccination.

Example 30**Costimulation of CD4⁺ and CD8⁺ T cells by Progenitor Dendritic Cells and Dendritic Cells Infected with rV-B7/ICAM-1/LFA-3**

[0193] Fresh CD34⁺ bone marrow cells (dendritic cell precursors) were obtained from C57BL/6 mice by the method of Inaba et al (41). These precursor cells were either used immediately or cultured for 6 days in GM-CSF and IL-4 (42) to generate mature dendritic cells (DC). CD34⁺ precursor cells and DC were infected for 18 hours with the recombinant vaccinia virus encoding multiple costimulatory molecules rV-B7/ICAM-1/LFA-3 (rV-Tricom), 10 MOI. After 5 hours of infection, a sample of cells were harvested and a phenotypic analysis was performed. Dendritic cells are though of in

the art as the 'ultimate' APC, expressing a large array of costimulatory molecules at high levels. Table 3 shows that murine DC indeed express the costimulatory molecules B7-1, B7-2, ICAM-1, and LFA-3 at relatively high levels (mean fluorescent intensity, MFI; depicted in parenthesis). However, when DC were infected with rV-B7/ICAM-1/LFA-3, there was a significant increase in both the level of costimulatory molecule expression as well as the percentage of cell expressing the multiple costimulatory molecules. The percentage of cells expressing B7-1 increased from 65% to 86%, while the MFI increased 4-fold; the percentage of cells expressing ICAM-1 increased from 32% to 68%, while the MFI increased 2.5 fold; the percentage of cells expressing LFA-3 increased from 44% to 75%.

Table 3

Phenotypic Analysis of Progenitor DC Pre and Post Infection ¹ with rV-COS ²								
Marker								
Infection	H2- K ^b	I-A ^b	CD11b	CD11c	B7-2	B7-1	ICAM-1	LFA-3
None	90 ³ (994) ⁴	64 (621)	63 (397)	29 (223)	38 (319)	65 (300)	32 (33 6)	44 (378)
V-Wyeth	75 (554)	60 (633)	59 (398)	27 (218)	36 (317)	65 (311)	33 (296)	43 (322)
rV-B7	76 (516)	67 (755)	70 (419)	34 (213)	41 (320)	83 (661)	43 (363)	51 (333)
rV-B7/ICAM/ LFA-3	79 (579)	63 (696)	63 (408)	30 (203)	42 (360)	86 (1253)	68 (810)	75 (484)
¹ 5 hour infection at 10 MOI ² rV-COS = recombinant vaccinia encoding a foreign costimulatory molecule. ³ = % cells expressing marker ⁴ = mean fluorescent intensity								

[0194] For use as stimulator cells, the infected CD34⁺ precursor cells and DC were irradiated (2000 rad) and used to stimulate naive CD4⁺ and CD8⁺ T-cells in the presence of Con A as outlined in Figure 31.

[0195] Progenitor dendritic cells infected with recombinant poxvirus encoding B7.1, ICAM-1, and LFA-3 were able to stimulate both CD4⁺ and CD8⁺ T cells. The stimulation of CD8⁺ T cells by the B7.1, ICAM-1, LFA-3 expressing progenitor dendritic cells was greater than that achieved using non-infected mature CD34⁺ dendritic cell (Figure 32). Moreover, infection and expression of the three costimulatory molecules in mature CD34⁺ dendritic cells (pretreated with IL-4 and GM-CSF) resulted in a dramatic increase in stimulation of both CD4⁺ and CD8⁺ T cells (Figure 33).

[0196] One skilled in the art can also measure the quality of a dendritic cell population by its ability to support an alloreactive response (mixed lymphocyte reaction, MLR) (43). Figure 34 shows the results of a mixed lymphocyte culture using dendritic cells infected with rV-TRICOM. The mixed lymphocyte reaction uses DCs from C57BL/6 mice which are stimulating T lymphocytes from Balb/c, (i.e. an anti-allotype reaction).

[0197] These data show that the degree of proliferation in a mixed lymphocyte reaction is dramatically higher using DCs infected with rV-TRICOM as compared to uninfected DCs or DCs infected with wild-type vaccinia.

[0198] Figure 35 demonstrates that DCs infected with rV-TRICOM are far superior than standard DCs in stimulating a CEA peptide-specific murine T cell line. This T-cell line is CD8⁺ and is specific for the CEA D^b Class-I restricted epitope EAQNTTYL (CAP-M8). The combination of DCs pulsed with the CEA peptide (1 μ g/ml) and previously infected with rV-TRICOM is clearly superior in stimulating CEA-specific T cell responses, especially at low T-cell to DC ratios.

Example 31

Murine T Cell Stimulation In Vitro and In Vivo Using rV- or rF-TRICOM Infected Murine Bone Marrow-Derived Dendritic Cells

Experimental Protocol

Peptides

[0199] The H-2k^b-restricted peptides OVA (ovalbumin₂₅₇₋₂₆₄, SIINFEKL)⁴¹ and VSVN (vesicular stomatitis virus N₅₂₋₅₉, RGYVYQGL)⁴², and the H-2D^b restricted peptides CAP-M8 (CEA₅₂₆₋₅₃₃, EAQNTTYL) and FLU-NP (NP₃₆₆₋₃₇₄, ASNEN-

MDAM)⁴³ were either purchased (Multiple Peptide Systems, San Diego, CA) or synthesized in-house (Applied Biosystems 432A Synergy Peptide Synthesizer, Foster City, CA).

Cell Lines and Cell Cultures

[0200] The OVA and Cap-M8 CD8⁺ cytotoxic T-cell lines were generated in-house from C57BL/6 mice and recognize the OVA and Cap-M8 peptides, respectively. The CTL lines were maintained by weekly *in vitro* stimulation cycles with irradiated naive splenocytes in complete medium (CM) [RPMI 1640 with fetal calf serum (10%); glutamine (2mM), sodium pyruvate (1mM), Hepes (7mM), gentamicin (50 µg/ml), 2-mercaptoethanol (50 µM), and non-essential amino acids (0.1mM), (Biofluids, Rockville, MD)], supplemented with 1 µg/ml specific peptide and 10 U/ml murine IL-2 (Boehringer Mannheim, Indianapolis, IN). Twenty-four hours prior to using these cells as responders in antigen-specific proliferation assays, the cells were purified by centrifugation over a Ficoll-Hypaque gradient (density = 1.119 g/ml, Sigma Chemical Co., St. Louis, MO) and replated in six-well culture plates (10⁶ cells/ml, 5 ml/well) in CM supplemented with 10 U/ml murine IL-2 only. For cytotoxicity assays, the target tumor-cell line used was EL-4 (C57BL/6, H-2^b, thymoma, ATCC TIB-39).

DC Preparation

[0201] Bone marrow was derived from six- to eight-week-old female C57BL/6 mice (Taconic Farms, Germantown, NY). The procedure used in this study was a slightly modified version of that described by Inaba et al.⁴¹. Briefly, bone marrow was flushed from the long bones of the limbs and passed over a Ficoll-Hypaque gradient. Bone-marrow cells were depleted of lymphocytes and Ia⁺ cells using a cocktail of magnetic beads specific for CD4, CD8, and anti-MHC Class-II (MiniMACS, Miltenyi Biotec, Auburn, CA). Cells were plated in six-well culture plates (10⁶ cells/ml, 5 ml/well) in CM supplemented with 10 ng/ml GM-CSF and 10 ng/ml IL-4 (R&D Systems, Minneapolis, MN). Cells were replated in fresh cytokine-supplemented media on days 2 and 4. At 6 days of culture, cells were harvested for infection, analysis and immunizations. For specified experiments, DC were treated with murine TNF-α (100ng/ml, Boehringer Mannheim, Indianapolis, IN) or CD40 mAb (5 µg/ml, PharMingen, San Diego, CA) during the final 24h of culture.

Recombinant Poxviruses

[0202] The rV virus containing the gene that encodes the murine costimulatory molecule B7-1 (CD80) under control of the synthetic early/late (sE/L) promoter (designated rV-B7-1) has been described herein. The rV virus containing the murine LFA-3 gene (CD48) under control of the vaccinia 30K (M2L) promoter, the murine ICAM-1 (CD54) gene under control of the vaccinia I3 promoter, and the murine B7-1 gene under control of the synthetic early/late (sE/L) promoter has been designated rV-TRICOM. The vectors rF-B7-1 and rF-B7-1/ICAM-1/LFA-3 (designated rF-TRICOM) are rF viruses that were constructed similarly to rV-B7-1 and rV-TRICOM, respectively. A fowlpox-TRICOM construct containing a reporter gene, human CEA, was used in certain experiments. Non-recombinant wild-type vaccinia virus (Wyeth strain) was designated V-WT, while wild-type fowlpox virus was designated FP-WT.

Infection of DC

[0203] DC were harvested on day 6 and washed with Opti-Mem (Gibco-BRL, Gaithersburg, MD). The cells were then either mock-infected with HBSS; infected with V-WT, rV-B7, or rV-TRICOM at 25 MOI (multiplicity of infection; PFU/cell); or infected with FP-WT, rF-B7-1, or rF-TRICOM at 50 MOI in Opti-Mem for 5h. Warm CM was added after infection, and the cells were incubated at 37° C overnight. After infection, the cells were harvested for immunostaining, *in vitro* costimulation analysis, and *in vivo* administration.

Flow Cytometric Analysis

[0204] Cell-surface staining utilized three-color immunofluorescence. Staining was performed with primary FITC-labeled antibodies CD11c, CD11b, H-2K^b, H-2D^b, CD19, Pan-NK; primary PE-labeled antibodies IA^b, CD48 (mLFA-3), CD86 (B7-2), CD3, CD14; and the biotin-labeled antibodies CD80 (B7-1), CD57 (ICAM-1), CD40. Biotin-labeled antibodies were subsequently labeled with Cychrome-streptavidin. All antibodies were purchased from PharMingen. Cell fluorescence was analyzed and compared with the appropriate isotype matched controls (PharMingen) with a FACSCAN cytometer (Becton Dickinson, Mountain View, CA) using the Lysis II software.

In vitro Costimulation Analysis: Pharmacological Signal-1

[0205] Female, six- to eight-week-old C57BL/6 mice were obtained (Taconic Farms, Germantown, NY), and naive T cells were isolated as previously described⁵. T cells were added at 10^5 /well in 96-well, flat-bottomed plates (Costar, Cambridge, MA). Stimulator cells consisted of either uninfected DC, mock-infected DC, or DC infected with vaccinia vectors (V-WT, rV-B7-1, rV-TRICOM) or fowlpox vectors (FP-WT, rF-B7-1 or rF-TRICOM) irradiated (20 Gy) and added at 10^4 /well. Cells in all wells were cultured in a total volume of 200 μ l of CM in the presence of several concentrations (2.5 to 0.9 μ g/ml) of Con A (Sigma) for 2 days. Cells were labeled for the final 12-18 hr of the incubation with 1 μ Ci/well 3 H- Thymidine (New England Nuclear, Wilmington, DE) and harvested with a Tomtec cell harvester (Wallac Incorporated, Gaithersburg, MD). The incorporated radioactivity was measured by liquid scintillation counting (Wallac 1205 Betaplate, Wallac, Inc.). The results from triplicate wells were averaged and are reported as mean CPM \pm SEM.

Mixed-Lymphocyte Reaction

[0206] MLR was used to assess the stimulatory function of DC for allogeneic and syngeneic naïve T cells. T cells were isolated from Balb/C or C57BL/6 mice as before. Stimulator cells consisted of DC that were either uninfected; mock infected; or infected with V-WT, rV-137-1, rV-TRICOM, FP-WT, rF-B7-1 or rF-TRICOM and irradiated (20 Gy). T cells (5×10^4 /well) were co-cultured with graded numbers of stimulator cells in CM in flat-bottom 96-well culture plates and incubated at 37° C, 5% CO₂ for 4 days, labeled for the final 12-18 hr of the incubation with 1 μ Ci/well 3 H-Thymidine, harvested, and analyzed as before.

In vitro Costimulation Analysis: Peptide-Specific Signal

[0207] Rested OVA or CAP-M8 T cells (responders) were added at 5×10^4 /well in 96-well, flat-bottomed plates. Stimulator cells consisted of DC that were either uninfected, or infected with V-WT, rV-137-1, or rV-TRICOM and irradiated (20 Gy). Cells in all wells were cultured in a total volume of 200 μ l of CM. The costimulation assay was carried out using two sets of conditions: (1) a 10:1 fixed ratio of responder:stimulator cells that were cultured in the presence of several concentrations of specific peptide or appropriate control peptide or (2) a fixed concentration of specific peptide or control peptide cultured at various responder:stimulator cell ratios. Cells were cultured for 72h, labeled for the final 12-18 h of incubation with 1 μ Ci/well 3 H-Thymidine, harvested, and analyzed as before.

CTL Induction In Vivo and Cytotoxic Analysis

[0208] DC (1×10^6) that were either uninfected or infected with V-WT or rV-TRICOM were washed twice in Opti-Mem and resuspended in 1 ml of the same medium containing 10 μ M of either OVA or CAP-M8 peptides. After 2h incubation at 37° C, cells were washed twice in HBSS and resuspended in HBSS for injections. Peptide-pulsed DC (1×10^5 cell/mouse) were injected 1-3 times intravenously at 7-day intervals. Control mice were immunized subcutaneously with 100 μ g indicated peptide in Ribi/Detox adjuvant (Ribi ImmunoChem Research, Hamilton, MT). Fourteen days following the final inoculation, spleens from two animals per group were removed, dispersed into single-cell suspensions, pooled, and co-incubated with 10 μ g/ml of appropriate peptide for six days. Bulk lymphocytes were recovered by centrifugation through a density gradient (LSM, Organon Teknika, West Chester, PA). EL-4 cells were prepared for use as targets in a standard cytolytic assay using 111 In, as previously⁴⁵. Target cells were pulsed with 10 μ M specific peptide for 1 hour at 37°C, while a second group of target cells was pulsed with control peptide. Lymphocytes and peptide-pulsed targets (5×10^3 cells/well) were suspended in CM, combined at effector:target ratios of 80:1 to 10: 1 in 96-well U-bottomed plates (Costar) and incubated for 5h at 37° C with 5% CO₂. After incubation, supernatants were collected using a Supernatant Collection System (Skantron, Sterling, VA), and radioactivity was quantified using a gamma counter (Cobra Autogamma, Packard, Downers Grove, IL). The percentage of specific release of 111 In was determined by the standard equation: % specific lysis = [(experimental-spontaneous)/(maximum-spontaneous)] x 100. Where indicated, CTL activity was converted to lytic units (LU) as described by Wunderlich et al, 1994.

Anti-Vaccinia Antibody Analysis

[0209] V-WT was added at 5×10^5 /well to polyvinyl chloride plates (Dynatech, Chantilly, VA), dried overnight at 37°C and blocked with 5% BSA. Graded dilutions of sera from immunized mice was added in triplicate and incubated for 1 h at 37° C. Plates were washed and incubated with peroxidase labeled goat anti-mouse IgG (Kirkegaard and Perry Laboratories, Gaithersburg, MD) for an additional hour. Wells were developed with o-phenylenediamine dihydrochloride (Sigma, St. Louis, MO) and H₂O₂. Reactions were stopped with H₂SO₄. The absorbance of each well was read at 405 nm using a Bio-Tek EL312e microplate ELISA reader (Winooski, VT).

Results

Increased Expression of Costimulatory Molecules on DC

[0210] To determine the efficiency of poxvirus infection of DC, these cells were infected with either a rV virus encoding B7-1, ICAM-1, and LFA-3 (designated rV-TRICOM) or a rF virus encoding B7-1, ICAM-1, LFA-3 and human carcinoembryonic antigen (CEA) (designated rF-CEA/TRICOM). In the latter case, CEA was used as a reporter gene since fowlpox structural proteins are not expressed in infected cells. After 18h, cells were analyzed for the expression of cell-surface markers associated with the particular viral infection. Uninfected control DC expressed CD 11b (97%) and were negative for the expression of vaccinia proteins. After infection with rV-TRICOM, 94% of DC co-expressed both CD11b and vaccinia proteins. DC infected with rF-CEA/TRICOM co-expressed both CD11b and CEA (87%). These DC failed to express fowlpox proteins as detected by polyclonal rabbit anti-fowlpox sera (data not shown), which is in agreement with reports stating that fowlpox does not replicate in mammalian cells. Taken together, these data indicate that DC are efficiently infected by both rV and rF vectors.

[0211] The cardinal characteristics of DC are high expression levels of both histocompatibility antigens and costimulatory molecules. To further characterize the phenotype of DC after virus infection, cells were infected with wild-type vaccinia virus (V-WT), rV-B7-1, rV-TRICOM, wild-type fowlpox (FP-WT) or rF-TRICOM and analyzed for the expression of cell-surface markers associated with the DC phenotype (Table 4). As expected, uninfected and mock-infected DC expressed high levels of MHC Class I and II, CD11b, B7-2 and CD40 molecules, as well as high levels of B7-1, ICAM-1, and LFA-3. DC infected with V-WT expressed lower cell-surface densities (as determined by MFI) of several molecules, while DC infected with rV-B7-1 expressed 5-fold more B7-1 than uninfected DC (MFI from 329 to 1689). Infection of DC with rV-TRICOM substantially increased MFI and the percentage of cells positive for B7-1, ICAM-1, and LFA-3. DC infected with FP-WT had a similar phenotypic profile to that of uninfected DC. Infection of DC with rF-TRICOM also substantially increased MFI and the percentage of cells positive for B7-1, ICAM-1, and LFA-3. All DC populations remained negative for T-cell (CD3), B-cell (CD19), monocyte/neutrophil (CD 14), and NK-cell (Pan NK) markers both before and after infection with rF or N vectors (Table 4).

55 50 45 40 35 30 25 20 15 10 5

TABLE 4

Infection of BMDC with rV-TRICOM or FP-TRICOM Increases the Expression Level of B7-1, ICAM-1, and LFA-3													
Infection	DC Panel [% positive cells (MFI)]									Non-DC Markers			
	I-A ^b	H-2K ^b /D ^b	CD11b	CD11c	B7-2	CD40	B7-1	ICAM-1	LFA-3	CD14	CD19	CD3	Pan NK
None	88(1124)	89(125)	93 (935)	20(74)	68 (490)	68 (82)	91 (329)	96(595)	88(153)	2(20)	2(26)	0.3(33)	2(56)
Mock	87(989)	88(125)	90 (1129)	25 (49)	77 (432)	71(99)	85(330)	97(519)	86 (189)	1 (42)	4 (30)	0.6 (37)	2 (29)
V-WT	87 (890)	86 (83)	86 (588)	29 (54)	61 (274)	79 (98)	90 (197)	95 (241)	70(196)	3 (20)	3 (45)	1 (59)	5 (50)
rV-B7-1	85(856)	85 (104)	81 (693)	25(62)	73 (304)	73 (103)	94 (1689)	97(364)	72 (131)	3 (42)	3 (40)	0.8 (67)	4 (37)
rV-TRICOM	87(901)	78 (103)	77 (558)	22 (54)	66 (298)	71 (81)	96 (1442)	94 (1528)	92 (304)	3 (32)	4 (29)	0.9 (70)	4 (31)
FP-WT	91 (985)	98 (126)	89 (889)	24 (69)	65 (487)	71 (90)	94 (382)	97 (464)	91 (130)	2 (18)	2 (10)	1 (60)	2 (31)
rF-B7-1	88 (987)	99 (114)	86 (793)	28(72)	74 (404)	68 (90)	95 (1559)	98 (437)	90 (180)	2(30)	2 (29)	1 (45)	2 (54)
rF-TRICOM	90 (900)	99 (115)	84 (789)	27 (66)	76 (499)	73 (93)	99 (1824)	98 (1697)	95 (530)	3(22)	3 (13)	1 (50)	3 (33)
DC were uninfected, mock infected, or infected with 25 MOI of either V-WT, rV-B7, or rV-TRICOM or 50 MOI of either WT-FP or FP-TRICOM for 5h. After 18h incubation, cells were phenotyped by 3-color flow cytometric analysis. Bold numbers indicate a >100% change in cell-surface expression (MFI).													

DC Infected with TRICOM Vectors Exhibit Enhanced Capacity to Stimulate Naïve T cells

[0212] An *in vitro* model was used to analyze how increased levels of B7-1, ICAM-1 and LFA-3 expression help induce naïve T-cell proliferation. In this model, the first signal for T-cell activation was delivered via a pharmacological reagent (Con A) and the additional, or costimulatory, signal was delivered to the T-cell via DC or DC expressing higher levels of TRICOM as a consequence of recombinant poxvirus infection. In these and all subsequent studies reported here, V-WT and FP-WT were also used to rule out effects due to the vector alone. As shown in Fig. 36A, both uninfected and mock-infected DC induced proliferation of T-cells. DC infected with V-WT (designated DC/V-TRICOM) induced less T-cell proliferation than uninfected DC. Delivery of additional costimulatory signals via DC infected with rV-B7-1 (designated DC/rV-B7-1) increased proliferation compared with uninfected DC. However, DC infected with rV-TRICOM (designated DC/rV-TRICOM) induced further increases in T-cell proliferation at all concentrations of Con A. In addition, when T-cells were stimulated with DC/rV-TRICOM, 28-fold less Con A was needed to induce proliferation to levels comparable to that of uninfected DC. When these experiments were repeated using fowlpox vectors, DC/rF-TRICOM induced increases in T-cell proliferation at all Con A concentrations, unlike DC or DC/rF-B7-1 (Fig. 36B). These experiments were repeated 4 times with similar results.

Enhanced Allostimulatory Activity by DC Infected with TRICOM Vectors

[0213] The effect of rV-TRICOM (Fig. 37A, C, E) or rF-TRICOM (Fig. 37B, D, E) infection on DC stimulatory capacity was assessed in an allospecific mixed-lymphocyte reaction. Both uninfected DC and mock-infected DC populations induced a strong proliferation (78,000 CPM) of allogeneic T cells (Fig. 37A, B). The stimulatory capacity of DC was increased after infection with rV-B7-1 (Fig. 37C). Infection of DC with rV-TRICOM increased the stimulatory capacity over DC and DC/rV-B7-1 at all DC/responder ratios (Fig. 37C). Importantly, DC populations infected with rV-TRICOM vectors failed to stimulate syngeneic T cells (Fig. 37E). When these experiments were repeated using fowlpox vectors (Fig. 37B, D), DC/rF-TRICOM induced larger increases in allogeneic T-cell proliferation than DC and DC/rF-B7-1, DC/rF-TRICOM, however, failed to stimulate syngeneic T cells (Fig. 37F). These experiments were repeated 3 times with similar results.

In vitro Costimulation Analysis: Presentation of Peptides to Effector T Cells

[0214] Studies were undertaken to determine if the stimulatory capacity of peptide-pulsed DC could be enhanced by infecting DC with rV-TRICOM. To that end, the H-2K^b-restricted OVA (ovalbumin₂₅₇₋₂₆₄, SIINFEKL) peptide and an OVA-specific CD8⁺ effector T-cell line were used. DC were exposed to different concentrations of OVA peptide and incubated in the presence of the OVA T-cell line (Fig. 38A-38F). The conventional (i.e., uninfected) DC induced a strong proliferation of OVA-specific T cells when incubated with the OVA peptide (Fig. 38A). These DC did not induce proliferation of OVA-specific T cells when incubated with the control peptide VSVN (vesicular stomatitis virus N₅₂₋₅₉ RGYVYQGL) (Fig. 38A, open squares). DC/rV-B7-1 increased the overall peptide-specific proliferation of these cells 1.8-fold (Fig. 38C). In addition, DC/rV-B7-1 induced similar proliferation to that of uninfected or mock-infected DC in the presence of 4-fold less peptide. In contrast, DC/rV-TRICOM increased the overall proliferation of these T-cells several-fold, and in the presence of 32-fold less OVA peptide, induced proliferation comparable to that of uninfected DC (Fig. 38C). To further evaluate the capacity of vaccinia-infected DC to present peptide, DC were pulsed with a single concentration of OVA peptide (1 μ M) and incubated in the presence of several ratios of T cells (Fig. 38E). On a per-cell basis, 4-fold fewer DC/rV-B7-1 were required to induce proliferation levels comparable to that of DC (open triangles vs. closed squares). The greatest stimulatory effect was that of DC/rV-TRICOM, which induced proliferation levels comparable to that of DC with 32-fold less cells (open circles vs. closed squares).

[0215] A second peptide system employing peptide-pulsed DC and an established T-cell line were employed to determine if results similar to those obtained with the OVA peptide could be noted. These experiments were conducted using the H-2D^b-restricted peptide CAP-M8 (CEA₅₂₆₋₅₃₃, EAQNTTYL) and a CAP-M8-specific CD8⁺ effector T-cell line; similar results were noted (Fig. 38B, D, F). These experiments were repeated 5 additional times with the same results.

Effect of rV-TRICOM Infection on TNF α or CD40-Matured DC

[0216] Since the functional maturation of DC is believed to correlate with the upregulation of T-cell costimulatory molecules, experiments were conducted to examine the effect of rV-TRICOM infection on DC that had been matured by co-culture with either TNF- α or CD40 mAb. Treatment of DC with TNF- α during the final 24h of culture resulted in some upregulation of MHC-II, B7-2, and ICAM-1 as determined by flow cytometric analysis (Table 5), while treatment of DC with CD40 mAb resulted in the upregulation of ICAM-1 expression and a slight upregulation of MHC-II. Functionally, treatment of DC with TNF- α or CD40 mAb culminated in a 28% and 16% increase, respectively, in peptide-specific

proliferation over that of unmanipulated DC (Fig. 39A). Similar data were also obtained after treating DC with lipopoly-saccharide (LPS). Infection of untreated DC with rV-TRICOM resulted in a substantial increase in T-cell proliferation (Fig. 39A vs. 39B). Pretreatment with TNF- α or CD40 mAb followed by infection with rV-TRICOM, however, conferred only a slight stimulatory capacity in excess of that seen with rV-TRICOM infection alone (Fig. 39B). These experiments were repeated 3 additional times with similar results.

5

10

15

20

25

30

35

40

45

50

55

55 50 45 40 35 30 25 20 15 10 5

TABLE 5

Effect of Pretreatment of DC with TNF- α or CD40 mAb Prior DC rV-TRICOM Infection										
DC Panel [% positive cells (MFI)]										
Infection	Pretreatment	I-A ^b	H.2K ^b /D ^b	CD11b	CD11c	B7-2	CD40	B7-1	ICAM-1	LFA-3
DC (Uninfected)	None	90 (924)	93 (225)	90(835)	26(174)	65(340)	62(182)	93(389)	96 (415)	90 (253)
DC (Uninfected)	TNF- α	95 (1189)	91 (195)	84 (729)	20 (149)	71 (412)	65 (159)	85 (320)	97 (421)	87 (249)
DC (Uninfected)	CD40 mAb	91 (990)	89 (183)	87 (788)	22 (154)	68 (374)	69 (198)	90 (297)	95 (690)	86 (216)
DC/rV-TRICOM	None	87 (756)	89(214)	85 (684)	24(98)	69 (301)	66 (103)	95 (1989)	98 (1487)	93(413)
DC/rV-TRICOM	TNF- α	92 (991)	90(230)	79 (558)	21 (62)	72(398)	68(81)	96 (1442)	94 (1993)	90(394)
DC/rV-TRICOM	CD40 mAb	91 (905)	90(216)	81 (614)	23 (69)	65 (387)	71 (120)	94 (1382)	97 (1444)	89(310)
DC were treated with TNF- α (100 ng/ml) or CD40 mAb (1 μ g/ml) during the final 24h of culture. DC or treated DC were then infected with 25 MOI of rV-TRICOM for 5h. After 18h incubation, cells were phenotyped by 3-color flow cytometric analysis.										

DC Infected with W-TRICOM Are More Efficient at Priming CTL Responses In Vivo

[0217] Experiments were conducted to determine if the enhanced stimulatory capacity of DC/rV-TRICOM noted *in vitro* using Con A (Fig. 36E-F), mixed-lymphocyte reactions (Fig. 37) and two effector T-cell models (Fig. 38) would translate to enhanced efficacy in priming naive T-cell responses *in vivo*. To that end, DC, DC/V-WT, and DC/rV-TRICOM were pulsed with 10 μ M OVA peptide and administered intravenously to C57BL/6 mice. Control mice were immunized with OVA peptide in Ribi/Detox adjuvant subcutaneously. Splenocytes were harvested 14 days following vaccination, restimulated *in vitro* for 6 days, and assessed for their peptide-specific lytic ability against OVA-pulsed EL-4 cells. EL-4 cells pulsed with VSVN peptide were used as control target cells. As seen in Fig. 40A, CTL generated from mice immunized with peptide/adjuvant exhibited modest levels of CTL activity (Fig. 40A). Mice immunized with peptide-pulsed DC exhibited a greater peptide-specific CTL response (Fig. 40B). The induced CTL response was somewhat blunted in mice immunized with DC/V-WT (Fig. 40C, <2.5 lytic units (LU) vs. 5.2 LU). In contrast, mice immunized with peptide-pulsed DC/rV-TRICOM (Fig. 40D) exhibited a CTL response that was significantly stronger than that of DC (LU=14.3, $p=0.001$). Similar experiments were then conducted using a second model peptide, CEA peptide CAP-M8 (Fig. 40E-H). Again, peptide-pulsed DC elicited much greater CTL activity than that induced by peptide/adjuvant (5.7 LU vs. <2.5 LU). In addition, mice immunized with peptide-pulsed DC/rV-TRICOM (Fig. 40H) exhibited a strong CTL response (>20 LU) compared with that induced by peptide-pulsed DC (5.7 LU, $p<0.001$; Fig. 40F).

Efficacy of Multiple Vector-Infected DC Vaccinations

[0218] It is generally believed that the generation of anti-vaccinia antibodies can prevent the repeated use of vaccinia virus as immunogens. However, little is known about the repeated use of vaccinia-infected cells as immunogen. To address this issue, an immunization scheme was carried out in which CAP-M8 peptide-pulsed DC immunogens were administered one, two, or three times, at 7-day intervals. As before, splenocytes were harvested 14 days following the final immunization, restimulated *in vitro* for 6 days, and assessed for their peptide-specific lytic ability against CAP-M8-pulsed EL-4 cells. As seen in Fig. 41A, peptide-pulsed DC/rV-TRICOM induced higher levels of CTL activity when compared with peptide-pulsed DC. These data are similar to those seen in Figure 40E-H. This single administration of DC/V-WT or DC/rV-TRICOM induced significant anti-vaccinia IgG antibody titers, with values ranging from 1:4,000 to 1:9,000 as determined by qualitative ELISA. These titers, however, had no effect on the capacity of these immunogens to boost CTL activity upon subsequent immunizations (Fig. 41 B and 41 C). While anti-vaccinia virus titers after the second vaccination ranged from 1:12,000 to 1:50,000, a boost in the induction of peptide-specific CTL was seen in all groups. Again, the CTL activity observed employing DC/rV-TRICOM-pulsed cells was greater than that observed with peptide-pulsed DC.

Example 32**Splenocytes or Bone Marrow Progenitor Cells Infected With TRICOM Vectors Induce T-cell Activation Comparable to Dendritic Cells****Materials and Methods***Generation of Bone Marrow Progenitor Cells and Dendritic Cell Cultures.*

[0219] The procedure used for generation of bone marrow-derived DC was that described by Inaba et al. with minor modifications. Briefly, the femurs were taken from 6-8 week old female C57BL/6 mice (Taconic Farms, Germantown, NY) and the bone marrow was flushed and passed over a Ficoll-Hypaque gradient. Bone marrow cells were depleted of lymphocytes and Ia⁺ cells using a cocktail of magnetic beads specific for CD4, CD8, and MHC Class II (MiniMACS, Miltenyi Biotec, Auburn, CA). Designated as dendritic cell progenitors, these depleted bone marrow cells were then prepared for infection, or for dendritic cell cultures depleted bone marrow cells were plated in six-well culture plates (106 cells/ml, 5 ml/well) in CM supplemented with 10 ng/ml GM-CSF and 10 ng/ml IL-4 (R&D Systems, Minneapolis, MN). DC cultures were replated in fresh cytokine-supplemented CM on days 2 and 4, and split to new plates on day 4. At day 7 of culture, cells were harvested for analysis, *in vitro* assays, and *in vivo* immunizations.

Generation of Splenocyte Stimulator Cells.

[0220] Spleens were harvested from naïve female C57BL/6 mice, crushed into a single-cell suspension, and passed over a Ficoll-Hypaque gradient. Splenocytes were depleted of lymphocytes and Ia⁺ cells using a cocktail of magnetic beads specific for CD90, and MHC Class II. Purified splenocytes were then washed twice with Opti-Mem (Gibco-BRL)

and prepared for infection with the recombinant poxviruses.

Infection of Stimulator Cells.

[0221] Bone marrow-derived dendritic cell progenitor and splenocyte cells were washed twice with Opti-Mem and mock infected or infected with either 25 MOI V-WT, rV-B7-1, rV-TRICOM, or 50 MOI FP-WT, rF-B7-1 or rF-TRICOM at 25 MOI (multiplicity of infection, PFU/cell) in 1 ml final volume of Opti-Mem for 5 hours. After infection, warm (37 degree) CM was added and the cells were incubated at 37° C overnight. After infection the cells were harvested for immunostaining, *in vitro* costimulation analysis, and *in vivo* administration.

Costimulation Analysis

[0222] Rested CAP-M8 T-cells (responders) were added at 5×10^4 /well in a 96-well flat-bottomed plates (Costar, Cambridge, MA). Stimulator cells consisted of BMDC, splenocytes, or bone marrow progenitors, either uninfected, mock infected, or infected with either V-WT, rV-B7-1, rV-TRICOM, FP-WT, or rF-TRICOM and irradiated (20 Gy). Cells in wells were cultured in a total volume of 200 μ l of CM. The costimulation assay was carried out using two sets of conditions: a) fixed ratio of responder:stimulator cell of 2.5:1 for non-BMDC stimulators, and 10:1 for BMDC, cultured in the presence of several concentrations of Con-A as signal one, specific peptide, or appropriate control peptide, or b) a fixed concentration of Con-A as signal one, specific peptide, or control peptide, cultured at various responder:stimulator cell ratios. Cells were cultured for 48 or 72 hours for Con-A and peptide-specific assays, respectively, and labeled for the final 12-18 hours of the incubation with 1 mCi/well ³H-Thymidine, harvested, and analyzed as described above.

[0223] Table 6 shows splenocyte and bone marrow (BM) cell surface expression of costimulatory molecules after infection with recombinant vectors. Purified murine splenocytes or bone marrow cells were infected for 5 hours with 25 MOI of vaccinia vectors or 50 MOI of fowlpox vectors. Cell phenotype was compared with that of DC. All cells were immunostained with costimulatory molecule-specific mAbs labeled with fluorescein isothiocyanate, phycoerythrin, or biotin/streptavidin-cychrome. Isotype control were negative (data no shown). Numbers indicate percent positive cells and mean fluorescence intensity in parentheses.

TABLE 6

Infection of BMDC, Splenocytes, and BMDC Progenitors with either rV-Tricom or rF-TRICOM increases the level of expression of B7-1, ICAM-1, and LFA-3¹

DC ²	I-A ^b	H-2K ^b /Db	CD11b	CD11c	CD40	B7-2	B7-1	ICAM-1	LFA-3	CD19
Splenocytes ³	Uninfected	88 (124)	89 (125)	93 (935)	20 (74)	68 (82)	91 (329)	96 (595)	88 (153)	2 (26)
	Uninfected	92 (102)	96 (389)	3 (136)	1 (54)	87 (494)	46 (540)	85 (258)	77 (40)	42 (25)
	V-WT	91 (114)	94 (400)	3 (182)	0.7 (82)	75 (408)	55 (490)	76 (257)	47 (32)	25 (24)
	rV-B7	91 (123)	95 (402)	3 (89)	1 (159)	81 (369)	61 (89)	87 (1134)	45 (29)	33 (27)
	rV-Tricom	93 (188)	98 (433)	3 (41)	3 (83)	81 (327)	49 (69)	92 (788)	97 (192)	27 (33)
	FP-WT	90 (104)	90 (410)	2 (162)	0.9 (92)	79 (418)	55 (460)	70 (157)	49 (32)	53 (29)
	rF-B7-1	91 (133)	86 (422)	1 (81)	1 (149)	85 (399)	83 (830)	83 (215)	51 (29)	52 (31)
BMF ⁴	rF-Tricom	89 (238)	96 (399)	3 (91)	2 (80)	86 (387)	51 (99)	92 (588)	99 (292)	48 (33)
	Uninfected	9 (289)	99 (389)	80 (114)	1 (909)	26 (136)	28 (72)	68 (144)	37 (89)	1 (147)
	V-WT	8 (218)	98 (236)	66 (144)	1 (1131)	19 (161)	19 (98)	63 (151)	33 (64)	5 (50)
	rV-B7	8 (192)	97 (159)	71 (144)	2 (394)	25 (233)	22 (125)	56 (204)	31 (65)	2 (106)
	rV-Tricom	7 (242)	92 (183)	70 (129)	1 (875)	16 (171)	16 (91)	92 (880)	38 (112)	3 (62)
	FP-WT	8 (318)	98 (298)	64 (133)	1 (1101)	23 (175)	22 (88)	60 (112)	35 (69)	2 (30)
	rF-B7-1	7 (292)	99 (259)	75 (129)	2 (1001)	26 (245)	26 (101)	50 (104)	34 (72)	1 (86)
	rF-Tricom	8 (233)	96 (213)	72 (118)	1 (984)	25 (111)	13 (99)	79 (310)	39 (109)	1 (52)

¹ Cells were uninfected, or infected with 25 MOI of V-WT, rV-B7-1, rV-Tricom or 50 MOI FP-WT, rF-B7-1, or rF-TRICOM for five hours. After an eighteen hour incubation period, cells were phenotyped by 3-color flow cytometric analysis. Values are given as percentage cells (Mean Fluorescence Intensity). Bold numbers indicate a > 2-fold change in cell surface expression (MFI).

² BMDC: day 6 bone marrow derived dendritic cells (cultured in 10 ng/ml GM-CSF/IL-4).

³ Splenocytes depleted of T-cells via α -CD90 (Thy 1.2) magnetic beads.

⁴ BMDC Progenitors: bone marrow cells were depleted of T-cells and MHC-II cells via α -CD4 α -CD8 α -MHCI magnetic beads.

[0224] Figures 42A through 46 demonstrate that TRICOM-infected splenocytes are comparable to TRICOM infected

bone marrow cells in stimulating T cell responses.

Example 33

Human T cell Stimulation Using Allogeneic rF-TRICOM Infected Human Dendritic Cells Pulsed with Peptides

[0225] Human dendritic cells were isolated for a normal, healthy individual by leucophoresis. The human dendritic cells were cultured in the presence of GM-CSF and IL-4 for 6-9 days, followed by the addition of rF-TRICOM or rF-Controls for infection of the dendritic cells. The rF-TRICOM-infected dendritic cells were pulsed with a CEA peptide (CAP-1 or CAP I, 6D) (Figure 47); a PSA peptide (PSA-3) (Figure 48); an influenza peptide (Flu peptide 58-66) (Figure 49 and 50); or an HPV peptide (11-20) (Figures 51-45) for 1 hour. Human T cells isolated from peripheral blood mononuclear cells (PBMC) were cultured in the presence of the peptide-pulsed rF-TRICOM-infected dendritic cells and production of IFN- α by the T cells determined. Figures 47-54 show that peptide-pulsed rF-TRICOM infected human dendritic cells stimulated T cells to a greater extent than the controls. Figures 47-54, as well as Table 7 demonstrate that allogeneic human dendritic cells infected with rF-TRICOM can efficiently present any antigenic peptide to T cells for enhancement of an immune response.

Table 7

CTL activity of T cell lines by using DC pulsed with HPV E7(11-20) peptide

Target	T cell lines established by using			
	A	B		
	rF-Tricom + P	rF-B7.1 + P	rF-FPV + P	DC + P
C1R-A2 + HPV	39.6 (3.1)	24.7(0.4)	19.9(2.9)	7.3(0.4)
C1R-A2	5.1 (2.0)	6.9 (4.0)	7.6 (2.0)	8.0(0.2)
E:T ratio = 25:1				
An 6 hour ¹¹¹ In release assay was performed. C1R-A2 cells were pulsed with HPV E7 peptide (11-20) YMDLQPETT at a concentration of 10 μ g/ml.				

[0226] The results presented in Table 7 demonstrate that DC infected with rF-TRICOM (A), are better as APC to generate CTL than are standard DC (B) when both are pulsed with peptide.

Example 34

Human Clinical Trials of a rV-huTRICOM, rV-CEA huTRICOM Vaccine and rF-CEA TRICOM

[0227] The objective of the human clinical trial is to determine the optimum tolerated dose (OTD) of the recombinant rV-huTRICOM and rV-CEA-huTRICOM vaccine that elicits a host anti-tumor immune response and is associated with acceptable toxicity in patients with advanced CEA-expressing adenocarcinomas.

[0228] The rV-huTRICOM and rV-CEA-huTRICOM vaccines are produced under conditions suitable for Phase I and Phase II human clinical trial.

[0229] In an initial trial, escalating doses of recombinant rV or rF CEA-huTRICOM live virus vaccine or rV-huTRICOM plus rV-CEA vaccine is provided at an initial dose of 10^6 pfu virus, I.M., followed by a dose of 10^7 pfu virus, I.M., which is followed later by of 10^8 pfu virus, or 10^9 S.C. or by scarification.

[0230] The anti-tumor response to each recombinant vaccine is determined using clinical, laboratory and radiologic evidence of tumor size, extent and growth using accepted standard criteria for measuring response of tumors to new forms of therapy as are known in the art.

[0231] The patient's immune response to the recombinant vaccine is assessed using a variety of immunological assays including anti-CEA antibody assay, anti-poxvirus antibody assay, immune complex assay, CEA-specific lymphoproliferative assay, CEA-specific cytotoxic T-lymphocyte assays, precursor frequency of CEA-reactive T cells in gamma-interferon release T-cell assay, a ELISPOT, Fast Immune, Tetramere assays for T-cell responses (Scheibenhogen et al Int. J. Cancer 71:932-936, 1997), HLA assays and the like. A comparison of pre-treatment and post-treatment samples are made to document development of humoral and cellular immune responses directed against the CEA tumor antigen.

Example 35**Human Clinical Trials of an Recombinant Fowlpox-CEA-huTRICOM**

[0232] In an initial trail, escalating doses of recombinant fowlpox-CEA huTRICOM vaccine of 10^6 pfu virus, 10^7 pfu virus and 10^8 pfu virus is injected directly into a tumor mass of a patient with advanced CEA-expressing adeno carcinomas.

[0233] The specific anti-tumor and immune response to the recombinant vaccine is determined as described in Example 34.

Example 36**Human Clinical Trial of T Lymphocytes Activated by Multiple Costimulatory Molecule-Overexpressing Dendritic Cells**

[0234] Peripheral blood lymphocytes and dendritic cells are obtained from a patient with advanced prostate cancer. The peripheral blood lymphocytes are enriched for CD8⁺ lymphocytes. The dendritic cells are infected with rV-PSA epitope QVHPQKVTK/B7.1/ICAM-1/LFA-3 for a period of time sufficient to allow expression of the PSA epitope and overexpression of the multiple costimulatory molecules. PSA epitope-specific CD8⁺ lymphocytes are activated and expanded in the presence of these treated dendritic cells. The activated PSA epitope-specific CD8⁺ autologous T lymphocytes are injected into the patient alone and in combination with the PSA epitope. The specific anti-tumor and PSA-specific immune response to the treatment is determined by methods comparable to those described in Example 34.

[0235] Similar human clinical trials may be conducted for treatment of patients with other TAA-expressing cancers, by replacement of the gene encoding CEA with a gene encoding another TAA into the recombinant vector of the present invention.

Example 37**Screen for Immunogenic Peptides and/or Human T Cells Immunoreactive with a Specific Peptide Using DC Infected with rF-TRICOM**

[0236] The present invention encompasses anticancer therapies using *ex vivo* engineering of DC with viral vectors carrying a tumor associated antigen gene to activate tumor-specific CTL. DC infected with rF-CEA in combination with TRICOM costimulatory molecules are used to augment CEA-specific immune responses. The CTL induction capacity of DC infected with rF-CEA/TRICOM and rF-TRICOM are evaluated. Tetrameric MHC class I CAP-1 complex are used to visualize CAP-1 specific CTL. This protocol is not limited to the tumor associate antigen, CEA, but may be modified to elicit antigen-specific immune responses for any antigenic peptide or immunogenic epitope thereof for immunotherapy against cancer, pathogenic bacteria, virus, protozoans, yeast and the like. Moreover, the method may be modified to screen for and identify immunogenic peptides from a source such as a natural protein, recombinant protein, synthetic protein, or fragments from each, combinatorial libraries, and the like.

Materials and Methods**Cell Cultures**

[0237] Colorectal carcinoma cell lines SW1463 (HLA-A1,2), LS174T (HLA-A2,-), were purchased from American Type Culture Collection (Manassas, MD). The cultures were free of mycoplasma and were maintained in complete medium [DMEM (Life Technologies, Inc., Grand Island, NY) supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 μ g/ml streptomycin (Life Technologies, Inc.)]. The C1R cell line is a human plasma leukemia cell line that does not express endogenous HLA-A or B antigens (Storkus, W.J. et al, J. Immunol. 138(6):1657-1659, 1987). C1R-A2 cells are C1R cells that express a transfected genomic clone of HLA-A2.1 (Hogan, K.T. et al, J. Exp. Med. 168(2):725-736, 1988). These cells were obtained from Dr. William E. Biddison (National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD). C1R-A2 culture was mycoplasma free and was maintained in RPMI 1640 complete medium (Life Technologies, Inc.). The V8T cell line, a CTL line directed against the CAP-1 epitope, was established from a patient with metastatic colon carcinoma who was enrolled in a Phase I trial using rV-CEA (Tsang, K.Y. et al., Clin. Cancer Res. 3(12):2439-2449, 1997). V8T cells were cultured in RPMI 1640 complete medium containing 10% human AB serum and IL-2 (provided by the National Cancer Institute, Surgery Branch, 20 units/ml). V8T cells were restimulated with CAP-1 peptide (25 μ g/ml) on day 16 after prior restimulation at an effector cell-to-APC ratio of 1:3. Irradiated (23,000 rads) autologous EBV transformed B cells were used as APC.

Culture of DC from peripheral blood mononuclear cells

[0238] Peripheral blood mononuclear cells (PBMC) were obtained from heparinized blood from a patient (#15) with metastatic pelvic carcinoma who was enrolled in a Phase I trial using a combination of rV-CEA and ALVAC-CEA. All experiments involving patient materials were conducted according to NIH guidelines, and written, informed consent was obtained from all individuals. PBMC were separated using lymphocyte separation medium gradient (Organon Teknika, Durham, NC) as described previously (Boyum, A. Scand J Clin Lab Invest Suppl. 97:51-76, 1968). DC were prepared using a modification of the procedure described by Sallusto et al. (Sallusto, F. et al, J. Exp. Med. 179(4):1109-1118, 1994). PBMC (1.5×10^8) were resuspended in AIM-V medium containing 2 mM glutamine, 50 μ g/ml streptomycin, 10 μ g/ml gentamycin (Life Technologies, Inc.) and allowed to adhere to a T-150 flask (Corning Costar Corp., Cambridge, MA). After 2 hours at 37°C, the non-adherent cells were removed with a gentle rinse. The adherent cells were cultured for 6-7 days in AIM-V medium containing 50 ng/ml of recombinant human GM-CSF (rhGM-CSF) and 0.5 ng/ml of recombinant human IL-4 (rhIL-4). The culture medium was replenished every three days.

Recombinant virus and infection of DC with avipox virus containing CEA, CEA/TRICOM and TRICOM

[0239] A 2109 bp DNA fragment encoding the entire open reading frame of CEA was obtained as described by Kaufman et al (Kaufman, F. et al. Int. J. Cancer 48(6):900-907, 1991). The recombinant CEA avipox virus (fowlpox CEA; vCP248) was supplied by Theron Corp using methods described by Taylor et al (Taylor, J. et al, Virology 187(1):321-328, 1992), Cox et al (Cox, W.I. et al, Virology 187(1):321-328, 1992) and Perkus et al (Perkus, M.E. et al, J. Virol. 63(9):3829-3836). The recombinant avipox virus encoding CEA and human Tricom gene (designated rF-CEA-Tricom) and the recombinant human fowlpox-TRICOM (rF-Tricom) were made as disclosed herein. Wild type fowlpox (FP-WT) was used as a negative control in selected experiments. DC (1×10^6) were incubated in 1 ml of Optim-MEM medium (Life Technologies, Inc.) at 37°C with rF TRICOM, rF-CEA, rF-CEA/TRICOM, FP-WT. Titration experiments indicated that 2×10^7 plaque-forming units/ml, equal to a multiplicity of infection (MOI) of 40:1 for 2 hours, were able to consistently induce expression of CEA in approximately 75% of the infected DC. The infected DC were suspended in 10 ml of fresh, warm RPMI-1640 complete medium containing 50 ng/ml of rhGM-CSF and 0.5 ng/ml rhIL-4 cultured for 24 hours, and then subsequently used as stimulators.

Peptide

[0240] CAP-1 (Tsang, K.Y. et al, J. Natl Cancer Inst. 87(13):982-990, 1995), CEA amino acid position 571-579 YLSGANLNL, CAP1-6D (Zaremba, S. et al, Cancer Res. 57(20):4570-4577, 1997) YLSGADLNL and Flu peptide, influenza matrix protein peptide 58-66 GILGFVTL greater than 96% pure, were made by Multiple Peptide System (San Diego, CA).

Generation of T-cell lines

[0241] Modification of the protocol described by Tsang et al (Tsang, K.Y. et al, J. Natl Cancer Inst. 87(13):982-990, 1995) was used to generate CEA-specific CTL. Uninfected DC and DC infected with rF-TRICOM, rF-CEA, or rF-CEA/TRICOM were used as APC. CAP-1 peptide was added to the uninfected or rF-TRICOM infected DC at a final concentration of 25 μ g/ml. Autologous non adherent cells were then added to APC at an APC-to-effector ratio of 1:10. Cultures were then incubated for 3 days at 37°C in a humidified atmosphere containing 5% CO₂. After removal of the peptide-containing medium, the cultures were then supplemented with recombinant human IL-2 at a concentration of 20 units/ml for 7 days, with IL-2 containing medium was replenished every 3 days. The 3-day incubation with peptide and 7 day IL-2 supplement constituted one IVS cycle. Primary cultures were restimulated with CAP-1 peptide (25 μ g/ml) on day 11 to begin the next IVS cycle. Irradiated (23,000 rads) autologous EBV- transformed B cells were used as APC. A similar procedure was employed for CTL generation when DC infected with rF-CEA or rF-CEA/TRICOM were used as APC, with the exception that no CAP-1 peptide was in the stimulation.

Construction of peptide MHC tetramers

[0242] Peptide-MHC complexes were synthesized as described by Altman et al (Altman, J.D. et al Science 274(5284): 94-95, 1996). In brief, the β_2 microglobulin (β_2 M) clone was obtained from Dr. Garboczi (Harvard University, Cambridge, MA) (Garboczi, D.N. et al, Proc Natl Acad Sci USA 89(8):3429-3433, 1992) and the HLA-A2 construct was obtained from Immunotech (Beckman-Coulter, Marseille, France). The soluble HLA-A2 molecules containing the 15 amino acid substrate peptide for BirA-dependent biotinylation to the COOH-terminus of the HLA-A2 heavy chain and β_2 M were grown separately in *E. coli* and isolated as inclusion bodies. HLA-A2 and β_2 M were solubilized and renatured in the

presence of CAP-1 or Flu-M1 58-66 peptide. The complex was purified by FPLC on Superdex 200 (Pharmacia, Piscataway, NJ). Purified peptide-MHC complex was biotinylated using the BirA enzyme (Avidity, Denver, CO). Tetramers were produced by mixing the biotinylated peptide-MHC complex with phycoerythrin-labeled UltraAvidin (Leinco Technologies, Inc. Ballwin, MO) at a molar ratio of 4:1.

Flow cytometry

[0243] *Staining and sorting of T-cells:* CAP-1-MHC tetramer-PE was used for flow cytometric analysis and sorting of T-cells. Similar procedure as described above was used for tetramer staining. CAP-1-MHC tetramer-PE was used at a concentration of 0.33 $\mu\text{g}/2 \times 10^5$ cells. Cells were stained with CAP-1 MHC tetramer-PE for 1 hour at 4°C and then stained with anti-CD8 FITC for an additional hour. Cells were washed and analyzed on a Vantage Cell sorter (Becton Dickinson) or a FACScan (Becton Dickinson) using CellQuest software (Becton Dickinson). Sorter cells were cultured and expanded as described previously. Cells stained with UltraAvidin-PE and Flu-MHC tetramer were used as negative controls.

Cytotoxic Assay

[0244] Target cells were labeled with 50 μCi of $^{111}\text{Indium}$ -labeled oxyquinoline (Medi-Physics Inc., Arlington, IL) for 15 min at room temperature. Target cells (0.3×10^4) in 100 μl of RPMI-1640 complete medium were added to each of 96 wells in flat-bottomed assay plates (Corning Costar, Corp.). The labeled target cells were incubated with peptides for 60 min at 37°C in 5% CO_2 before adding effector cells. No peptide was used when carcinoma cell lines were used as targets. Effector cells were suspended in 100 μl of RPMI-1640 complete medium supplemented with 10% pooled human AB serum and added to the target cells. The plates were then incubated at 37°C in 5% CO_2 for 4 or 16 hours. Supernatant was harvested for gamma counting with the use of harvester frames (Skatron, Inc., Sterling, VA). Determinations were carried out in triplicate, and standard deviations were calculated. Specific lysis was calculated with the use of the following formula (all values in cpm):

$$\% \text{ lysis} = \frac{\text{Observed release} - \text{Spontaneous release} \times 100}{\text{Total release} - \text{Spontaneous release}}$$

Spontaneous release was determined from wells to which 100 μl of RPMI-1640 complete medium was added. Total releasable radioactivity was obtained after treatment of targets with 2.5% Triton x-100.

HLA typing

[0245] The HLA phenotyping was performed by the Blood Bank of the National Institutes of Health using a standard antibody-dependent microcytotoxicity assay and a defined panel of anti-HLA antisera. The class I phenotypes of V8T cell line and patient #15 were HLA-A2, -; B 18 (W6), 44 (12, W4) and HLA-A2, 28; B 13 (BW4), B51 (BW4); CW6, respectively.

Detection of cytokine

[0246] Supernatant of T cells exposed for 24 hours to DC infected with rF-CEA, rF-CEA/TRICOM or to peptide pulsed uninfected DC and rF-TRICOM-infected DC in IL-2-free medium at various responder:stimulator ratio were screened for secretion of $\text{IFN}\gamma$ using an ELISA kit (R&D Systems, Minneapolis, MN). The results were expressed in pg/ml.

ELISPOT assay

[0247] A modification of the method described by Scheibenbogen et al (Scheibenbogen, C. et al, Clin Cancer Res 3 (2):221-226, 1997) was used to measure $\text{IFN}\gamma$ production to determine CAP-1 specific T cells. Briefly, 96-well Milliliter HA plates (Millipore Corporation, Bedford, MA) were coated with 100 μl of capture antibody against human $\text{IFN}\gamma$ at a concentration of 10 $\mu\text{g}/\text{ml}$. After 24 hours incubation at room temperature, plates were blocked for 30 min with RPMI-1640 containing 10% human pool AB serum. 1×10^5 cells to be assayed were added to each well. CAP-1-6D-pulsed C1R-A2 cells were added into each well as APC at an effector:APC ratio of 1:3. Unpulsed C1R-A2 cells were used as negative control. HLA-A2 binding Flu Matrix peptide 58-66 (GILGFVFTL) were also used as control. The responding cells were determined by the use of a Domino Image Analyzer (Otpomax, Hollis, NH).

Statistical analysis

[0248] Statistical analysis of differences between means was done using a two-tailed t test.

Discussion

[0249] When a naive T cell encounters antigen, several distinct outcomes are possible including proliferation, cytokine secretion, and differentiation into effector cells, as well as inactivation, death, and unresponsiveness (anergy). The predominant outcome under physiologic conditions may be determined by whether appropriate costimulatory signals are delivered to the responding T cell (26). At least three distinct molecules normally found on the surface of professional APC have been thought to be capable of providing the signals critical for T-cell activation: B7-1, ICAM-1, and LFA-3. Here, the role of costimulatory molecules in naive T-cell activation was examined by utilizing vectors engineered to express either B7-1, ICAM-1, LFA-3, or a combination of all three molecules.

[0250] Several groups have investigated the cooperation of two of these molecules in T-cell costimulation. Dubey et al. have reported that costimulation by both B7-1 and ICAM-1 is a prerequisite for naive T-cell activation (26), while Cavallo et al. determined that B7-1 and ICAM-1 must be coexpressed by tumor cells to establish an antitumor memory response (27). In addition, costimulation by B7-1 and LFA-3 has been shown to act additively both upon T-cell proliferation and cytokine production (6, 23, 24). These previous studies were carried out using two costimulatory molecules and retroviral vectors. One gene was transduced into the target cell line, drug selected, and then transduced again with a second recombinant retroviral construct followed by selection with a different agent. This process often requires weeks or months. Utilizing recombinant poxvirus vectors, one is able to achieve the coexpression of three costimulatory molecules 5 hours post-infection. *In vitro* MC38 cells infected with either rV-B7-1/ICAM-1/LFA-3 or rF-CEA/B7-1/ICAM-1/LFA-3 were shown to enhance proliferation of T cells to a much greater extent than MC38 cells infected with vectors containing the gene for any single costimulatory molecule. In addition, the relative strength of the second signal delivered to the T cell by the combination of costimulatory molecules appeared to be several-fold (>6) greater than that delivered by MC38 cells expressing any single costimulatory molecule. Dubey et al. have demonstrated that at low stimulator to T-cell ratios, moderate to strong synergy was noted with B7-1 and ICAM-1 (26). Our studies confirm these findings. However, at very low stimulator cell to T-cell ratios or weak signal-1 (0.625 μ g/ml Con A), the two-gene construct (rV-B7-1/ICAM-1) had little if any effect on proliferation; in contrast, stimulation via the triad construct (rV-B7-1/ICAM-1/LFA-3) had a substantial and statistically significant effect on proliferation. The predominant effect of stimulation via the multi-gene construct (rV-B7-1, ICAM-1, LFA-3) was IL-2 elaboration from CD4⁺ cells and IFN- γ elaboration from CD8⁺ T cells, while few, if any, type 2 cytokines were produced. Cytokine expression analysis by RNase protection provided a profile compatible with the *in vitro* cytokine assay, manifested by significantly higher expression of IL-2 and IFN- γ in both CD4⁺ and CD8⁺ T cells stimulated with all three costimulatory molecules, as compared to stimulation by any single costimulatory molecule. These data are in accordance with previous studies which demonstrated that in the context of low CD28 costimulation, T cells produced low levels of IL-1, whereas strong CD28 costimulation supported production of IL-2, IFN- γ and IL-13 (28). Furthermore, it has been reported that IL-13 synergizes with IL-2 in regulating IFN- γ synthesis in T cells (29). Interestingly, our results further support this observation in that stimulation of CD4⁺ T cells with MC38B7-1/ICAM-1/LFA-3 results in a high level of IL-2 and IFN- γ expression, with some increased expression of IL-13. Moreover, it was noted that IL-9 expression was further enhanced in CD4⁺ T cells upon stimulation with MC38B7-1/ICAM-1/LFA-3. The increased expression of IL-9 in conjunction with upregulation of IL-2 noted in our studies is in agreement with previous studies which demonstrated that optimal production of IL-9 is regulated by IL-2 (30). Taken together, these studies suggest that optimal naive T-cell responses require a higher level of costimulation than was previously thought, and that this could be provided by the combined action of three costimulatory molecules.

[0251] Perhaps the most studied T-cell costimulatory molecule is B7-1. This molecule's ability to enhance T-cell activation using retroviral vectors, anti-CTLA-4 antibodies, and poxvirus vectors is well established. The studies reported here rank the order of T-cell stimulation by a single costimulatory molecule as B7-1 > ICAM-1 > LFA-3. However, the employment of three costimulatory molecules was far superior to B7-1 alone or in B7 in combination with a second costimulatory molecule in both T-cell proliferation and cytokine production.

[0252] While not being bound by theory, there are several possible mechanisms for efficient cooperation between B7-1, ICAM-1 and LFA-3. The ICAM-1/LFA-3 interaction reportedly costimulates the TCR-mediated activation of T cells by sustaining the increase in the same intracellular second messengers as generated by TCR engagement. This observation suggests that the ligation of LFA-1 by ICAM-1 costimulates T cells by enhancing the signal delivered via the CD3/TCR complex (6). The ICAM-1/LFA-1 interaction is necessary to upregulate expression of the IL-2R- α chain and CD28 on T cells, which is required to render them competent to respond to IL-2 and B7-1 costimulation. On the other hand, the B7-1/CD28 interaction delivers a TCR-independent costimulatory signal that increases both transcriptionally and post-transcriptionally the expression of IL-2 and other immunoregulatory lymphokines. The LFA-3/CD2 interaction induces tyrosine phosphorylation of several intracellular second messengers, Ca²⁺ mobilization, and cAMP

production, resulting in elaboration of a variety of cytokines, notably IL-2 and IFN- γ (6). Thus, it appears that the three costimulatory molecules could be cooperating by enhancing the antigen-dependent activation of T cells, as well as their production of and response to autocrine and paracrine growth factors.

[0253] In conclusion, this invention demonstrates for the first time the ability of vectors to introduce three or more costimulatory molecules into a cell, and to rapidly and efficiently activate both CD4⁺ and CD8⁺ T-cell populations to levels far greater than those achieved when one or two of these costimulatory molecules is used. This new threshold of T-cell activation has broad implications in vaccine design and development.

[0254] The effect of the triad of costimulatory molecules on DCs was completely unexpected. DCs are known by those skilled in the art as the most potent APC. The data presented in this invention demonstrates that when DCs are infected with the "Tricom" vector, their ability to activate T-cells increases dramatically. These studies demonstrate for the first time that a DC is not the most potent APC.

References

[0255]

1. Hellstrom, K. E., Chen, L. & Hellstrom, I. (1996) Cancer Chemother Pharmacol 38, S40-1.
2. Damle, N. K., Klussman, K., Linsley, P. S. & Aruffo, A. (1992) J Immunol 148, 1985-92.
3. Green, J. M., Zheng, X. G., Shimizu, Y., Thompson, C. B. & Turka, L. A. (1994) Eur J Immunol 24, 265-72.
4. Guinan, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J. & Nadler, L. M. (1994) Blood 84, 3261-82.
5. Hodge, J. W., McLaughlin, J. P., Abrams, S. I., Shupert, W. L., Schlom, J. & Kantor, J. A. (1995) Cancer Res 55, 3598-603.
6. Wingren, A. G., Parra, E., Varga, M., Kalland, T., Sjogren, H. O., Hedlund, G. & Dohlsten, M. (1995) Crit Rev Immunol 15, 235-53.
7. Parra, E., Wingren, A. G., Hedlund, G., Sjogren, H. O., Kalland, T., Sansom, D. & Dohlsten, M. (1993) Scand J Immunol 38, 508-14.
8. Harding, F. A. & Allison, J. P. (1993) JExp Med 177, 1791-6.
9. Hellstrom, K. E., Hellstrom, I., Linsley, P. & Chen, L. (1993) Ann N.Y Acad Sci 690, 225-30.
10. Hodge, J. W., Abrams, S., Schlom, J. & Kantor, J. A. (1994) Cancer Res 54, 5552-5.
11. Uzendoski, K., Kantor, J. A., Abrams, S. I., Schlom, J. & Hodge, J. W. (1997) Hum Gene Ther 8, 851-60.
12. Lorenz, M. G. O., Kantor, J. A., Schlom, J. & Hodge, J. W. (1998) Human Gene Therapy In Press.
13. Gritz, L., Destree, A., Cormier, N., Day, E., Stallard, V., Caiazzo, T., Mazzara, G. & Panicali, D. (1990) J Virol 64, 5948-57.
14. Mazzara, G. P., Destree, A. & Mahr, A. (1993) Methods Enzymol 217, 557-81.
15. Jenkins, S., Gritz, L., Fedor, C. H., O'Neill, E. M., Cohen, L. K. & Panicali, D. L. (1991) AIDS Res Hum Retroviruses 7, 991-8.
16. Chakrabarti, S., Sisler, J. R. & Moss, B. (1997) BioTechniques 23, 1094-7.
17. Perkus, M. E., Piccini, A., Lipinskas, B. R. & Paoletti, E. (1985) Science 229, 981-4.
18. Schmitt, J. F. & Stunnenberg, H. G. (1988) J Virol 62, 1889-97.
19. Venkatesan, S., Baroudy, B. M. & Moss, B. (1981) Cell 25, 805-13.

20. Fox, B. A., Spiess, P. J., Kasid, A., Puri, R., Mule, J. J., Weber, J. S. & Rosenberg, S. A. (1990) *J Biol Response Mod* 9,499-511.
- 5 21. Abrams, S. I., Dobrzanski, M. J., Wells, D. T., Stanziale, S. F., Zaremba, S., Masuelli, L., Kantor, J. A., Schlom, J. & Masuelle, L. (1995) *Eur J Immunol* 25,2588-97.
22. Sabzevari, H., Propp, S., Kono, D. H. & Theofilopoulos, A. N. (1997) *EurJ Immunol* 27, 1901-10.
- 10 23. Parra, E., Wingren, A. G., Hedlund, G., Bjorklund, M., Sjogren, H. O., Kalland, T., Sansom, D. & Dohlsten, M. (1994) *J Immunol* 153, 2479-87.
24. Parra, E., Wingren, A. G., Hedlund, G., Kalland, T. & Dohlsten, M. (1997) *J Immunol* 158, 637-42.
- 15 25. Sperling, A. I., Auger, J. A., Ehst, B. D., Rulifson, I. C., Thompson, C. B. & Bluestone, J. A. (1996) *J Immunol* 157, 3909-17.
26. Dubey, C., Croft, M. & Swain, S. L. (1995) *J Immunol* 155, 45-57.
- 20 27. Cavallo, F., Martin-Fontecha, A., Bellone, M., Heltai, S., Gatti, E., Tomaghi, P., Freschi, M., Forni, G., Dellabona, P. & Casorati, G. (1995) *Eur J Immunol* 25, 1154-62.
28. Delespesse, G., Yang, L. P., Ohshima, Y., Demeure, C., Shu, U., Byun, D. G. & Sarfati, M. (1998) *Vaccine* 16, 1415-9.
- 25 29. Minty, A., Chalon, P., Derocq, J. M., Dumont, X., Guillemot, J. C., Kaghad, M., Labit, C., Leplatois, P., Liauzun, P., Miloux, B. & et al. (1993) *Nature* 362, 248-50.
- 30 30. Schmitt, E., Germann, T., Goedert, S., Hoehn, P., Huels, C., Koelsch, S., Kuhn, R., Muller, W., Palm, N. & Rude, E. (1994) *J Immunol* 153, 3989-96.
31. Chakrabarti, S., Brechling, K. and Moss, B (1985) *Mol. Cell. Biol.* 5:3403-3409.
32. Chakrabarti, S., Sisler, J.R., and Moss, B. (1997) *BioTechniques* 23:1094-1097.
- 35 33. Gillard, S., Spehner, D., Drillien, R., and Kim, A. (1986) *Proc. Natl. Acad. Sci. USA* 83:5573-5577.
34. Morgan, J.R, and Roberts, B.E. (1994) *J. Virol.* 51:283-297.
35. Panicali, D., Grzelecki, A., and Huang, C. (1986) *Gene* 47:193-199.
- 40 36. Sambrook, J., Fritsch, E.F., and Maniatis, T., eds. *Molecular Cloning*, Cold Spring Harbor Laboratory, 1989.
37. Schmitt, J.F.C. and Stunnenberg, H.G. 1988) *J. Virol.* 62:1889-1897.
- 45 38. Smith, K., Stallard, V., Ross, J., Hart, C., Cormier, N., Cohen, L., Roberts, B., and Payne, L. (1993) *Vaccine* 11: 43-53.
39. Venkatesan, S., Baroudy, B.M., and Moss, B. (1981) *Cell* 125:805-813.
- 50 40. Bacchetti, S. and Graham, F.L. *Proc. Nat'l. Acad. Sci. USA* 74:1590-1594, 1977.\
41. Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S. & Steinman, R.M. (1992) *J. Exp. Med.* 176, 1693-702.
- 55 42. Sallusto, F. & Lanzavecchia, A. (1994) *J. Exp. Med.* 179, 1109-8.
43. Fields, R.C., Osterholzer, J. J., Fuller, J.A., Thomas, E.K., Geraghty, P.J. & Mule, J.J. (1998) *J. Immunother.* 21, 323-39.

44. Zaremba et al Cancer Res. 57:4570-4577, 1997.
45. Gong, J. et al Proc. Natl. Acad. Sci. USA 95:6279-6283, 1998.
- 5 46. Correale, P. et al 1998, J. Immunol. 161 (6):3186-94.

SEQUENCE LISTING

[0256]

10

<110> The Government of the United States of America as

<120> A recombinant vector expressing multiple constimulatory molecules and uses thereof

15

<130> 20264292PC

<140> TBA

<141> 1999-11-12

20

<150> 60/111,582

<151> 1998-12-09

<160> 41

25

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

30

<213> Artificial Sequence

<220>

<220>

35

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 1

40

Lys Thr Trp Gly Gln Tyr Trp Glx Tyr
1 5

<210> 2

<211> 9

45

<212> PRT

<213> Artificial Sequence

<220>

50

<220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 2

55

Ile Thr Asp Gln Val Pro Pro Ser Val
1 5

EP 1 137 792 B9

<210> 3
 <211> 9
 <212> PRT
 <213> Artificial Sequence
 5
 <220>
 <220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE
 10
 <400> 3
 15
 .. Tyr Leu Glu Pro Gly Pro Val Thr Ala
 1 5
 <210> 4
 <211> 10
 <212> PRT
 <213> Artificial Sequence
 20
 <220>
 25
 <220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE
 <400> 4
 30
 Leu Leu Asp Gly Thr Ala Thr Leu Arg Leu
 1 5 10
 <210> 5
 <211> 10
 <212> PRT
 <213> Artificial Sequence
 35
 <220>
 40
 <220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE
 <400> 5
 45
 Val Leu Tyr Arg Tyr Gly Ser Phe Ser Val
 1 5 10
 50
 <210> 6
 <211> 9
 <212> PRT
 <213> Artificial Sequence
 55
 <220>
 <220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

EP 1 137 792 B9

<400> 6

5 Ala Ala Gly Ile Gly Ile Leu Thr Val
1 5

<210> 7

<211> 9

<212> PRT

10 <213> Artificial Sequence

<220>

<220>

15 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 7

20 Ile Leu Thr Val Ile Leu Gly Val Leu
1 5

<210> 8

<211> 9

25 <212> PRT

<213> Artificial Sequence

<220>

30 <220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 8

35 Met Ser Leu Gln Arg Gln Phe Leu Arg
1 5

<210> 9

40 <211> 9

<212> PRT

<213> Artificial Sequence

<220>

45 <220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 9

50 Met Leu Leu Ala Val Leu Tyr Cys Leu
1 5

55 <210> 10

<211> 9

<212> PRT

<213> Artificial Sequence

EP 1 137 792 B9

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

5

<400> 10

Tyr Met Asn Gly Thr Met Ser Gln Val
1 5

10

<210> 11

<211> 9

<212> PRT

15

<213> Artificial Sequence

<220>

<220>

20

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 11

Ser Glu Ile Trp Arg Asp Ile Asp Phe
1 5

25

<210> 12

<211> 9

30

<212> PRT

<213> Artificial Sequence

<220>

35

<220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 12

Ala Phe Leu Pro Trp His Arg Leu Phe
1 5

40

<210> 13

<211> 15

45

<212> PRT

<213> Artificial Sequence

<220>

50

<220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 13

55

Gln Asn Ile Leu Leu Ser Asn Ala Pro Leu Gly Pro Gln Phe Pro
1 5 10 15

EP 1 137 792 B9

<210> 14
 <211> 13
 <212> PRT
 <213> Artificial Sequence
 5
 <220>
 <220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE
 10
 <400> 14
 Ser Tyr Leu Gln Asp Ser Asp Pro Asp Ser Phe Gln Asp
 15 1 5 10
 <210> 15
 <211> 9
 <212> PRT
 <213> Artificial Sequence
 20
 <220>
 <220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE
 25
 <400> 15
 Glu Ala Asp Pro Thr Gly His Ser Tyr
 30 1 5
 <210> 16
 <211> 9
 <212> PRT
 <213> Artificial Sequence
 35
 <220>
 <220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE
 40
 <400> 16
 Ser Ala Tyr Gly Glu Pro Arg Lys Leu
 45 1 5
 <210> 17
 <211> 9
 <212> PRT
 <213> Artificial Sequence
 50
 <220>
 <220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE
 55
 <400> 17

EP 1 137 792 B9

Glu Val Asp Pro Ile Gly His Leu Tyr
1 5

5 <210> 18
<211> 9
<212> PRT
<213> Artificial Sequence

10 <220>

<220>
<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

15 <400> 18

Phe Leu Trp Gly Pro Arg Ala Leu Val
1 5

20 <210> 19
<211> 9
<212> PRT
<213> Artificial Sequence

25 <220>

<220>
<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

30 <400> 19

Ala Ala Arg Ala Val Phe Leu Ala Leu
1 5

35 <210> 20
<211> 8
<212> PRT
40 <213> Artificial Sequence

<220>

<220>
45 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 20

50 Tyr Arg Pro Arg Pro Arg Arg Tyr
1 5

<210> 21
<211> 9
55 <212> PRT
<213> Artificial Sequence

<220>

EP 1 137 792 B9

<220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 21

5

Val Leu Pro Asp Val Phe Ile Arg Cys
1 5

10

<210> 22

<211> 9

<212> PRT

<213> Artificial Sequence

15

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

20

<400> 22

Ala Tyr Gly Leu Asp Phe Tyr Ile Leu
1 5

25

<210> 23

<211> 9

<212> PRT

<213> Artificial Sequence

30

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

35

<400> 23

Tyr Leu Ser Gly Ala Asn Leu Asn Leu
1 5

40

<210> 24

<211> 9

<212> PRT

<213> Artificial Sequence

45

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

50

<400> 24

Tyr Leu Ser Gly Ala Asp Leu Asn Leu
1 5

55

<210> 25

EP 1 137 792 B9

<211> 9
 <212> PRT
 <213> Artificial Sequence

5 <220>

<220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

10 <400> 25

Ser Tyr Leu Asp Ser Gly Ile His Phe
 1 5

15

<210> 26
 <211> 9
 <212> PRT
 <213> Artificial Sequence

20

<220>
 <220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

25

<400> 26

Glu Glu Lys Leu Ile Val Val Leu Phe
 1 5

30

<210> 27
 <211> 10
 <212> PRT
 <213> Artificial Sequence

35

<220>

<220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

40

<400> 27

Ala Cys Asp Pro His Ser Gly His Phe Val
 1 5 10

45

<210> 28
 <211> 9
 <212> PRT
 <213> Artificial Sequence

50

<220>

<220>
 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

55

<400> 28

EP 1 137 792 B9

Ile Ile Ser Ala Val Val Gly Ile Leu
1 5

5 <210> 29
<211> 9
<212> PRT
<213> Artificial Sequence

10 <220>

<220>
<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

15 <400> 29

Lys Ile Phe Gly Ser Leu Ala Phe Leu
1 5

20 <210> 30
<211> 10
<212> PRT
<213> Artificial Sequence

25 <220>

<220>
<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

30 <400> 30

Tyr Met Leu Asp Leu Gln Pro Glu Thr Thr
1 5 10

35 <210> 31
<211> 20
<212> PRT
<213> Artificial Sequence

<220>

<220>
<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

45 <400> 31

50 Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly
1 5 10 15

Val Thr Ser Ala
20

55 <210> 32
<211> 30
<212> PRT

EP 1 137 792 B9

<213> Artificial Sequence

<220>

5

<220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 32

10

Phe Leu Thr Pro Lys Lys Leu Gln Cys Val Asp Leu His Val Ile Ser
1 5 10 15

Asn Asp Val Cys Ala Gln Val His Pro Gln Lys Val Thr Lys
20 25 30

15

<210> 33

<211> 10

<212> PRT

20

<213> Artificial Sequence

<220>

<220>

25

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 33

30

Phe Leu Thr Pro Lys Lys Leu Gln Cys Val
1 5 10

<210> 34

<211> 9

35

<212> PRT

<213> Artificial Sequence

<220>

40

<220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 34

45

Lys Leu Gln Cys Val Asp Leu His Val
1 5

<210> 35

50

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

55

<220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

EP 1 137 792 B9

<400> 35

	Val	Ile	Ser	Asn	Asp	Val	Cys	Ala	Gln	Val
5				1		5				10

<210> 36

<211> 9

<212> PRT

10 <213> Artificial Sequence

<220>

<220>

15 <223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 36

	Gln	Val	His	Pro	Gln	Lys	Val	Thr	Lys
20					1	5			

<210> 37

<211> 8

25 <212> PRT

<213> Artificial Sequence

<220>

30 <220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 37

	Glu	Ala	Gln	Asn	Thr	Thr	Tyr	Leu
35				1		5		

<210> 38

40 <211> 8

<212> PRT

<213> Artificial Sequence

<220>

45 <220>

<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

<400> 38

	Ser	Ile	Ile	Asn	Phe	Glu	Lys	Leu
50								

55				1			5	
----	--	--	--	---	--	--	---	--

<210> 39

EP 1 137 792 B9

<211> 8
<212> PRT
<213> Artificial Sequence

5 <220>

<220>
<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

10 <400> 39

Arg Gly Tyr Val Tyr Gln Gly Leu
1 5

15

<210> 40
<211> 9
<212> PRT
<213> Artificial Sequence

20

<220>

<220>
<223> Description of Artificial Sequence: SYNTHETIC PEPTIDE

25

<400> 40

Ala Ser Asn Glu Asn Met Asp Ala Met
1 5

30

<210> 41
<211> 2297
<212> DNA
<213> Artificial Sequence

35

<220>
<223> Description of Artificial Sequence: SNYTHETIC PEPTIDE

40

<220>

<400> 41

45

50

55

atgaccatga ttacgccaag cgcgcaatta accctcacta aagggaaaca aagctgggta 60
 ccggggcccc cctcgaggtc gacggtatcg ataagcttga tatcgaattt cgaggtcgac 120
 atgacaccgg gcacccagtc tcctttcttc ctgctgctgc tcctcacagt gcttacagct 180
 accacagccc ctaaaccgc aacagttgtt acgggttctg gtcacgcaag ctctaccca 240
 5 ggtggagaaa aggagacttc ggctaccag agaagttcag tgcccagctc tactgagaag 300
 aatgctgtga gtatgacaag cttgatatcg aattccggtg tccggggctc caccgcccc 360
 ccagcccacg gtgtcacctc ggccccggac accaggccgg ccccgggcag tactgcacca 420
 ccggcacatg gcgtaacatc agcacctgat acaagacctg cacctggatc caccgcgccg 480
 cctgcgcacg gagtgacgtc ggcgcccgac acgcgccccg ctcccgggtc aacagctcct 540
 10 cccgctcatg gggttacttc tgcctccagat actcgcccag ctccagggtc gacggcccc 600
 cctgctcacg gtgtaacatc cgccccggat accagaccgg cccctggcag caccgcaccg 660
 cccgcccacg gagttacaag tgcacccgat acccgccggg cacccggaag taccgctcca 720
 cctgcacacg gggtcacaag cgcgccagac actcgacctg cgccagggtc gactgcccc 780
 ccggcgcatg gtgtgacctc agctcctgac acaaggccag cccaggttc aacggcacct 840
 ccagcacacg gagtcacgtc tgcacccgac acccgctccag ctccgggtag tacagcgcca 900
 15 cccgcacatg gcgtcacgag cgctccggat acgagaccgg cgctgctag cactctgggt 960

cacaacggca cctctgccag ggctaccaca accccagcca gcaagagcac tccattctca 1020
 20 attcccagcc accactctga tactcctacc acccttgcca gccatagcac caagactgat 1080
 gccagtagca ctacccatag caggtacct ccttcacct cctccaatca cagcacttct 1140
 cccagttgt ctactggggt ctctttcttt ttctgtctt ttacatttc aaacctccag 1200
 ttttaattct ctctggaaga tcccagcacc gactactacc aagagctgca gagagacatt 1260
 tctgaaatgt ttttgagat ttataaaca gggggttttc tgggcctctc caatattaag 1320
 25 ttcaggccag gatctgtggt ggtacaattg actctggcct tccgagaagg taccatcaat 1380
 gtccacgacg tggagacaca gttcaatcag tataaaacgg aagcagcctc tcgatataac 1440
 ctgacgatcc cagacgtcag cgtgagtgtg gtgccatttc ctttctctgc ccagtctggg 1500
 gctgggggtc caggctgggg catcgcgctg ctggtgctgg tctgtgttct gggtgcgctg 1560
 gccattgtct atctcattgc ctggctgtc tgcagtgcc gccgaaagaa ctacgggcag 1620
 ctggacatct ttccagccc ggatacctac catcctatga gcgagtacc cactaccac 1680
 30 acccatgggc gctatgtgcc cctagcagt accgatcgta gccctatga gaaggtttct 1740
 gcaggtaatg gtggcagcag cctctcttac acaaacccag cagtggcagc cacttctgcc 1800
 aacttgtagg ggcacgtcgc ccgctgagct gaggggccag ccagtgccat tccactccac 1860
 tcagggtctt cagggccaga cccctgcacc ctgtttgggc tggtagctg ggagttcagg 1920
 tgggctgctc acagcctcct tcagaggccc caccaatttc tcggacactt ctcagtgtgt 1980
 35 ggaagctcat gtgggccctt gagggtcat gcctgggaag tgttgtggtg ggggctccca 2040
 agaggactgg cccagagagc cctgagatag cggggatcca ctagtctag agcggcgcca 2100
 ccgcggtgga gctccaattc gcctaatagt gagtctgatt acgcgcgctc actggccgctc 2160
 gttttacaac gtcgtgactg ggaaaacctg gcgttaccaa cttatcgct tgcaacacat 2220
 cccctttcgc agctggcgta atacgaagag gccgcacgat cgcccttcca acagttgcgc 2280
 40 acctgaatgg caatgga 2297

Claims

1. A recombinant vector comprising foreign nucleic acid sequences encoding three different costimulatory molecules, one from the B7 family consisting of B7-1 and B7-2 or human homologues or functional portion thereof, and two selected from a group consisting of: ICAM-1, LFA-3, 4-1BBL, CD59, CD40, CD70, OX-40L, VCAM-1 or human homologues or functional portion thereof.
2. The recombinant vector according to claim 1 wherein said three costimulatory molecules are B7-1, ICAM-1 and LFA-3.
3. The recombinant vector according to claim 2 wherein said costimulatory molecules are human derived, simian derived or murine derived.
4. The recombinant vector according to any one of claims 1-3 further comprising a foreign nucleic acid sequence encoding at least one cytokine, chemokine, Flt-3L, or combination thereof.

5. The recombinant vector according to any one of claims 1-4 further comprising a selectable marker.
6. The recombinant vector according to claim 5 wherein the selectable marker is selected from the group consisting of *lacZ* gene, thymidine kinase, gpt, GUS and a vaccinia K1L host range gene.
7. The recombinant vector according to any one of claims 1-6 further comprising at least one promoter derived from a eukaryotic source, prokaryotic source, or viral source.
8. The recombinant vector according to claim 7 wherein the promoter is selected from the group consisting of an SV40 early promoter, RSV promoter, adenovirus major late promoter, human CMV immediate early I promoter, poxvirus promoter, 30K promoter, 13 promoter, sE/L promoter, 7.5K promoter, 40K promoter, and C1 promoter.
9. The recombinant vector according to any one of claims 1-8 selected from the group consisting of a bacteria, virus, and nucleic acid-based vector.
10. The recombinant vector according to claim 9 wherein said virus vector is selected from the group consisting of poxvirus, adenovirus, Herpes virus, alphavirus, retrovirus, picornavirus, and iridovirus.
11. The recombinant vector according to claim 10 **characterized in that** it is a recombinant poxvirus.
12. The recombinant vector according to claim 11 wherein the recombinant poxvirus is orthopox, avipox, capripox or suipox.
13. The recombinant vector according to claim 12 wherein the avipox is fowlpox, canary pox or derivatives thereof.
14. The recombinant vector according to claim 12 wherein the orthopox is vaccinia, vaccinia-Copenhagen strain, vaccinia-Wyeth strain, NYVAC, vaccinia-MVA strain, raccoon pox or rabbit pox.
15. The recombinant poxvirus according to any one of claims 11-14 further comprising at least one poxvirus promoter capable of controlling expression of the foreign DNA.
16. The recombinant vector according to claim 9 **characterized in that** said bacteria vector is a plasmid vector.
17. The recombinant vector according to claim 16 comprising (a) at least one poxviral promoter, (b) the foreign nucleic acid sequences encoding LFA-3, ICAM-1 and at least one B7 molecule, (c) DNA sequences flanking the construct of elements (a) and (b), the flanking sequences of both the 5' and 3' ends being homologous to a region of a parental poxvirus genome where elements (a) and (b) are to be inserted for recombination with a poxvirus designed to produce a recombinant poxvirus capable of expressing foreign nucleic acid sequences encoding three costimulatory molecules, LFA-3, ICAM-1 and at least one B7 molecule.
18. The recombinant vector according to claim 16 designated pT5064 deposited with the ATCC under Accession No. 203482.
19. The recombinant vector according to claim 16, designated pT5049 deposited with the ATCC under Accession No. 203481.
20. The recombinant vector according to any one of claims 1-19 further comprising a foreign nucleic acid sequence encoding at least one target antigen or immunological epitope thereof.
21. The recombinant vector according to claim 20 wherein the target antigen has an amino acid sequence selected from the group consisting of SEQ ID NO: 2 through SEQ ID NO: 40.
22. The recombinant vector according to claim 20 wherein the target antigen is selected from the group consisting of a tumor specific antigen, tumor associated antigen (TAA), tissue-specific antigen, bacterial antigen, viral antigen, yeast antigen, fungal antigen, protozoan antigen, and parasite antigen and mitogen.
23. The recombinant vector according to claim 22 wherein the bacterial antigen is derived from a bacterium selected from the group consisting of Chlamydia, Mycobacteria, Legionella, Meningioccus, Group A Streptococcus, *He-*

mophilus influenzae, Salmonella, and Listeria.

24. The recombinant vector according to claim 22 wherein the viral antigen is derived from a virus selected from the group consisting of Lentivirus, Herpes virus, Hepatitis virus, Orthomyxovirus and Papillomavirus.

25. The recombinant vector according to claim 24 wherein the Lentivirus is HIV-1 or HIV-2.

26. The recombinant vector according to claim 24 wherein the Herpes virus is HSV or CMV.

27. The recombinant vector according to claim 24 wherein the Hepatitis virus is Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D or Hepatitis E.

28. The recombinant vector according to claim 24 wherein the orthomyxovirus is influenza virus.

29. The recombinant vector according to claim 22 wherein the tumor associated antigen, tumor specific antigen or tissue-specific antigen is selected from the group consisting of CEA, MART-1, MAGE-1, MAGE-3, GP-100, MUC-1, MUC-2, point mutated ras oncogene, normal or point mutated p53, overexpressed p53, CA-125, PSA, C-erb/B2, BRCA I, BRCA II, PSMA, tyrosinase, TRP-1, TRP-2, NY-ESO-1, TAG72, KSA, HER-2/neu, bcr-abl, pax3-fkhr, ewsfli-1, modified TAAs, splice variants of TAAs, functional epitopes and epitope agonists thereof.

30. The recombinant vector according to claim 29 wherein the antigen is CEA (6D) having an amino acid aspartic acid at amino acid position 576.

31. The recombinant vector according to claim 29 wherein the antigen is PSA or PSMA.

32. The recombinant vector according to claim 29 wherein the antigen is MUC-1 or portion thereof.

33. The recombinant vector according to claim 22 wherein the yeast or fungal antigen is derived from a yeast or fungus selected from the group consisting of Aspergillus, Nocardia, Histoplasmosis, Candida, and Cryptosporidia.

34. The recombinant vector according to claim 22 wherein the parasite antigen is derived from a *Plasmodium species*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Trypanosoma species*, or *Leishmania species*.

35. An isolated host cell comprising the recombinant vector according to any one of claims 1- 34

36. The host cell according to claim 35 further comprising a foreign nucleic acid sequence encoding at least one target antigen or immunological epitope thereof.

37. The host cell according to any one of claims 35-36 **characterized in that** said cell is an antigen presenting cell or precursor thereof, a premalignant cell, a hyperplastic cell or tumor cell.

38. The host cell according to claim 37 wherein said antigen presenting cell is a dendritic cell or precursor or derivative thereof, a monocyte, macrophage, B-cell, fibroblast or muscle cell.

39. The host cell according to claim 37 wherein the antigen presenting cell is derived from bone marrow, spleen, skin, peripheral blood, tumor, lymph node, or muscle.

40. The host cell according to claim 37 wherein said antigen presenting cell is a progenitor antigen presenting cell, an antigen presenting cell or an engineered antigen presenting cell.

41. The host cell according to claim 38 wherein said dendritic derivative is a TNF- α -treated dendritic cell, a CD40-treated dendritic cell, or a subpopulation of adherent cells.

42. The host cell according to claim 36 wherein the foreign nucleic acid sequence encoding at least one target antigen or immunological epitope thereof is provided by a recombinant vector, RNA or DNA from a tumor cell lysate, or by fusion with a tumor cell comprising said sequence.

43. A pharmaceutical composition comprising at least one recombinant vector according to any one of claims 1-34 and

a pharmaceutically acceptable carrier.

44. The pharmaceutical composition according to claim 43 comprising a recombinant poxvirus according to any one of claims 11-15 and optionally as a second recombinant vector a poxvirus comprising at least one foreign nucleic acid sequence encoding at least one target antigen or immunological epitope thereof.

45. The pharmaceutical composition according to any one of claims 43-44 further comprising a cytokine, chemokine or Flt-3L.

46. The pharmaceutical composition according to any one of claims 43-44 suitable for administration via the intravenous, subcutaneous, intralymphatic, intratumoral, intradermal, intramuscular, intraperitoneal, intrarectal, intravaginal, intranasal or oral route or via bladder instillation or via scarification.

47. A pharmaceutical composition comprising the dendritic cells and derivatives thereof according to claim 38 and a pharmaceutically acceptable carrier.

48. An *in vitro* process to enhance an antigen specific immune response in an isolated cell of the immune system **characterized in that** the recombinant vector according to any one of claim 1-34 or the host cells according to claims 35-42 are used.

49. A process according to claim 48 wherein the host cells according to any one of claims 35-42 are used and further optionally comprising a step of pulsing said cells with a target antigen or epitope thereof.

50. The process according to claim 48 wherein the isolated cells of the immune system are T-lymphocytes and **characterized in that** it comprises the step of exposing an isolated T-lymphocyte to a host cell according to any one of claims 35-42 alone or in combination with a target antigen or immunological epitope thereof.

51. A process according to claim 50 wherein said T-lymphocytes are autologous with an individual.

52. Use of the recombinant vector according to any one of claims 1-34 for the preparation of a medicament for the treatment or the prevention of cancer or of diseases caused by a pathogenic microorganism.

53. Use of the recombinant vector according to any one of claims 1-34 for the preparation of a medicament for the treatment or the prevention of preneoplastic or hyperplastic states.

54. Use of the recombinant vector according to any one of claims 1-34 for the preparation of a medicament to enhance the immune response.

55. Use of a host cell according to any one of claims 37-42 alone or in combination with a target antigen for the preparation of a medicament for immunotherapy or vaccination

56. A process for the production of a recombinant poxvirus comprising allowing the recombinant vector according to any one of claims 16-19 to undergo recombination with a parental poxvirus genome.

57. A kit for the production of a recombinant poxvirus comprising the recombinant vector according to any one of claims 16-19 and optionally a parental poxvirus.

58. A process for assessing *in vitro* the efficacy of a vaccine against a target antigen comprising determining the number and the function of target- antigen specific lymphocytes in the presence of the antigen presenting cell according to claim 37 wherein an increase in number, function or combination thereof of target-antigen specific lymphocytes being indicative of efficacy of the vaccine against a target antigen.

59. A method of screening for immunogenic peptides from a multiplicity of peptides comprising:

- (a) pulsing antigen presenting cells infected with a recombinant vector according to any one of claims 1-34 with a multiplicity of peptides to form peptide-pulsed antigen presenting cells;
- (b) measuring lymphoid immunoreactivity in the presence of the peptide-pulsed antigen presenting cells,

wherein enhanced immunoreactivity, is indicative of an immunogenic peptide on the peptide-pulsed antigen presenting cell.

60. The method according to claim 59, wherein the source of the multiplicity of peptides is a combinatorial peptide library.

Patentansprüche

1. Rekombinanter Vektor, der Fremdkern-Säuresequenzen umfasst, die drei verschiedene kostimulatorische Moleküle, eines aus der B7-Familie, die aus B7-1 und B7-2 oder menschlichen Homologen oder einem Funktionsabschnitt davon besteht, und zwei, die aus einer Gruppe ausgewählt sind, die aus ICAM-1, LFA-3, 4-1 BBL, CD59, CD40, CD70, OX-40L, VCAM-1 oder menschlichen Homologen oder einem Funktionsabschnitt davon besteht, codieren.
2. Rekombinanter Vektor gemäß Anspruch 1, bei dem die genannten drei kostimulatorischen Moleküle B7-1, ICAM-1 und LFA-3 sind.
3. Rekombinanter Vektor gemäß Anspruch 2, bei dem die genannten kostimulatorischen Moleküle vom Menschen abgeleitet, vom Affen abgeleitet oder von der Ratte abgeleitet sind.
4. Rekombinanter Vektor gemäß einem der Ansprüche 1-3, der ferner eine Fremdkern-Säuresequenz umfasst, die wenigstens ein Cytokin, Chemokin, Flt-3L oder eine Kombination davon codiert.
5. Rekombinanter Vektor gemäß einem der Ansprüche 1-4, der ferner einen wählbaren Marker umfasst.
6. Rekombinanter Vektor gemäß Anspruch 5, bei dem der wählbare Marker aus der Gruppe ausgewählt ist, die aus dem lacZ-Gen, aus Thymidin-Kinase, aus gpt, aus GUS und aus einem Impfpocken-K1 L-Wirtsbereichsgen besteht.
7. Rekombinanter Vektor gemäß einem der Ansprüche 1-6, der ferner wenigstens einen Promotor umfasst, der von einer eukaryontischen Quelle, von einer prokaryontischen Quelle oder von einer Virusquelle abgeleitet ist.
8. Rekombinanter Vektor gemäß Anspruch 7, bei dem der Promotor aus der Gruppe ausgewählt ist, die aus einem SV40-Early-Promotor, aus einem RSV-Promotor, aus einem Adenovirus-Major-Late-Promotor, aus einem menschlichen CMV-Immediate-Early-I-Promotor, aus einem Pockenvirus-Promotor, aus einem 30K-Promotor, aus einem 13-Promotor, aus einem sE/L-Promotor, aus einem 7.5K-Promotor, aus einem 40K-Promotor und aus einem C1-Promotor besteht.
9. Rekombinanter Vektor gemäß einem der Ansprüche 1-8, der aus der Gruppe ausgewählt ist, die aus einem bakteriellen-, aus einem virus- und aus einem nukleinsäurebasierten Vektor besteht.
10. Rekombinanter Vektor gemäß Anspruch 9, bei dem der genannte Virusvektor aus der Gruppe ausgewählt ist, die aus Pockenvirus, Adenovirus, Herpesvirus, Alphavirus, Retrovirus, Picornavirus und Iridovirus besteht.
11. Rekombinanter Vektor gemäß Anspruch 10, **dadurch gekennzeichnet, dass** er ein rekombinantes Pockenvirus ist.
12. Rekombinanter Vektor gemäß Anspruch 11, bei dem das rekombinante Pockenvirus Orthopox, Avipox, Capripox oder Suipox ist.
13. Rekombinanter Vektor gemäß Anspruch 12, bei dem das Avipox Geflügelpocken, Kanarienvpocken oder Ableitungen davon ist.
14. Rekombinanter Vektor gemäß Anspruch 12, bei dem das Orthopox Impfpocken, der Kopenhagen-Impfpockenstamm, der Wyeth-Impfpockenstamm, NYVAC, der MVA-Impfpockenstamm, Waschbärpocken oder Hasenpocken sind.
15. Rekombinantes Pockenvirus gemäß einem der Ansprüche 11-14, das ferner wenigstens einen Pockenviruspromotor umfasst, der die Expression der Fremd-DNA steuern kann.
16. Rekombinanter Vektor gemäß Anspruch 9, **dadurch gekennzeichnet, dass** der genannte Bakterienvektor ein

Plasmidvektor ist.

- 5 17. Rekombinanter Vektor gemäß Anspruch 16, der Folgendes umfasst: (a) wenigstens einen Pockenviruspromotor, (b) die Fremdnukleinsäuresequenzen, die LFA-3, ICAM-1 und wenigstens ein B7-Molekül codieren, (c) DNA-Sequenzen, die das Konstrukt aus den Elementen (a) und (b) flankieren, wobei die flankierenden Sequenzen sowohl der 5'- als auch der 3'-Enden Homologe zu einem Gebiet eines Eltern-Pockenvirusgenoms sind, wobei die Elemente (a) und (b) zur Rekombination mit einem Pockenvirus einzuführen sind, das so beschaffen ist, dass es ein rekombinantes Pockenvirus erzeugt, das Fremdnukleinsäuresequenzen exprimieren kann, die drei kostimulatorische Moleküle, LFA-3, ICAM-1 und wenigstens ein B7-Molekül, codieren.
- 10 18. Rekombinanter Vektor gemäß Anspruch 16, der als pT5064 bezeichnet ist und bei der ATCC unter der Zugriffsnummer 203482 gelagert ist.
- 15 19. Rekombinanter Vektor gemäß Anspruch 16, der mit pT5049 bezeichnet ist und bei der ATCC unter der Zugriffsnummer 203481 gelagert ist.
- 20 20. Rekombinanter Vektor gemäß einem der Ansprüche 1-19, der ferner eine Fremdnukleinsäuresequenz umfasst, die wenigstens ein Zielantigen oder ein immunologisches Epitop davon codiert.
- 25 21. Rekombinanter Vektor gemäß Anspruch 20, bei dem das Zielantigen eine Aminosäuresequenz besitzt, die aus der Gruppe ausgewählt ist, die aus der SEQ ID NO: 2 bis zu der SEQ ID NO: 40 besteht.
- 30 22. Rekombinanter Vektor gemäß Anspruch 20, bei dem das Zielantigen aus der Gruppe ausgewählt ist, die aus einem tumorspezifischen Antigen, aus einem tumorassoziierten Antigen (TAA), aus einem gewebespezifischen Antigen, aus einem bakteriellen Antigen, aus einem Virusantigen, aus einem Hefeantigen, aus einem Pilzantigen, aus einem Protozoon-Antigen und aus einem Parasitenantigen und aus einem Mitogen besteht.
- 35 23. Rekombinanter Vektor gemäß Anspruch 22, bei dem das bakterielle Antigen von einem Bakterium abgeleitet ist, das aus der Gruppe ausgewählt ist, die aus Chlamydia, Mycobacteria, Legionella, Meningococcus, Streptococcus der Gruppe A, *Hemophilus influenzae*, Salmonella und Listeria besteht.
- 40 24. Rekombinanter Vektor gemäß Anspruch 22, bei dem das Virusantigen von einem Virus abgeleitet ist, das aus der Gruppe ausgewählt ist, die aus Lentivirus, Herpesvirus, Hepatitisvirus, Orthomyxovirus und Papillomavirus besteht.
- 45 25. Rekombinanter Vektor gemäß Anspruch 24, bei dem das Lentivirus HIV-1 oder HIV-2 ist.
26. Rekombinanter Vektor gemäß Anspruch 24, bei dem das Herpesvirus HSV oder CMV ist.
- 50 27. Rekombinanter Vektor gemäß Anspruch 24, bei dem das Hepatitisvirus Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D oder Hepatitis E ist.
28. Rekombinanter Vektor gemäß Anspruch 24, bei dem das Orthomyxovirus das Influenzavirus ist.
- 55 29. Rekombinanter Vektor gemäß Anspruch 22, bei dem das tumorassoziierte Antigen, das tumorspezifische Antigen oder das gewebespezifische Antigen aus der Gruppe ausgewählt ist, die aus CEA, MART-1, MAGE-1, MAGE-3, GP-100, MUC-1, MUC-2, aus einem punktmutierten ras-Onkogen, aus normalem oder punktmutiertem p53, aus überexprimiertem p53, aus CA-125, PSA, C-erbB2, BRCA I, BRCA II, PSMA, Tyrosinase, TRP-1, TRP-2, NY-ESO-1, TAG72, KSA, HER-2/neu, bcr-abl, pax3-fkhr, ews-fli-1, aus modifizierten TAAs, aus Spleißvarianten von TAAs, aus funktionellen Epitopen und aus Epitopagonisten davon besteht.
30. Rekombinanter Vektor gemäß Anspruch 29, bei dem das Antigen CEA (6D) ist, das bei der Aminosäureposition 576 eine Aminosäure Asparaginsäure besitzt.
31. Rekombinanter Vektor gemäß Anspruch 29, bei dem das Antigen PSA oder PSMA ist.
32. Rekombinanter Vektor gemäß Anspruch 29, bei dem das Antigen MUC-1 oder ein Abschnitt davon ist.
33. Rekombinanter Vektor gemäß Anspruch 22, bei dem das Hefe- oder Pilzantigen von einer Hefe oder von einem

Pilz abgeleitet ist, die/der aus der Gruppe ausgewählt ist, die aus Kolbenschemmel, Nocardia, Histoplasmose, Candida und Cryptosporidia besteht.

34. Rekombinanter Vektor gemäß Anspruch 22, bei dem das Parasitenantigen von einer *Plasmodium-Species*, von *Toxoplasma gondii*, von *Pneumocystis carinii*, von einer *Trypanosoma-Spezies* oder von einer *Leishmania-Spezies* abgeleitet ist.

35. Isolierte Wirtszelle, die den rekombinanten Vektor gemäß einem der Ansprüche 1-34 umfasst.

36. Wirtszelle gemäß Anspruch 35, die ferner eine Fremdnukleinsäuresequenz umfasst, die wenigstens ein Zielantigen oder ein immunologisches Epitop davon codiert.

37. Wirtszelle gemäß einem der Ansprüche 35-36, **dadurch gekennzeichnet, dass** die genannte Zelle eine antigenpräsentierende Zelle oder ein Vorläufer davon, eine präkanzeröse Zelle, eine hyperplastische Zelle oder eine Tumorzelle ist.

38. Wirtszelle gemäß Anspruch 37, bei der die genannte antigenpräsentierende Zelle eine dendritische Retikulumzelle oder ein Vorläufer oder ein Abkömmling davon, ein Monozyt, ein Makrophage, eine B-Zelle, eine juvenile Bindegewebszelle oder eine Muskelzelle ist.

39. Wirtszelle gemäß Anspruch 37, bei der die antigenpräsentierende Zelle von Knochenmark, von der Milz, von der Haut, von peripherem Blut, von einem Tumor, von einem Lymphknoten oder von einem Muskel abgeleitet ist.

40. Wirtszelle gemäß Anspruch 37, bei der die genannte antigenpräsentierende Zelle eine vorläuferantigenpräsentierende Zelle, eine antigenpräsentierende Zelle oder eine gentechnisch hergestellte antigenpräsentierende Zelle ist.

41. Wirtszelle gemäß Anspruch 38, bei der der genannte Dendritenabkömmling eine TNF- α -behandelte Dendritenzelle, eine CD40-behandelte Dendritenzelle oder eine Unterpopulation von Haftzellen ist.

42. Wirtszelle gemäß Anspruch 36, bei der die Fremdnukleinsäuresequenz, die wenigstens ein Zielantigen oder ein immunologisches Epitop davon codiert, durch einen rekombinanten Vektor, durch RNA oder durch DNA von einem Tumorzellenlysat oder durch Fusion mit einer Tumorzelle, die die genannte Sequenz umfasst, bereitgestellt ist.

43. Arzneimittelzusammensetzung, die wenigstens einen rekombinanten Vektor gemäß einem der Ansprüche 1-34 und einen pharmazeutisch akzeptablen Träger umfasst.

44. Arzneimittelzusammensetzung gemäß Anspruch 43, die ein rekombinantes Pockenvirus gemäß einem der Ansprüche 11-15 und optional als einen zweiten rekombinanten Vektor ein Pockenvirus, das wenigstens eine Fremdnukleinsäuresequenz umfasst, die wenigstens ein Zielantigen oder ein immunologisches Epitop davon codiert, umfasst.

45. Arzneimittelzusammensetzung gemäß einem der Ansprüche 43-44, die ferner ein Cytokin, ein Chemokin oder Flt-3L umfasst.

46. Arzneimittelzusammensetzung gemäß einem der Ansprüche 43-44, die für die Verabreichung über den intravenösen, über den subkutanen, über den intralymphatischen, über den intratumoralen, über den intradermalen, über den intramuskulären, über den intraperitonealen, über den intrarektalen, über den intravaginalen, über den intranasalen oder über den oralen Weg oder über Blasentropfinfusion oder über Hautritzung geeignet ist.

47. Arzneimittelzusammensetzung, die die Dendritenzellen und Abkömmlinge davon gemäß Anspruch 38 und einen pharmazeutisch akzeptablen Träger umfasst.

48. *In-vitro*-Verfahren zum Verbessern einer antigenspezifischen Immunreaktion in einer isolierten Zelle des Immunsystems, **dadurch gekennzeichnet, dass** der rekombinante Vektor gemäß einem der Ansprüche 1-34 oder die Wirtszellen gemäß den Ansprüchen 35-42 verwendet werden.

49. Verfahren gemäß Anspruch 48, bei dem die Wirtszellen gemäß einem der Ansprüche 35-42 verwendet werden und das ferner optional einen Schritt des Pulsens der genannten Zellen mit einem Zielantigen oder mit einem Epitop davon umfasst.

50. Verfahren gemäß Anspruch 48, bei dem die isolierten Zellen des Immunsystems T-Lymphozyten sind, **dadurch gekennzeichnet, dass** das verfahren den Schritt umfasst, dass ein isolierter T-Lymphozyt einer Wirtszelle gemäß einem der Ansprüche 35-42 allein oder in Kombination mit einem Zielantigen oder mit einem immunologischen Epitop davon ausgesetzt wird.

51. Verfahren gemäß Anspruch 50, bei dem die genannten T-Lymphozyten autogen mit einem Individuum sind.

52. Verwendung des rekombinanten Vektors gemäß einem der Ansprüche 1-34 für die Zubereitung eines Medikaments für die Behandlung oder für die Verhütung von Krebs oder von durch einen pathogenen Mikroorganismus verursachten Erkrankungen.

53. Verwendung des rekombinanten Vektors gemäß einem der Ansprüche 1-34 für die Zubereitung eines Medikaments für die Behandlung oder für die Verhütung präneoplastischer oder hyperplastischer Zustände.

54. Verwendung des rekombinanten Vektors gemäß einem der Ansprüche 1-34 für die Zubereitung eines Medikaments zur Verbesserung der Immunreaktion.

55. Verwendung einer Wirtszelle gemäß einem der Ansprüche 37-42 allein oder in Kombination mit einem Zielantigen für die Zubereitung eines Medikaments für die Immuntherapie oder für die Schutzimpfung.

56. Verfahren für die Herstellung eines rekombinanten Pockenvirus, wobei das Verfahren umfasst, dass zugelassen wird, dass der rekombinante Vektor gemäß einem der Ansprüche 16-19 eine Rekombination mit einem Elternpockenvirusgenom erfährt.

57. Ausrüstung für die Herstellung eines rekombinanten Pockenvirus, das den rekombinanten Vektor gemäß einem der Ansprüche 16-19 und optional ein Elternpockenvirus umfasst.

58. Verfahren zum In-vitro-Beurteilen der Wirksamkeit eines Impfstoffs gegen ein Zielantigen, das das Bestimmen der Anzahl und der Funktion der zielantigenspezifischen Lymphozyten in Anwesenheit der antigenpräsentierenden Zelle gemäß Anspruch 37 umfasst, in dem eine Zunahme der Anzahl, der Funktion oder einer Kombination davon zielantigenspezifischer Lymphozyten die Wirksamkeit des Impfstoffs gegen ein Zielantigen angibt.

59. Verfahren zum Selektieren für immunogene Peptide aus einer Mehrzahl von Peptiden, wobei das Verfahren umfasst:

- (a) Pulsen antigenpräsentierender Zellen, die mit einem rekombinanten Vektor gemäß einem der Ansprüche 1-34 infiziert sind, mit einer Mehrzahl von Peptiden, um peptidgepulste antigenpräsentierende Zellen zu bilden;
- (b) Messen der Lymphoidimmunreaktivität in Anwesenheit der peptidgepulsten antigenpräsentierenden Zellen,

wobei eine erhöhte Immunreaktivität ein immunogenes Peptid an der peptidgepulsten antigenpräsentierenden Zelle angibt.

60. Verfahren gemäß Anspruch 59, bei dem die Quelle der Mehrzahl von Peptiden eine kombinatorische Peptidbibliothek ist.

Revendications

1. Vecteur recombinant comprenant des séquences d'acides nucléiques étrangers codant pour trois molécules costimulatrices différentes, une de la famille B7 consistant en B7-1 et B7-2 ou leurs homologues humains ou une portion fonctionnelle, et deux sélectionnées dans un groupe consistant en: ICAM-1, LFA-3, 4-1BBL, CD59, CD40, CD70, OX-40L, VCAM-1 ou leurs homologues humains ou une portion fonctionnelle.

2. Vecteur recombinant selon la revendication 1 où lesdites trois molécules costimulatrices sont B7-1, ICAM-1 et LFA-3.

3. Vecteur recombinant selon la revendication 2 où lesdites molécules costimulatrices sont dérivées d'un humain, dérivées d'un simien ou dérivées d'un muridé.

4. Vecteur recombinant selon l'une quelconque des revendications 1-3 comprenant de plus une séquence d'acide nucléique étranger codant pour au moins une cytokine, une chimiokine, Flt-3L, ou une combinaison.
- 5 5. Vecteur recombinant selon l'une quelconque des revendications 1-4 comprenant de plus un marqueur sélectionnable.
6. Vecteur recombinant selon la revendication 5, où le marqueur sélectionnable est sélectionné dans le groupe consistant en gène *lacZ*, thymidine kinase, gpt, GUS et un gène de la gamme des hôtes de la vaccine K1L.
- 10 7. Vecteur recombinant selon l'une quelconque des revendications 1-6 comprenant de plus au moins un promoteur dérivé d'une source eucaryote, d'une source procaryote, ou d'une source virale.
8. Vecteur recombinant selon la revendication 7 où le promoteur est sélectionné dans le groupe consistant en un promoteur précoce de SV40, un promoteur de RSV, un promoteur tardif majeur d'adénovirus, un promoteur immédiat précoce I de CMV de l'humain, un promoteur du virus de la variole, un promoteur 30K, un promoteur 13, un promoteur sE/L, un promoteur 7.5K, un promoteur 40K, et un promoteur C1.
- 15 9. Vecteur recombinant selon l'une quelconque des revendications 1-8 sélectionné dans le groupe consistant en un vecteur à base d'une bactérie, d'un virus, et d'un acide nucléique.
- 20 10. Vecteur recombinant selon la revendication 9 où ledit vecteur de virus est sélectionné dans le groupe consistant en virus de la variole, adénovirus, virus de l'Herpès, alphavirus, rétrovirus, picornavirus, et iridovirus.
- 25 11. Vecteur recombinant selon la revendication 10, **caractérisé en ce que** c'est un virus recombinant de la variole.
12. Vecteur recombinant selon la revendication 11, où le virus recombinant de la variole est l'orthovariole, la variole aviaire, la variole de capridé ou la variole de suidé.
- 30 13. Vecteur recombinant selon la revendication 12 où la variole aviaire est la variole de la volaille, la variole du canari ou leurs dérivés.
14. Vecteur recombinant selon la revendication 12, où l'orthovariole est la vaccine, la souche de vaccine de Copenhague, la souche de vaccine Wyeth, NYVAC, la souche de vaccine MVA, la variole du raton laveur ou la variole du lapin.
- 35 15. Virus recombinant de la variole selon l'une quelconque des revendications 11-14 comprenant de plus au moins un promoteur du virus de la variole capable de contrôler l'expression de l'ADN étranger.
16. Vecteur recombinant selon la revendication 9, **caractérisé en ce que** ledit vecteur de bactérie est un vecteur plasmidique.
- 40 17. Vecteur recombinant selon la revendication 16, comprenant (a) au moins un promoteur du virus de la variole, (b) les séquences d'acides nucléiques étrangers codant pour LFA-3, ICAM-1 et au moins une molécule B7, (c) des séquences d'ADN adjacentes à la construction des éléments (a) et (b), les séquences adjacentes des deux extrémités 5' et 3' étant homologues avec une région du génome du virus de la variole parental où les éléments (a) et (b) doivent être insérés pour une recombinaison avec un virus de la variole conçu pour produire un virus recombinant de la variole capable d'exprimer des séquences d'acides nucléiques étrangers codant pour trois molécules co-stimulatrices, LFA-3, ICAM-1 et au moins une molécule B7.
- 45 18. Vecteur recombinant selon la revendication 16 désigné par pT5064 déposé sous le numéro d'Accession ATCC No. 203482.
- 50 19. Vecteur recombinant selon la revendication 16, désigné par pT5049 déposé au ATCC sous le No. d'Accession 203481.
- 55 20. Vecteur recombinant selon l'une quelconque des revendications 1-19 comprenant de plus une séquence d'acide nucléique étranger codant pour au moins un antigène cible ou son épitope immunologique.
21. Vecteur recombinant selon la revendication 20 où l'antigène cible a une séquence d'acides aminés qui est sélectionné

tionnée dans le groupe consistant en SEQ ID NO: 2 à SEQ ID NO:40.

22. Vecteur recombinant selon la revendication 20, où l'antigène cible est sélectionné dans le groupe consistant en un antigène spécifique de la tumeur, un antigène associé à la tumeur (TAA), un antigène spécifique du tissu, un antigène bactérien, un antigène viral, un antigène de la levure, un antigène fongique, un antigène protozoaire et un antigène parasite et un mitogène.
23. Vecteur recombinant selon la revendication 22 où l'antigène bactérien est dérivé d'un bactérium sélectionné dans le groupe consistant en Chlamydiae, Mycobactéries, Legionella, Meningiocoque, Streptocoque Groupe A, *Hemophilus influenzae*, Salmonella, et Listeria.
24. Vecteur recombinant selon la revendication 22 où l'antigène viral est dérivé d'un virus sélectionné dans le groupe consistant en Lentivirus, virus de l'Herpès, virus de l'hépatite, Orthomyxovirus et Papillomavirus.
25. Vecteur recombinant selon la revendication 24 où le Lentivirus est VIH-1 ou VIH-2.
26. Vecteur recombinant selon la revendication 24 où le virus de l'herpès est HSV ou CMV.
27. Vecteur recombinant selon la revendication 24 où le virus de l'Hépatite est l'Hépatite A, l'Hépatite B, l'Hépatite C, l'Hépatite D ou l'Hépatite E.
28. Vecteur recombinant selon la revendication 24 où l'orthomyxovirus est le virus de la grippe.
29. Vecteur recombinant selon la revendication 22 où l'antigène associé à une tumeur, l'antigène spécifique d'une tumeur ou l'antigène spécifique du tissu est sélectionné dans le groupe consistant en CEA, MART-1, MAGE-1, MAGE-3, GP-100, MUC-1, MUC-2, l'oncogène ras muté par points, p53 normal ou muté par points, p53 surexprimé, CA-125, PSA, C-erbB2, BRCA I, BRCA II, PSMA, tyrosinase, TRP-1, TRP-2, NY-ESO-1, TAG72, KSA, HER-2/neu, bcr-ab, pax3-fkhr, ews-fli-1, TAAs modifié, variantes par épissure de TAAs des épitopes fonctionnels et des agonistes d'épitopes de ceux-ci.
30. Vecteur recombinant selon la revendication 29 où l'antigène est CEA (6D) ayant un acide aminé d'acide aspartique à la position d'acide aminé 576.
31. Vecteur recombinant selon la revendication 29 où l'antigène est PSA ou PSMA.
32. Vecteur recombinant selon la revendication 29 où l'antigène est MUC-1 ou une portion de celui-ci.
33. Vecteur recombinant selon la revendication 22 où l'antigène de levure ou de champignon est dérivé d'une levure ou d'un champignon sélectionné dans le groupe consistant en Aspergillus, Nocardia, Histoplasmosis, Candida, et Cryptosporidia.
34. Vecteur recombinant selon la revendication 22 où l'antigène du parasite est dérivé d'une espèce *Plasmodium*, de *Toxoplasma gondii*, *Pneumocystis carinii*, espèce *Trypanosoma*, ou espèce *Leishmania*.
35. Cellule hôte isolée comprenant le vecteur recombinant selon l'une quelconque des revendications 1-34.
36. Cellule hôte selon la revendication 35 comprenant de plus une séquence d'un acide nucléique étranger codant pour au moins un antigène cible ou son épitope immunologique.
37. Cellule hôte selon l'une quelconque des revendications 35-36 **caractérisée en ce que** ladite cellule est une cellule présentant un antigène ou son précurseur, une cellule pré-maligne, une cellule hyperplasique ou une cellule de tumeur.
38. Cellule hôte selon la revendication 37, où ladite cellule présentant l'antigène est une cellule dendritique ou son précurseur ou dérivé, un monocyte, un macrophage, une cellule-B, un fibroblaste ou une cellule du muscle.
39. Cellule hôte selon la revendication 37, où la cellule présentant l'antigène est dérivée de moëlle osseuse, de la rate, de la peau, du sang périphérique, d'une tumeur, d'un ganglion lymphatique ou d'un muscle.

40. Cellule hôte selon la revendication 37 où ladite cellule présentant l'antigène est une cellule progénitrice présentant un antigène, une cellule présentant un antigène ou une cellule manipulée présentant un antigène.
- 5 41. Cellule hôte selon la revendication 38 où ledit dérivé dendritique est une cellule dendritique traitée par TNF- α , une cellule dendritique traitée par CD40, ou une sous-population de cellules adhérentes.
- 10 42. Cellule hôte selon la revendication 36, où la séquence de l'acide nucléique étranger codant pour au moins un antigène cible ou son épitope immunologique est formée d'un vecteur recombinant, l'ARN ou l'ADN d'un lysat de cellules de tumeur ou par fusion avec une cellule de tumeur comprenant ladite séquence.
- 15 43. Composition pharmaceutique comprenant au moins un vecteur recombinant selon l'une quelconque des revendications 1-34 et un support pharmaceutiquement acceptable.
- 20 44. Composition pharmaceutique selon la revendication 43 comprenant un virus recombinant de la variole selon l'une quelconque des revendications 11-15 et facultativement, en tant que second vecteur recombinant, un virus de la variole comprenant au moins une séquence d'un acide nucléique étranger codant pour au moins un antigène cible ou son épitope immunologique.
- 25 45. Composition pharmaceutique selon l'une quelconque des revendications 43-44 comprenant de plus une cytokine, une chimiokine ou Flt-3L.
- 30 46. Composition pharmaceutique selon l'une quelconque des revendications 43-44 appropriée pour une administration par voie intraveineuse, sous-cutanée, intralymphatique, intratumorale, intradermique, intramusculaire, intrapéritonéale, intrarectale, intravaginale, intranasale ou orale ou via une instillation dans la vessie ou via scarification.
- 35 47. Composition pharmaceutique comprenant les cellules dendritiques et leurs dérivés selon la revendication 38 et un support pharmaceutiquement acceptable.
- 40 48. Procédé *in vitro* pour améliorer une réponse immunitaire spécifique d'un antigène dans une cellule isolée du système immunitaire **caractérisé en ce que** le vecteur recombinant selon l'une quelconque des revendications 1-34 ou les cellules hôtes selon les revendications 35-42 sont utilisés.
- 45 49. Procédé selon la revendication 48, où les cellules hôtes selon l'une quelconque des revendications 35-42 sont utilisées et comprenant de plus facultativement une étape de pulser lesdites cellules avec un antigène cible ou son épitope.
- 50 50. Procédé selon la revendication 48 où les cellules isolées du système immunitaire sont des lymphocytes T et **caractérisé en ce qu'**il comprend l'étape d'exposer un lymphocyte T isolé à une cellule hôte selon l'une quelconque des revendications 35-42 seul ou en combinaison avec un antigène cible ou son épitope immunologique.
- 55 51. Procédé selon la revendication 50 où lesdits lymphocytes T sont autologues avec un individu.
52. Utilisation du vecteur recombinant selon l'une quelconque des revendications 1-34 pour la préparation d'un médicament pour le traitement ou la prévention du cancer ou de maladies provoquées par un microorganisme pathogène.
53. Utilisation du vecteur recombinant selon l'une quelconque des revendications 1-34 pour la préparation d'un médicament pour le traitement ou la prévention d'états préneoplasiques ou hyperplasiques.
54. Utilisation du vecteur recombinant selon l'une quelconque des revendications 1-34 pour la préparation d'un médicament pour améliorer la réponse immunitaire.
- 55 55. Utilisation d'une cellule hôte selon l'une quelconque des revendications 37-42 seule ou en combinaison avec un antigène cible pour la préparation d'un médicament pour l'immunothérapie ou la vaccination.
56. Procédé de production d'un virus recombinant de la variole consistant à permettre au virus recombinant selon l'une quelconque des revendications 16-19 de subir une recombinaison avec un génome d'un virus de la variole parental.
57. Kit pour la production d'un virus recombinant de la variole comprenant le vecteur recombinant selon l'une quelconque

des revendications 16-19 et facultativement, un virus parental de la variole.

5 58. Procédé pour évaluer *in vitro* l'efficacité d'un vaccin contre un antigène cible consistant à déterminer le nombre et la fonction des lymphocytes spécifiques de l'antigène cible en présence de la cellule présentant l'antigène selon la revendication 37 où une augmentation du nombre, de la fonction ou de la combinaison des lymphocytes spécifiques de l'antigène cible indique l'efficacité du vaccin contre un antigène cible.


59. Méthode de dépistage de peptides immunogènes parmi une multiplicité de peptides comprenant:


10 (a) la pulsion des cellules présentant l'antigène infectées d'un vecteur recombinant selon l'une quelconque des revendications 1-34 avec une multiplicité de peptides pour former des cellules présentant l'antigène pulsées par des peptides;

(b) la mesure de l'immunoréactivité lymphoïde en présence des cellules présentant l'antigène pulsées par des peptides,

15 où une meilleure immunoréactivité est indicative d'un peptide immunogène sur la cellule présentant l'antigène pulsé par des peptides.

20 60. Méthode selon la revendication 59, où la source de la multiplicité de peptides est une bibliothèque de peptides en combinaison.








FIG 3




FIG 4A




FIG 4B




FIG 4C




FIG 5




FIG 6




FIG 7A




FIG 7B

Fowlpox rF-MUC-1/TRICOM



FIG 7C

Fowlpox rF-TAA/TRICOM



FIG 7D




FIG 8




FIG 9A




FIG 9B




FIG 9C




FIG 10




FIG 11




FIG 12




FIG 13A





FIG 13B







FIG 15







FIG 17






FIG 19





FIG 20






FIG 22




FIG 23




FIG 24A




FIG 24B




FIG 25A




FIG 25B




FIG 25C









FIG 25D



% MC38 Cells Expressing Constitutively Stimulatory Molecule(s)

FIG 26



MC38 Stimulator Cells Infected With:

FIG 27C

FIG 27D




FIG 28A




FIG 28B




FIG 28C





FIG 28D

MC38 Stimulator Cells Infected With:

FIGURE 29






FIG 29B





FIG 29C

**FIG 30**

*In-Vitro Costimulation Assay:
Dendritic Cells*




FIG 31




FIG 32A

FIG 32B




FIG 33A

FIG 33B






FIG 34

**FIG 35**

**FIG 36A****FIG 36B**




FIG 37A FIG 37B




FIG 37C FIG 37D




FIG 37E FIG 37F




FIG 38A

FIG 38B




FIG 38C

FIG 38D




FIG 38F

FIG 38E






FIG 39A

FIG 39B






FIG 41A **FIG 41B** **FIG 41C**




FIG 42A

FIG 42B




FIG 43C

FIG 43D





FIG 44A **FIG 44B** **FIG 44C** **FIG 44D** **FIG 44E** **FIG 44F**




FIG 455A **FIG 455B** **FIG 455C**




FIG 455D **FIG 455E** **FIG 455F**




FIG 46A

FIG 46B




FIG 46C

FIG 46D




FIG 47




FIG 48





FIG 49

**FIG 50**




FIG 51






FIG 52

**FIG 53**

**FIG 54**

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 9102805 A [0004]
- WO 9610419 A [0018]
- US 9512624 W [0018]
- US 5738852 A [0019]
- US 5093258 A [0071] [0086]
- US 5827703 A [0072]
- US 5719054 A [0090]
- US 5780036 A [0090]
- US 5709995 A [0090]
- US 5869608 A [0090]
- US 5955596 A [0090]
- US 5645992 A [0091]
- US 5965242 A [0092]
- US 5589343 A [0092]
- US 5750395 A [0094]
- US 5648226 A [0094]
- US 5840839 A [0094]
- US 5550214 A [0094]
- US 4514506 A [0094]
- US 5554512 A [0105]
- US 5843423 A [0105]
- US 5788963 A [0132] [0135]
- WO 901443 A [0141] [0141]
- WO 9014424 A [0141]
- WO 60111582 A [0256]

Non-patent literature cited in the description

- **AKAGI et al.** *J. Immunotherapy*, 1997, vol. 20 (1), 38-47 [0005]
- **CAVALLO, P et al.** *Eur. J. Immunol.*, 1995, vol. 25, 1154-1162 [0006]
- **CHEN, L et al.** *J. Exp. Med.*, 1994, vol. 179, 523-532 [0007]
- **DAMLE, N.K. et al.** *J. Immunol*, 1992, vol. 148 (7), 1985-1992 [0008]
- **DUBEY, C et al.** *J Immunol*, 1995, vol. 155, 45-57 [0009]
- **FENTON, R.G et al.** *J. IMMUNOL*, 1998, vol. 21 (2), 95-108 [0010]
- **GJORLOFF WINGREN, A et al.** *Critical Reviews in Immunol*, 1995, vol. 15 (3 & 4), 235-253 [0011]
- **GOLDBACH-MANSKY, R et al.** *International Immunol.*, 1992, vol. 4 (12), 1351-1360 [0012]
- **HODGE, J.W et al.** *Cancer Research*, 1994, vol. 54, 5552-5555 [0013]
- **HODGE, J.W. et al.** *Cancer Research*, 1995, vol. 55, 3598-3603 [0014]
- *Cancer Research*, vol. 55, 3598-3603 [0014]
- **PARRA et al.** *Scand J. Immunol*, 1993, vol. 38, 508-514 [0015]
- **PARRA, E et al.** *J. Immunol*, 1994, vol. 153, 2479-2487 [0015]
- **PARRA et al.** *J. Immunol.*, 1997, vol. 458, 637-642 [0015]
- **THOMAS, R et al.** *J. Immunol.*, 1993, vol. 151, 6840-6852 [0016]
- **UZENDOSKI, K et al.** *Human Gene Therapy*, May 1997, vol. 8, 851-860 [0017]
- **FREEMAN et al.** (*J. Immunol.*, 1989, vol. 143, 2714-2722 [0059]
- **AZUMA et al.** (*Nature*, 1993, vol. 366, 76-79 [0059]
- **HURTADO, J.C. et al.** *J. Immunol.*, 1997, vol. 158 (6), 2600-2609 [0064]
- **VINAY, D.S et al.** *Seminars in Immunology*, 1998, vol. 10, 481-489 [0064]
- **WEINBERG, A.D et al.** *Seminars in Immunology*, 1998, vol. 10, 471-480 [0065]
- **GRAMAGLIA, I et al.** *J. Immunology*, 1998, vol. 161, 6510-7 [0065]
- **PERKUS et al.** *Science*, 1985, vol. 229, 981-984 [0068]
- **KAUFMAN et al.** *Int. J. Cancer*, 1991, vol. 48, 900-907 [0068]
- **MOSS.** *Science*, 1991, vol. 252, 1662 [0068]
- **SUTTER ; MOSS.** *Proc. Nat'l Acad. Sci. U.S.A.*, vol. 89, 10847-10851 [0068]
- **SUTTER et al.** *Virology*, 1994 [0068]
- **BAXBY ; PAOLETTI.** *Vaccine*, 1992, vol. 10 (8-9) [0068]
- Recombinant Poxviruses. CRC Press, Inc, 1992 [0068]
- **PAOLETTI, E.** *Proc. Nat'l Acad. Sci. USA*, 1996, vol. 93, 11349-11353 [0068]
- **DAVISON ; MOSS.** *J. Mol. Biol.*, 1989, vol. 210, 749-769 [0071]
- **PLEIDERER et al.** *J. Gen. Virol.*, 1995, vol. 76, 2957-2962 [0086]
- **MERCHLINSKY et al.** *Virol.*, 1997, vol. 238, 444-451 [0086]
- HIV Molecular Immunology Database. 1977 [0090]

- **KAWAKAMI et al.** *J. Exp. Med.*, 1994, vol. 180, 347-352 [0094]
- **KAWAKAMI et al.** *Proc. Nat'l Acad. Sci. USA*, 1992, vol. 91, 6458-6462 [0094]
- **HOLLSTEIN et al.** *Nucleic Acids Res.*, 1994, vol. 22, 3551-3555 [0094]
- **ISRAELI et al.** *Cancer Res.*, 1993, vol. 53, 227-230 [0094] [0170]
- **KWON et al.** *PNAS*, 1987, vol. 84, 7473-7477 [0094]
- **COHEN et al.** *Nucleic Acid Res.*, 1990, vol. 18, 2807-2808 [0094]
- **CHEN et al.** *PNAS*, 1997, vol. 94, 1914-1918 [0094]
- **JACKSON et al.** *EMBOJ*, 1992, vol. 11, 527-535 [0094]
- **GONG, J et al.** *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 6279-6283 [0130] [0255]
- **BANCHEREAU ; STEINMAN.** *Nature*, 1998, vol. 392, 245-252 [0132]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495-497 [0141]
- **CAMPBELL et al.** *Monoclonal Antibody Technology, the Production and Characterization of Rodent and Human Hybridomas.* 1985 [0141]
- *Laboratory Techniques in Biochemistry and Molecular Biology.* Elsevier Science Publishers, vol. 13 [0141]
- **HUSE et al.** *Science*, 1989, vol. 246, 1275-1281 [0141]
- *Antibodies A Laboratory Manual.* Cold Spinning Harbor Press, 1988 [0143]
- *Current Protocols In Molecular Biology.* John Wiley and Sons, 1987 [0143]
- **ZAREMBA et al.** *Cancer Res.*, 1997, vol. 57, 4570-4577 [0164] [0255]
- **GENDLER et al.** *J. Biol. Chem.*, 1990, vol. 265, 15286-15293 [0167]
- **LUNDWALL ; LILJA.** *FEBS Lett.*, 1987, vol. 214, 317-322 [0170]
- **MEYER et al.** *J. Gen. Virol.*, 1991, vol. 72, 1031-10381 [0171]
- **MEYER et al.** *J. Gen. Virol.*, 1991, vol. 72, 1031-1038 [0172]
- **GAVRIELI, Y et al.** *J. Cell Biol*, 1992, vol. 119, 493-501 [0188]
- **KASS, E et al.** *Cancer Res*, 1999, vol. 59, 676-683 [0190]
- **KASS ; THOMPSON, J.A et al.** *J. Clin. Lab. Anal.*, 1999, vol. 5, 344-366 [0192]
- **SCHEIBENHOGEN et al.** *Int. J. Cancer*, 1997, vol. 71, 932-936 [0231]
- **STORKUS, W.J et al.** *J. Immunol.*, 1987, vol. 138 (6), 1657-1659 [0237]
- **HOGAN, K.T. et al.** *J. Exp. Med.*, 1988, vol. 168 (2), 725-736 [0237]
- **TSANG, K.Y et al.** *Clin. Cancer Res.*, 1997, vol. 3 (12), 2439-2449 [0237]
- **BOYUM, A.** *Scand J Clin Lab Invest Suppl.*, 1968, vol. 97, 51-76 [0238]
- **SALLUSTO, F et al.** *J. Exp. Med.*, 1994, vol. 179 (4), 1109-1118 [0238]
- **KAUFMAN, F et al.** *Int. J. Cancer*, 1991, vol. 48 (6), 900-907 [0239]
- **TAYLOR, J et al.** *Virology*, 1992, vol. 187 (1), 321-328 [0239]
- **COX, W.I et al.** *Virology*, 1992, vol. 187 (1), 321-328 [0239]
- **PERKUS, M.E et al.** *J. Virol.*, vol. 63 (9), 3829-3836 [0239]
- **TSANG, K.Y et al.** *J. Natl Cancer Inst.*, 1995, vol. 87 (13), 982-990 [0240] [0241]
- **ZAREMBA, S et al.** *Cancer Res.*, 1997, vol. 57 (20), 4570-4577 [0240]
- **ALTMAN, J.D et al.** *Science*, 1996, vol. 274 (5284), 94-95 [0242]
- **GARBOCZI, D.N et al.** *Proc Natl Acad Sci USA*, 1992, vol. 89 (8), 3429-3433 [0242]
- **SCHEIBENBOGEN, C et al.** *Clin Cancer Res*, 1997, vol. 3 (2), 221-226 [0247]
- **HELLSTROM, K. E ; CHEN, L ; HELLSTROM, 1.** *Cancer Chemother Pharmacol*, 1996, 40-1 [0255]
- **DAMLE, N. K ; KLUSSMAN, K ; LINSLEY, P. S ; ARUFFO, A.** *J Immunol*, 1992, 1985-92 [0255]
- **GREEN, J. M ; ZHENG, X. G ; SHIMIZU, Y ; THOMPSON, C. B ; TURKA, L. A.** *Eur J Immunol*, 1994, vol. 24, 265-72 [0255]
- **GUINAN, E. C ; GRIBBEN, J. G ; BOUSSIOTIS, V. A ; FREEMAN, G. J ; NADLER, L. M.** *Blood*, 1994, 3261-82 [0255]
- **HODGE, J. W ; MCLAUGHLIN, J. P ; ABRAMS, S. I ; SHUPERT, W. L ; SCHLOM, J. ; KANTOR, J. A.** *Cancer Res*, 1995, 3598-603 [0255]
- **WINGREN, A. G ; PARRA, E. ; VARGA, M ; KALLAND, T ; SJOGREN, H. O ; HEDLUND, G ; DOHLSTEN, M.** *Crit Rev Immunol*, 1995, 235-53 [0255]
- **PARRA, E ; WINGREN, A. G ; HEDLUND, G ; SJOGREN, H. O ; KALLAND, T ; SANSOM, D ; DOHLSTEN, M.** *Scand J Immunol*, 1993, 508-14 [0255]
- **HARDING, F. A ; ALLISON, J. P.** *JExp Med*, 1993, 1791-6 [0255]
- **HELLSTROM, K. E ; HELLSTROM, I ; LINSLEY, P ; CHEN, L.** *Ann N.Y Acad Sci*, 1993, 225-30 [0255]
- **HODGE, J. W ; ABRAMS, S. ; SCHLOM, J ; KANTOR, J. A.** *Cancer Res*, 1994, vol. 54, 5552-5 [0255]
- **UZENDOSKI, K. ; KANTOR, J. A ; ABRAMS, S. I ; SCHLOM, J ; HODGE, J. W.** *Hum Gene Ther*, 1997, vol. 8, 851-60 [0255]
- **LORENZ, M. G. 0 ; KANTOR, J. A ; SCHLOM, J ; HODGE, J. W.** *Human Gene Therapy*, 1998 [0255]
- **GRITZ, L ; DESTREE, A ; CORMIER, N ; DAY, E ; STALLARD, V ; CAIAZZO, T ; MAZZARA, G ; PANICALI, D.** *J Virol*, 1990, vol. 64, 5948-57 [0255]
- **MAZZARA, G. P ; DESTREE, A ; MAHR, A.** *Methods Enzymol*, 1993, vol. 217, 557-81 [0255]

- JENKINS, S ; GRITZ, L ; FEDOR, C. H ; O'NEILL, E. M ; COHEN, L. K. ; PANICALI, D. L. *AIDS Res Hum Retroviruses*, 1991, vol. 7, 991-8 [0255]
- CHAKRABARTI, S ; SISLER, J. R ; MOSS, B. *Bio-Techniques*, 1997, vol. 23, 1094-7 [0255]
- PERKUS, M. E ; PICCINI, A ; LIPINSKAS, B. R ; PAOLETTI, E. *Science*, 1985, vol. 229, 981-4 [0255]
- SCHMITT, J. F ; STUNNENBERG, H. G. *J Virol*, 1988, vol. 62, 1889-97 [0255]
- VENKATESAN, S ; BAROUDY, B. M ; MOSS, B. *Cell*, 1981, vol. 25, 805-13 [0255]
- FOX, B. A ; SPIESS, P. J ; KASID, A ; PURI, R ; MULE, J. J ; WEBER, J. S ; ROSENBERG, S. A. *J Biol Response Mod*, 1990, vol. 9, 499-511 [0255]
- ABRAMS, S. I ; DOBRZANSKI, M. J ; WELLS, D. T ; STANZIALE, S. F ; ZAREMBA, S ; MASUELLI, L ; KANTOR, J. A ; SCHLOM, J ; MASUELLE, L. *Eur J Immunol*, 1995, vol. 25, 2588-97 [0255]
- SABZEVARI, H ; PROPP, S ; KONO, D. H ; THEO-FILOPOULOS, A. N. *Eur J Immunol*, 1997, vol. 27, 1901-10 [0255]
- PARRA, E ; WINGREN, A. G ; HEDLUND, G ; BJORKLUND, M ; SJOGREN, H. O ; KALLAND, T ; SANSOM, D ; DOHLSTEN, M. *J Immunol*, 1994, vol. 153, 2479-87 [0255]
- PARRA, E ; WINGREN, A. G ; HEDLUND, G ; KALLAND, T ; DOHLSTEN, M. *J Immunol*, 1997, vol. 158, 637-42 [0255]
- SPERLING, A. I ; AUGER, J. A ; EHST, B. D ; RULIFSON, I. C ; THOMPSON, C. B ; BLUESTONE, J. A. *J Immunol*, 1996, vol. 157, 3909-17 [0255]
- DUBEY, C ; CROFT, M ; SWAIN, S. L. *J Immunol*, 1995, vol. 155, 45-57 [0255]
- CAVALLO, F ; MARTIN-FONTECHA, A ; BEL-LONE, M ; HELTAI, S ; GATTI, E ; TOMAGHI, P ; FRESCHI, M ; FORNI, G ; DELLABONA, P ; CASORATI, G. *Eur J Immunol*, 1995, vol. 25, 1154-62 [0255]
- DELESPESE, G ; YANG, L. P ; OHSHIMA, Y ; DE-MEURE, C ; SHU, U ; BYUN, D. G ; SARFATI, M. *Vaccine*, 1998, vol. 16, 1415-9 [0255]
- MINTY, A. ; CHALON, P. ; DEROCQ, J. M. ; DUMONT, X. ; GUILLEMOT, J. C. ; KAGHAD, M. ; LABIT, C. ; LEPLATOIS, P. ; LIAUZUN, P. ; MILOUX, B. et al. *Nature*, 1993, vol. 362, 248-50 [0255]
- SCHMITT, E ; GERMANN, T ; GOEDERT, S ; HOEHN, P ; HUELS, C ; KOELSCH, S ; KUHN, R ; MULLER, W ; PALM, N ; RUDE, E. *J Immunol*, 1994, vol. 153, 3989-96 [0255]
- CHAKRABARTI, S ; BRECHLING, K ; MOSS, B. *Mol. Cell. Biol.*, 1985, vol. 5, 3403-3409 [0255]
- CHAKRABARTI, S ; SISLER, J.R ; MOSS, B. *Bio-Techniques*, 1997, vol. 23, 1094-1097 [0255]
- GILLARD, S ; SPEHNER, D ; DRILLIEN, R ; KIM, A. *Proc. Natl. Acad. Sci. USA*, 1986, vol. 83, 5573-5577 [0255]
- MORGAN, J.R ; ROBERTS, B.E. *J. Virol*, 1994, vol. 51, 283-297 [0255]
- PANICALI, D ; GRZELECKI, A ; HUANG, C. *Gene*, 1986, vol. 47, 193-199 [0255]
- Molecular Cloning,. Cold Spring Harbor Laboratory, 1989 [0255]
- SCHMITT, J.F.C ; STUNNENBERG, H.G. *J. Virol.*, 1988, vol. 62, 1889-1897 [0255]
- SMITH, K ; STALLARD, V ; ROSS, J ; HART, C ; CORMIER, N ; COHEN, L ; ROBERTS, B ; PAYNE, L. *Vaccine*, 1993, vol. 11, 43-53 [0255]
- VENKATESAN, S ; BAROUDY, B.M ; MOSS, B. *Cell*, 1981, vol. 125, 805-813 [0255]
- BACCHETTI, S ; GRAHAM, F.L. *Proc. Nat'l. Acad. Sci. USA*, 1977, vol. 74, 1590-1594 [0255]
- INABA, K. ; INABA, M ; ROMANI, N ; AYA, H ; DEGUCHI, M ; IKEHARA, S ; MURAMATSU, S ; STEINMAN, R.M. *J. Exp. Med*, 1992, vol. 176, 1693-702 [0255]
- SALLUSTO, F ; LANZAVECCHIA, A. *J. Exp. Med.*, 1994, vol. 179, 1109-8 [0255]
- FIELDS, R.C ; OSTERHOLZER, J. J ; FULLER, J.A ; THOMAS, E.K ; GERAGHTY, P.J ; MULE, J.J. *J. Immunother.*, 1998, vol. 21, 323-39 [0255]
- CORREALE, P et al. *J. Immunol.*, 1998, vol. 161 (6), 3186-94 [0255]